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Abstract
Embryonic stem (ES) cells are of tremendous biological interest because they have
the capacity, termed pluripotency, to generate any cell type of the adult organism. Our
lab is interested in understanding the genetic circuitry that governs pluripotency. For my
thesis work I have contributed to a team effort to deduce the transcriptional regulatory
circuitry of ES cells.
This collaborative effort first sought to define the genes that are regulated by the
key pluripotency regulators, Oct4, Sox2 and Nanog. We then determined the genes
targeted by the Polycomb Repressive Complex in ES cells. These datasets allowed us to
define the core transcriptional regulatory circuitry for these cells and demonstrated that
pluripotency is mediated through the repression of developmental regulators. Finally, an
effort to understand how Wnt signaling modifies this circuitry led to the discovery that
the Wnt signaling component Tcf3 is a core component of the transcriptional regulatory
circuitry and serves to repress the pluripotency regulators, contributing to the balance
between pluripotency and differentiation.
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Preface
Empedocles, then, was in error when he said that many of the characters presented by
animals were merely the results of incidental occurrences during their development... In
so saying he overlooked the fact that propagation implies a creative seed endowed with
certain formative properties.
Aristotle
On the Parts of Animals, 350 BC
Elucidating the mechanisms that control differentiation willfacilitate the efficient,
directed differentiation of embryonic stem cells to specific cell types... Many diseases,
such as Parkinson's disease and juvenile-onset diabetes mellitus, result from the death of
dysfunction of just one or a few cell types. The replacement of those cells could offer
lifelong treatment.
Thomson et al.
Science, 1998
In 350 BC Aristotle proposed that an embryo develops according to an ordered
plan from a single creative seed (McKeon, 1973). The proposal that an embryo matures
through a series of sequential steps is in accordance with a contemporary understanding
of early embryonic development (Moody, 1999). The ordered steps of early mammalian
development have been defined, as the zygote undergoes a series of highly coordinated
cell divisions to progress through differentiation (Boiani and Scholer, 2005; Pera and
Trounson, 2004; Ralston and Rossant, 2005; Spagnoli and Hemmati-Brivanlou, 2006).
Embryonic stem (ES) cells derived from this creative seed can be grown in culture and
facilitate the study of its properties. ES cells self-renew in culture and maintain the
capacity, termed pluripotency, to generate into all cell types of the adult organism. The
discovery of ES cells has permitted the earliest steps of development to be recapitulated
in vitro. Moreover, as suggested by Thomson and colleagues in their initial
characterization of human ES cells, these cells may facilitate cell replacement therapies
critical for the treatment of disease (Thomson et al., 1998). From the ancient proposal of
a creative seed that can generate an adult organism to the isolation of human ES cells, the
potential to develop cell replacement therapies has been a driving force behind the study
of ES cell biology and will likely lead to new treatments for many human diseases.
A key challenge in understanding ES cell biology is deciphering how a single
genome can direct the embryo to give rise to any adult cell type through the course of
development. My interest in this challenge inspired me to join the Young lab, where I
have worked to understand how regulation of gene expression impacts ES cell
pluripotency. My thesis work has sought to characterize the transcriptional regulatory
circuitry that governs ES cells. Shortly after I joined the lab, I became involved in a
collaborative effort to unravel the genetic circuitry that defines ES cells. This effort
involved using genome-wide location analysis to identify the complete set of target genes
regulated by a number of factors critical for ES cell self-renewal and proliferation. These
datasets enabled us to determine the core transcriptional regulatory circuitry that defines
ES cell identity. During my third year in the lab, I became interested in understanding
how signaling pathways regulate this circuitry. My efforts demonstrated that Tcf3, a
component of the Wnt signaling pathway, directly regulates the core transcriptional
regulatory circuitry. This thesis will describe the history and current understanding of ES
cell biology that informed my research (Chapter 1), the contributions I have made to
understand the regulatory circuitry of ES cells (Chapters 2-4) and remaining issues that
must be addressed in order to realize the therapeutic potential of ES cells (Chapter 5).
Chapter 1
Introduction
This introduction will first provide background on the isolation and
characterization of ES cells in order to contextualize my thesis work as part of a broader
effort to understand and manipulate ES cells. Work over the last three decades has taken
scientists from the initial isolation of ES cells to an advanced characterization of these
cells. A proper framework for viewing this work is to consider how it has both been
informed by and, reciprocally, informed our understanding of early mammalian
development. Towards this end, this chapter will first review the critical steps of early
embryonic development and consider the remarkable achievements of the late 2 0 th
century that established ES as a key model system for understanding early mammalian
development. To do so, I will describe the discovery of both mouse and human ES cells
and discuss the characteristics that make these cells so unique, including a discussion of
their therapeutic potential.
I will then review the molecular characterization of ES cells that preceded and
informed the work I have done to define the transcriptional regulatory circuitry of ES
cells. Molecular and genetic tools have been applied to ES cell biology to elucidate a
number of factors essential for ES cell identity. I will review the key transcription
factors, chromatin regulators and signaling pathways that impact ES cells.
Finally, since this thesis will describe the transcriptional regulatory circuitry that
governs ES cells, I will briefly describe how such circuitry can contribute to an
understanding of cell state. An understanding of the transcriptional circuitry in ES cells
will also enable a better understanding of the genetic mechanisms that govern
pluripotency and methods to manipulate ES and somatic cells for therapeutic purposes.
Embryonic Stem Cell Isolation and Application
Embryonic stem cells are derived from the inner cell mass of the developing
blastocyst and reflect its pluripotent state. The fertilized zygote is totipotent since it has
the capacity to generate all tissues of the adult organism and extraembryonic tissues.
However, as development proceeds the embryo's developmental potential is restricted.
The coordinated differentiation events of early embryonic development include the
formation of the trophectoderm, epiblast and primitive endoderm. Following fertilization
of the oocyte, three rounds of cell division lead to the formation of the morula (Ralston
and Rossant, 2007). Cells compact during the morula stage and the outer layer of the late
morula forms an epithelium known as the trophectoderm, the first differentiation step in
early embryonic development (Figure 1). The blastocoel, a cavity within this sphere of
cells, forms, and the inner cell mass (ICM) becomes concentrated on one side of the
blastocyst. The second differentiation step occurs when the ICM differentiates into
epiblast and primitive endoderm, which happens in the late blastocyst. These three cell
fate decisions are important because they represent the first restrictions on the totipotent
embryo. Trophectoderm has the capacity to generate all of the non-maternal components
of the placenta. The epiblast gives rise to the embryo, and the primitive endoderm gives
rise to extraembryonic endoderm and the yolk sak. ES cells are isolated from the ICM
(Kaufman and Evans, 1981; Martin, 1981). They possess the same potency as their
source and have the capacity to give rise to the three primary germ layers, endoderm,
ectoderm and mesoderm, as well as extraembryonic tissues (Spagnoli and Hemmati-
Brivanlou, 2006).
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Figure 1. From Keller, 2005. Flowchart of early mouse development demonstrating the
relationship between different tissue types.
Isolation of ES Cells
Two key observations in teratocarcinomas paved the way for the isolation of ES
cells from the developing embryo (Damjanov, 2005; Friel et al., 2005; Smith, 2001).
Teratocarcinomas are malignant tumors that contain a large population of
undifferentiated cells, as well as differentiated cells of multiple lineages (Damjanov,
1990). First, it was reported that cells derived from teratocarcinomas, termed embryonic
carcinoma (EC) cells, could be cultured in vitro and give rise to multiple lineages (Finch
and Ephrussi, 1967; Friel et al., 2005). This provided evidence that teratocarcinomas
contained a pluripotent stem cell. Then, in 1970, it was reported that grafting mouse
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embryos onto an adult mouse led to teratocarcinoma formation (Solter et al., 1970;
Stevens, 1970). The implication of this observation was the epiblast founder population
of the early embryo was being maintained in the embryo-derived teratocarcinoma (Hogan
et al., 1994). In the years following EC cell isolation, culture techniques for EC cells
were improved (Smith, 2001). It was observed that EC cells proliferate best when in the
presence of differentiated cells, and therefore co-culture with mitotically inactivated
embryonic fibroblasts was introduced (Martin and Evans, 1975; Martin et al., 1977). It
also became clear that EC cells are karyotypically abnormal, which was thought to be
responsible for their capacity to self-renew indefinitely in culture (Friel et al., 2005;
McBurney, 1976). The observation that EC cells represented a pluripotent mouse cell
line and that such cells could be obtained from embryo-derived teratocarcinomas led to
the effort to isolate self-renewing, pluripotent cells from the mouse embryo that were
karyotypically normal.
In 1981, mouse ES cells were first isolated and shown to both self-renew and
maintain pluripotency in culture (Evans and Kaufman, 1981; Martin, 1981). These cells
were derived from cultures of preimplantation blastocysts and grown in medium
conditioned by an established teratocarcinoma stem cell line (Martin, 1981) or on a co-
culture with a mitotically inactivated mouse embryonic fibroblast (MEF) feeder
population (Evans and Kaufman, 1981). At the time of their discovery, it was noted that
these cells might contribute to the study of early mammalian development through the
generation of embryo-derived cell lines with specific genetic alterations (Martin, 1981).
It was also noted that these cells have a completely normal karyotype, unlike any
previously described EC cell line (Evans and Kaufman, 1981). The mouse ES cells were
capable of forming teratocarcinomas when explanted onto an adult mouse, a phenotype
similar to that observed in EC cells. They were also shown to be capable of
differentiating into a wide variety of cell types, indicating that their pluripotency was
similar to EC cells (Martin, 1981). The cells self-renewed indefinitely in culture when
grown on mitotically inactivated embryonic fibroblasts, or feeder cells, which were
thought to provide exogenous factors that maintained their capacity to proliferate in a
pluripotent state (Keller, 2005). The remarkable identification of ES cells presented
researchers with a tool to create transgenic models for mouse development and a
challenge to identify a similar ES cell population from human embryos.
It was not until 1998 that scientists were first able to isolate human ES cells from
the blastocyst, an achievement that has tremendous implications for therapeutic medicine
and modeling human development since there are a multitude of differences between
mouse and human ES cells (Thomson et al., 1998). An obvious challenge to the isolation
of human ES cells was that the simple assay for pluripotency, which tests the capacity to
contribute to germline and somatic chimerism, cannot be applied in humans (Smith,
2001). While there is now ample evidence that human ES cells can seed
teratocarcinomas in mice and differentiate into multiple lineages in vitro (Amit et al.,
2000; Itskovitz-Eldor et al., 2000; Reubinoff et al., 2000), it cannot be demonstrated that
the cells can contribute to all cell types in a chimera. Additionally, there are known
differences between the behavior of mouse and human ES cells (Pera and Trounson,
2004). Mouse ES cells grow in cohesive, rounded colonies while human ES cells flatten
out and grow in less cohesive colonies (Friel et al., 2005). Also, for reasons that are not
entirely clear, human ES cells grow more slowly and are more difficult to passage than
mouse ES cells. Interestingly, while mouse ES cell lines are incapable of differentiating
into trophectoderm, human ES cell lines can (Boiani and Scholer, 2005; Friel et al.,
2005). This observation, as well as the observation that the exogenous requirements for
molecules like LIF and bFGF differ between the two species (Pera and Trounson, 2004),
suggests that mouse ES cells may have limited utility for modeling human development.
For this reason, great effort has been applied to improving the culture and manipulation
of human ES cells (Andrews, 2006; Pera, 2001; Pera and Trounson, 2004; Pyle, 2006).
The isolation of ES cells from humans is subject to careful consideration and
limitations on research due to the ethical implications of manipulating human embryos
(Mendiola, 1999; Murry and Keller, 2008; Pera, 2001; Pera et al., 2001). A key criticism
of human ES cell experimentation is that these cells are derived from human embryos.
Some scientists have argued that these cells are not capable of growing into human
embryos (Meyer, 2000; Pera, 2001). Nonetheless, the issue of the source for human ES
cells has remained an ethical challenge for scientists. The principle source for human ES
cells is surplus human embryos created by in vitro fertilization for fertility clinics (Meyer,
2000; Thomson et al., 1998). Currently, a large amount of effort is aimed at
reprogramming somatic adult cells to become pluripotent cells that can be manipulated
for therapeutic purposes with fewer ethical issues (Lewitzky and Yamanaka, 2007).
While the functional qualities of ES cells make them ideal candidates for therapeutic
development, these ethical issues will continue to be present throughout this effort.
Embryonic stem cells are defined by a number of unique qualities, one of which is
their capacity for self-renewal. While their pluripotent counterparts, EC cells, are also
capable of self-renewal in culture, these cells are also karyotypically abnormal (Evans
and Kaufman, 1981). In fact, most primary cell lines can only be passaged several times
before they senesce (Smith, 2001). The ability for ES cells to proliferate in culture while
retaining normal karyotypes has been demonstrated for both mouse and human ES cells
for more than 100 passages (Keller, 2005). A key factor driving the self-renewal of
embryonic stem cells is their maintained expression of the telomerase gene TERT
(Armstrong et al., 2005; Hiyama, 2007). In fact, TERT overexpression in mouse ES cells
leads to increased proliferation in culture (Armstrong et al., 2005), and TERT is
downregulated and telomerase activity is reduced upon differentiation of human ES cells
(Tzukerman, 2000).
A second defining feature of embryonic stem cells is their pluripotency, or
capacity to generate all cell types of the adult organism. This aspect of ES cells is key to
their therapeutic potential and utility as a model for development. As described
previously, pluripotency was a quality first observed in EC cells isolated from
teratocarcinomas (Finch and Ephrussi, 1967). The quintessential indicator of
pluripotency is for the ES cells to contribute to all tissues in a chimeric animal. This was
demonstrated for mouse ES cells shortly after their original isolation (Bradley et al.,
1984). Mouse ES cells can contribute to all fetal lineages, yolk sac mesoderm, allanois
and amnion, though they do not contribute to trophoblast (Beddington and Robertson,
1989; Bradley et al., 1984). Determining the potency of human ES cells is made more
difficult by the impossibility of determining if cultured human ES cells can contribute to
somatic and germ-line chimerism (Smith, 2001). Moreover, this observation would not
get at the heart of the therapeutic value of these cells: their potential to be cultivated to
give rise to specific cell lineages or tissue types for use in regenerative medicine (Murry
and Keller, 2008). Alternative assays for pluripotency, such as embryoid body formation,
have confirmed the capacity of human ES cells to give rise to all cell types in the adult
organism (Iskovitz-Eldor et al, 2000). Embryoid bodies are multicellular aggregates of
ES cells that form in suspension culture and contain cells of various lineages (Pera,
2001). Embryoid bodies formed from human ES cells stain for markers of mesoderm,
endoderm and ectoderm, indicating that human ES cells can give rise to all three germ
cell layers.
Other qualities that have defined pluripotent cells, such as their origin in the ICM
and the absence of X inactivation, are becoming less pertinent as it becomes possible to
reprogram somatic cells into pluripotent cells that resemble ES cells (Smith, 2001;
Takahashi and Yamanaka, 2006). In recent years somatic cells have been converted to
pluripotent cells. This remarkable achievement has the potential to enable pluripotent
cells derived from a somatic origin to be used for therapies rather than embryo-derived
ES cells. In 2006 Takahashi and Yamanaka reported that four factors, Oct4, Sox2, c-Myc
and Klf4, were capable of reprogramming mouse fibroblasts to adopt a pluripotent, ES
cell-like identity. This landmark paper dramatically advanced the field of reprogramming
of somatic cells, and a number of studies in the past two years have reported success with
reprogramming differentiated cells to adopt an induced pluripotent state (iPS) (Aoi et al.,
2008; Nakagawa et al., 2008; Park et al., 2008; Takahashi et al., 2007; Wernig et al.,
2007; Yu et al., 2007). These important studies suggest that in the future human
pluripotent stem cells may be able to be derived from sources other than human embryos.
It also paves the way for personalized medical treatments, such that therapeutic cell types
may be created for patients from their own sample tissue.
Applications of ES cells
Perhaps the most revolutionary application of ES cells to date has been the
development of transgenic mice from genetically modified mouse ES cells. In fact, for
contributing to the production of transgenic mice through the isolation of mouse ES cells,
Martin Evans was awarded the Nobel Prize in Medicine in 2007 (Bradley et al., 1984).
ES cells are capable of integrating into an embryo and producing viable chimeras (Smith,
2001). Moreover, ES cells have a diploid karyotype that is necessary for meiosis and so
if they contribute to the germ line lineage in the chimera, they generate functional
gametes (Smith, 2001). The ability to introduce alterations to the genome of mouse ES
cells through homologous recombination and to create mice from these cells transformed
developmental biology by enabling scientists to use whole animal genetics to understand
gene function (Wobus and Boheler, 2005).
A second application of ES cells is their capacity to undergo directed
differentiation in culture, which has enabled scientists to model specific events of early
embryonic development through controlled differentiation experiments with ES cells.
The default differentiation pathway of both mouse and human ES cells is believed to be
neural (Evans and Kaufman, 1981). ES cells can be induced to differentiate in vitro
through a number of strategies (Keller, 2005; Murry and Keller, 2008). Embryoid bodies
can be formed from both mouse and human ES cells, which creates a heterogeneous
aggregate of cell types (Doetschman et al., 1985; Evans and Kaufman, 198 1; Itskovitz-
Eldor et al., 2000). A second strategy involves growing the ES cells on a supportive
layer of stromal cells that signal the ES cells to differentiate, which has been used to
generate lymphohematopoietic cells from ES cells (Nakano et al., 1994). This strategy
can be used to induce highly specific differentiation programs by using stromal cells that
express specific signaling molecules. For example, OP9 cells expressing the Notch
ligand Delta-like I are capable of inducing ES cell differentiation into competent T cells
(Schmitt et al., 2004). ES cells can also be stimulated to differentiate through the
addition of exogenous factors such as extracellular matrix proteins or soluble signaling
molecules (Cerdan et al., 2004; Laflamme et al., 2007; Nishikawa et al., 1998; Yao et al.,
2006). Finally, genetic manipulation has been used to stimulate the differentiation of ES
cells down specific lineages. Induction of Pax3 in mouse ES cell lines promotes
myogenesis and the development of functional muscle progenitors (Darabi et al., 2008).
The success of directing differentiation of ES cells in vitro has been encouraging for
those who believe that ES cells hold great therapeutic value in regenerative medicine.
Nonetheless, an improved knowledge of the regulatory circuitry that controls
pluripotency and differentiation would better facilitate directed differentiation of ES
cells.
While the above two applications of ES cells have already had considerable
impact, these cells' capacity to revolutionize human medicine is yet to be fully developed
for a number of reasons, including both technical and clinical obstacles. Several
challenges make it uniquely difficult to manipulate human ES cells. First, these cells
grow slowly and tend to spontaneously differentiate, making culture and manipulation of
the cells difficult. Secondly, genetic modification of human ES cells is very difficult
because of the inability to clone human ES cells (Trounson, 2006). Nonetheless, culture
conditions for ES cells are improving and DNA has been introduced into the human ES
cell genome through conventional transduction and lentiviral strategies (Eiges et al.,
2001; Gropp et al., 2003; Ma et al., 2003). Additionally, methods to introduce transgenes
through homologous recombination have been demonstrated (Zwaka and Thomson,
2003). These advances will make the manipulation of human ES cells considerably
easier. As studies in mouse and human ES cells begin to reveal factors that induce
differentiation down specific lineages and unique markers for differentiated cells,
manipulations of human ES cells towards particular lineages will become easier.
Nonetheless, a number of clinical concerns will also need to be resolved before ES cell-
based therapies will become feasible. These include risk of tumor formation, purity,
insufficient graft size and immune rejection (Murry and Keller, 2008). Differentiated ES
cells are unlikely to compose pure populations, and any remaining pluripotent cells could
form teratocarcinomas upon transplant. This was a problem in the transplant of ES cell-
derived skeletal muscle progenitors to dystrophic mice and was resolved by FACS
isolation for cells expressing markers of skeletal muscle (Darabi et al., 2008). Issues of
graft size and immune rejection have not yet been explored and will be significant
challenges to the use of ES cell-derived therapeutic cells. The latter concern could be
resolved by using reprogrammed somatic cells derived from the recipient patient as the
source of pluripotent cells, though this has not yet been demonstrated.
Studies in mice have indicated that ES cells can be differentiated in vitro and
reconstitute tissues or systems in the adult organism. As described, Darabi and
colleagues demonstrated that skeletal muscle progenitors differentiated from mouse ES
cells are capable of forming functional myofibers in dystrophic mice (Darabi et al.,
2008). This study demonstrates the great potential that ES cells may play in treating
muscular dystrophy. A second study recently demonstrated that pluripotent cells may
have significant therapeutic potential in treating sickle cell anemia (Hanna et al., 2007).
Here, the authors converted induced pluripotent stem (iPS) cells to hematopoietic
progenitors after correcting the human sickle cell hemoglobin by gene-specific targeting.
Remarkably, a sickle cell anemia mouse model was rescued after transplantation with
these hematopoietic progenitors. While this study did not use ES cells as the source for
the differentiated cell type, they used a pluripotent cell type (iPS) that was developed to
function like an ES cell. Recent work has also indicated that dopaminergic neurons can
be generated from primate and, most recently, human ES cells (Cho et al., 2008; Takagi
et al., 2005). These two studies used ES cells to generate neurospheres, which are
composed of neural progenitors, and transplanted these cells into parkinsonian rat or
monkey models to demonstrate that they can produce viable dopaminergic neurons in
vivo. These initial studies that use pluripotent cells to produce therapeutically viable
cells in vivo reinforces the hope that ES cells may have tremendous clinical significance
for a number of diseases.
Molecular Characterization of ES Cells
Tremendous effort has been applied to define the molecular factors that govern
ES cell identity. Characterization of genes expressed uniquely in ES cells has facilitated
both an improved understanding of the regulation of ES cells and the manipulation of
differentiated cell types to adopt a pluripotent state (Yamanaka, 2007). These factors
include transcription factors, chromatin regulators and signaling pathway components. I
will now review the large number of studies that have elucidated the roles of these
factors, indicating their critical contributions to ES cell pluripotency and self-renewal
(Boiani and Scholer, 2005).
Transcription Factors
Perhaps the best characterized transcription factor associated with ES cell identity
is the POU-domain transcription factor Oct4, which has been demonstrated to be a master
regulator of ES cell state. This protein is expressed by all pluripotent cells during mouse
embryogenesis and also by undifferentiated ES and EC cell lines of both mouse and
human (Okamoto et al, 1990; Rosner et al., 1990; Scholer et al., 1989a; Scholer et al.,
1989b). Oct4 is downregulated in differentiated tissues relative to pluripotent ES cells
(Brandenberger et al., 2004; Yeom et al., 1996), suggesting it plays a critical role in
pluripotency. In fact, Oct4 is essential for the formation of stem cells during
embryogenesis (Nichols et al., 1998). Mice deficient for Oct4 develop until the
blastocyst stage, but lack pluripotent cells in the ICM. In the absence of Oct4, ICM cells
differentiate along the extraembryonic trophoblast lineage. A separate study
demonstrated that depletion of Oct4 in mouse ES cells induces trophectoderm
differentiation (Velkey and O'Shea, 2003). Its essential role has also been shown for
human ES cells (Matin et al., 2004; Velkey et al., 2003). In the case of mouse ES cells, it
has also been shown that upregulation of Oct4 can cause differentiation into primitive
endoderm and mesoderm (Miwa et al., 2000). Despite the necessary contribution of Oct4
for pluripotency, the transcription factor is not sufficient for pluripotency since mouse ES
cells that constitutively express Oct4 will differentiate in the absence of LIF (Niwa et al.,
2000). Nonetheless, recent efforts to reprogram fibroblasts have shown that expression
of Oct4 in differentiated cells can help drive the cell towards a pluripotent state
(Takahashi and Yamanaka, 2006). Taken together, these studies indicate that Oct4 is a
pluripotency regulator since it can be characterized as a master regulator of the initiation
and maintenance of pluripotency (Niwa, 2001).
The exact mechanism by which Oct4 regulates its target genes is not yet clear,
though much is known about the proteins and DNA sequences with which it interacts.
Oct4 encodes a homeodomain-containing protein that is capable of binding DNA at
'octamer' sequences found throughout the mammalian genome (Boiani and Scholer,
2005). Its DNA-binding domain, or POU domain, is conserved within the POU
transcription factor family and consists of two structurally independent subdomains
joined by a linker. Depending on adjacent flanking sequences and binding targets, Oct4
can act to either repress or activate target genes (Boiani and Scholer, 2005; Friel et al.,
2005). Some of the earliest known binding targets for Oct4, such as Fgf4, Utf-1,
PDGFaR and Rexl, include genes that show stem cell-specific expression (Ben-Shushan
et al., 1998; Kraft et al., 1996; Nishimoto et al., 1999; Niwa, 2001; Yuan et al., 1995).
Oct4 has both amino-terminal and carboxy-terminal transactivation domains, which are
thought to share redundant functions such that one of them is sufficient to function with
the POU domain to maintain self-renewal (Niwa, 2001; Okamoto et al., 1990; Rosner et
al., 1990; Scholer et al., 1990a). A number of cofactors have been reported to associate
with Oct4. One of the first characterized cofactors is the adenoviral protein EIA, which
is thought to serve as a bridging factor between Oct4 and the basic transcriptional
machinery (Scholer et al., 1991). A very important cofactor whose association with Oct4
is highly characterized is the Sry-related factor Sox-2, a protein that is highly expressed
in the early embryo (Botquin et al., 1998).
Sox2 has been shown to cooperate with Oct4 to regulate target genes and
contribute to pluripotency and is therefore characterized as a pluripotency regulator.
Sox2 is an HMG-domain transcription factor that forms a complex with Oct4 (Boiani and
Scholer, 2005). Expression of Sox proteins is highly specific for different cell types at
different stages during animal development (Dailey and Basilico, 2001). While Sox2 is
expressed in the early embryo, its expression is not restricted to pluripotent cells, and it
can be detected in neural stem cells (Avilion et al., 2003). Mice lacking Sox2 have
defective epiblast and extraembryonic ectoderm, though it has been suggested that earlier
defects are avoided because of maternal stores of the protein. ES cells lacking Sox2 fail
to self-renew. Numerous studies have shown that Octamer binding and Sox factors
collaborate to potentiate transcriptional activation at specific subsets of genes
(Ambrosetti et al., 1997; Ambrosetti et al., 2000; Dailey and Basilico, 2001). This co-
occupancy was originally observed for the Octamer binding protein Oct2 (Zwilling et al.,
1995). It was known that POU domain proteins collaborate with other factors to regulate
transcription, and putative partners of Oct2 were identified through a mouse cDNA
screen. HMG2 was isolated using this method and shown to interact with the
homeodomain portion of the Oct2 POU domain through its HMG domain. This
interaction was demonstrated for a number of HMG and homeodomain proteins,
suggesting that the homeodomain of POU proteins preferentially interacts with HMG
proteins. It was later shown that Oct4 and Sox2 form a regulatory complex at the
promoters of target genes (Nishimoto et al., 1999; Remenyi et al., 2003; Yuan et al.,
1995). Interestingly, Sox2 can complex with either Octl or Oct4, but only the Sox2/Oct4
complex is able to promote transcriptional activation. These studies indicate that Sox2 is
a necessary cofactor for Oct4 in the regulation of gene expression in ES cells and can be
characterized as a pluripotency regulator.
A third transcription factor that plays a key role in ES cells and is classified as a
pluripotency regulator is the homeodomain protein Nanog (Chambers et al., 2003; Mitsui
et al., 2003). This factor was identified because its differential expression pattern was
similar to Oct4, and it is upregulated in pluripotent cells and downregulated in
differentiated tissues. Overexpression and gene disruption studies showed that Nanog is
required for maintenance of pluripotency in the mouse epiblast and in ES cells.
Overexpression of Nanog maintains mouse ES cells in their undifferentiated state
independent of LIF. Disruption of Nanog in ES cells results in differentiation into
extraembryonic endoderm. Nanog has a well conserved homeodomain, but the
remainder of the protein has no known homology to other characterized proteins (Pan and
Pei, 2003). Fusion of N- and C-terminal regions of Nanog to the Gal4 DNA binding
domain revealed that each of these regions possesses a potent transactivation domain
(Pan and Pei, 2003). Mass spectrometry and coimmunoprecipitations suggest that Nanog
biochemically interacts with Oct4 (Wang et al., 2006; Zhang et al., 2007). It has recently
been reported that Nanog expression fluctuates in ES cell populations, resulting in
heterogeneous expression (Chambers et al., 2007; Singh et al., 2007). Moreover, ES cells
can be maintained even upon disruption of Nanog, though the cells are predisposed
towards differentiation (Chambers et al., 2007). This same group reported that germ cell
formation is prevented in the absence of Nanog, suggesting that Nanog is dispensable for
pluripotency in somatic cells but required for pluripotency in germ cells. It is possible
that Nanog plays a critical role in balancing ES cells between pluripotency and
differentiation. However, given its critical role in maintaining pluripotency, Nanog is
considered a pluripotency regulator.
It is clear that, in addition to these pluripotency regulators, there exist a number of
other transcription factors that play key roles in pluripotency and self-renewal. For
example, the transcription factor FoxD3 has been shown to be required for early
embryonic development, and ES cells cannot be derived from mice deficient for this
factor (Hanna et al., 2002). Zic3, a zinc finger transcription factor, is highly expressed in
pluripotent cells and downregulated upon differentiation (Lim et al., 2007). Depletion of
Zic3 leads to reduction of Nanog protein, and Zic3 is also directly regulated by the
pluripotency regulators Oct4, Sox2 and Nanog. This suggests that Zic3 plays a critical
role in regulating pluripotency. The homeodomain containing protein Pem is also
important for maintaining pluripotency, and forced expression of Pem blocks
differentiation of ES cells (Fan et al., 1999). Pem is expressed in the preimplantation
embryo and undergoes lineage restriction upon implantation, similar to the pluripotency
regulator Sox2. The zinc finger transcription factor Klf4 also promotes pluripotency of
ES cells (Li et al., 2005; Nakatake et al., 2006). It is likely that in addition to FoxD3,
Zic3, Pem and Klf4, other transcription factors help maintain the expression state that is
important for pluripotency and self-renewal in ES cells. Recent studies reprogramming
somatic cells towards a pluripotent state have demonstrated that in addition to Oct4,
Sox2, Nanog and Klf4, c-myc and LIN28 are also capable of promoting pluripotency in
somatic cells (Takahashi and Yamanaka, 2006; Takahashi et al., 2007; Yu et al., 2007).
In addition to these putative pluripotency regulators, a number of transcription factors
have been shown to be able to induce differentiation of ES cells towards a specific
lineage, including GATA6 and Cdx2 (Boiani and Scholer, 2005). Given the large set of
transcription factors that can positively and negatively regulate ES cell identity, it is clear
that there is a unique gene expression program that must be maintained for ES cells to
remain pluripotent and be capable of self-renewal. Further characterization of the role of
these additional factors in ES cells will help to clarify how these factors contribute to the
gene expression program to influence pluripotency.
An important consideration when seeking to understand the role of the pluripotency
regulators in initiating and maintaining ES cell identity is how these factors are
themselves regulated. Early analyses of the 5' flanking sequence for the genes encoding
Oct4, Sox2 and Nanog revealed a high degree of regulation by one another (Catena et al.,
2004; Kuroda et al., 2005; Okumura-Nakanishi et al., 2005; Rodda et al., 2005). It has
also been shown that p53 is able to bind and downregulate the Nanog gene (Lin et al.,
2005) and that exposure to retinol (Vitamin A) leads to increased Nanog expression
(Chen et al., 2007). The cancer-associated factor Tpt I is capable of activating Oct4 and
Nanog, and premature increases in levels of Tptl in oocytes leads to earlier activation of
Oct4 (Koziol et al., 2007). PI3K signaling has been shown to be required for efficient
self-renewal of ES cells and is known to maintain expression of Nanog (Storm et al.,
2007). Interestingly, aggregation of ES cells has been shown to repress Nanog, which
may be indicative of a mechanism used by the embryo to repress Nanog upon blastocyst
growth (Hamazaki et al., 2004). A complete understanding of the mechanisms used to
control expression of the pluripotency regulators will reveal how a pluripotent state is
initiated and maintained, which will enhance our capacity to reprogram differentiated
cells towards a pluripotent state.
In summary, a number of the transcription factors that regulate ES cell identity have
been identified. Genetic and biochemical evidence indicates that these factors impact the
ES cell transcriptome to either maintain pluripotency or direct differentiation. An
important approach to characterizing the role of these factors in ES cells is to identify
their complete set of downstream target genes. By clarifying which sets of genes are
regulated by these factors, it will be possible to better understand how they modulate the
ES expression program in order to govern ES cell identity. Additional components
regulating transcription factor expression and ES cell identity, such as chromatin
regulators and signaling pathways, will now be discussed.
Chromatin Regulators
When considering the mechanisms used to modulate transcriptional programs during
development, it is necessary to consider the effect that chromatin structure has on gene
expression. Chromatin consists of the complex of DNA and packaging histone proteins
that allow the entire genome to compact and organize within the nucleus. Chromatin is
organized into higher order structures to regulate transcription (Li et al., 2007; Misteli,
2007). A number of modifications of chromatin can occur in the mammalian genome,
including phosphorylation, sumolation, ubiquitination, acetylation and methylation, and
the exact location of these modifications relative to a gene influences the effect of the
modification. These modifications are thought to modulate chromatin through their
effect on higher order chromatin structure or by recruiting factors that bind to specific
modifications on the chromatin template (Berger, 2007). In some cases these marks are
known to mediate binding by specific factors. Methylated lysines are recognized by
chromodomains (Bannister et al., 2001), and heterochromatin-like protein I (HPI)
associates with methylated histones through its chromodomain (Lachner et al., 2001).
Alternatively, some modifications are simply associated with activation or repression.
For example, histone acetylation is typically considered an activating mark while DNA
methylation is often repressive. Nonetheless, the putative activating trimethylation of
lysine 4 on histone H3 has recently been demonstrated to be associated with both silent
and transcribed genes, revealing that a mark may not be associated with exclusively
active or repressed genes (Guenther et al., 2007). Though our understanding of
chromatin modifications is constantly evolving, it is clear that chromatin modifications
affect gene expression. Therefore, these modifications have been explored as part of an
effort to understand how the ES cell genome is regulated.
Epigenetic modifications are carefully regulated in the developing embryo and ES
cells (Bibikova et al., 2008; Jaenisch and Bird, 2003). The term epigenetics has been
applied to explain the chromatin-based heritable changes that do not reflect DNA
sequence (Bird, 2002). Much effort has been applied to understanding the role of
epigenetic gene regulation during early embryonic development, and has revealed that
epigenetic modifications contribute to stable expression states in proliferating cells
(Bantignies and Cavalli, 2006; Bird, 2002; Niwa, 2007; Orlando, 2003; Sasaki and
Matsui, 2008). Epigenetic changes during development are precisely coordinated.
Chromatin modifications are essential for pluripotency, and epigenetic marks on somatic
cells must be reprogrammed to enable a pluripotent state. During embryonic
development, genome-wide demethylation during cleavage is followed by genome-wide
de novo methylation upon implantation (Jaenisch and Bird, 2003). This could explain
why cloning by nuclear transfer frequently fails (Jaenisch and Bird, 2003). It is thought
that nuclear reprogramming of epigenetic marks takes place during germ cell
development leading to the epigenetic state of a zygote as one with the capacity to
generate into any cell type. This epigenetic state is maintained in ES cells in order to
allow these cells to be pluripotent and self-renew. While the complete set of chromatin
modifications that distinguishes a pluripotent cell from a differentiated somatic cell are
unknown, the epigenetic signature of ES cells is beginning to be defined (Bernstein et al.,
2007; Bibikova et al., 2006; Fulka et al., 2008; Nishino et al., 2006).
Polycomb group proteins (PcG) were originally identified for their role during
Drosophila development in suppressing Hox gene expression (Orlando and Paro, 1995),
and are also implicated in regulating pluripotent cells in the early embryo and ES cells
(Faust et al., 1998; O'Carroll et al., 2001; Pasini et al., 2004). Polycomb proteins exist in
one of two complexes (Bantignies and Cavalli, 2006). Polycomb Repressive Complex 2
(PRC2) is composed of Ezh2, Suz 12 and Eed (Kuzmichev et al., 2004; Kuzmichev et al.,
2005). Ezh2 is capable of trimethylation of lysine 27 of histone H3. Polycomb
Repressive Complex I (PRCI) is composed of PC, PH, pSC and dRING. Embryos
deficient for Eed, Ezh2, and Suzl2 all display severe defects during gastrulation (Faust et
al., 1998; O'Carroll et al., 2001; Pasini et al., 2004). ES cell lines cannot be established
from Ezh2-deficient blastocysts, indicating that PRC2 is important for pluripotency and
self-renewal (O'Carroll et al., 2001). Interestingly, Eed and Suzl2 deficient ES cells can
be derived and expanded in culture (Montgomery et al., 2005; Pasini et al., 2007). The
PRC2 component Suzl2 has also been shown to be important for differentiation (Pasini
et al., 2007). Therefore, PRC2 components may have independent functions within ES
cells that are distinct from the H3K27 trimethylation mark that this complex deposits on
the chromatin template. Nonetheless, each of the PRC2 components plays a key role in
early embryogenesis and is thought to contribute to the unique epigenetic state that
mediates pluripotency and self-renewal in ES cells. Given Polycomb proteins' critical
role in repressing Hox genes during differentiation in Drosophila, it is possible that genes
associated with differentiation are repressed by PRC2 in ES cells. In order to more fully
understand the mechanisms that chromatin regulators use to regulate the ES cell
transcriptional program, it is important to identify the downstream targets of these
factors.
Chromatin modifications have been shown to regulate the expression of the
pluripotency regulators (Hattori et al., 2004; Hattori et al., 2007). The promoter of the
Oct4 gene contains hypomethylated DNA and acetylated histones in undifferentiated ES
cells (Hattori et al., 2004). Trophoblast stem (TS) cells do not normally express Oct4,
and the Oct4 promoter is hypermethylated in these cells. Treatment with an inhibitor of
DNA methylation leads to upregulation of Oct4. An inhibitor of histone deacetylase also
leads to upregulation of Oct4, indicating that both DNA methylation and hypoacetylation
are responsible for repressing Oct4 in differentiated cell types. The Nanog promoter also
displays DNA hypomethylation and histone acetylation in ES cells (Hattori et al., 2007).
Like the promoter of Oct4, the Nanog promoter is heavily methylated in TS cells. The
Nanog promoter is acetylated and displays H3K4 hypermethylation in ES cells, and all of
these marks are lost in TS cells. TS cells display H3K9 and H3K27 hypermethylation at
the Nanog promoter, a mark not observed on the Oct4 promoter in TS cells.
Cumulatively, these results indicate that chromatin structure is an important and
functional mechanism used by the cell to silence the pluripotency regulators upon
differentiation.
In summary, genetic and biochemical evidence indicates that chromatin
modifications are important for ES cell viability and carefully controlled during
development. Chromatin regulators and their downstream modifications govern the
expression of pluripotency regulators in ES cells. Chromatin modifications are also
likely to modify many additional genes to direct ES cell identity. An important approach
to characterizing the role of chromatin regulators in ES cells is to identify their genomic
targets. By clarifying which sets of genes are targeted by these regulators, it will be
possible to better understand how they impact the ES cell expression program in order to
control ES cell identity.
Signaling Pathways
A final aspect of molecular regulation of ES cells is mediated through external
signaling pathways. External signals can promote ES cell pluripotency or cause these
cells to differentiate. These signals are produced by the stem cell niche in the developing
blastocyst or, for cultured ES cells, can be produced by added factors or serum to
maintain stem cell identity or promote differentiation (Li and Xie, 2005; Moore and
Lemischka, 2006). For example, the IL-6 family cytokine leukemia inhibitory factor
(LIF) that signals via gp130 and the LIF receptor (LIFR) is essential for the maintenance
of mouse ES cells (Okita and Yamanaka, 2006; Smith et al., 1988; Williams et al., 1988).
Other signal transduction pathways are also known to play essential roles in regulating
the transcriptional response to external signals in ES cells. Recent studies have
demonstrated that activation of the Wnt and Activin/Nodal signaling pathways promote
pluripotency and self-renewal (Beattie et al., 2005; Sato et al., 2004; Valdimarsdottir and
Mummery, 2005), while Notch and BMP4 activation promote differentiation (Lowell et
al., 2006; Ying et al., 2003). These signaling pathways, and others discussed below,
influence the gene expression program of ES cells in order to affect ES cell identity. A
comprehensive understanding of how signaling pathways regulate the genomic
expression state and interact in combination will provide important clues to the means by
which cell fate can be manipulated and facilitate new therapeutic approaches in
regenerative medicine.
The first characterized signaling pathway associated with ES cells is the LIF/Stat3
signaling pathway, which is essential for mouse ES cell maintenance but dispensable for
the maintenance of human ES cells. The signaling ligand, LIF, was demonstrated to be
the molecule conferring the need to grow mouse ES cells on a mitotically inactivated
mouse MEF feeder population (Smith et al., 1988; Williams et al., 1988). LIF signals
through binding to a heterodimeric receptor consisting of LIFR and gp 130 (Okita and
Yamanaka, 2006). Binding promotes activation of the JAK kinase, which phosphorylates
gpl30 and LIFR causing recruitment of STAT3. STAT3 is then phosphorylated by JAK
kinase, homodimerizes and translocates to the nucleus to act as a transcription factor.
Constitutive activation of STAT3 replaces the need for LIF in culture in the presence of
serum (Matsuda et al., 1999). STAT3 is known to regulate the transcription factor Myc,
and constitutive Myc expression replaces the need for LIF (Cartwright et al., 2005). The
connection between LIF/gpl30 signaling and Myc represents an elegant example of
external signals connecting directly to key transcription factors that regulate pluripotency
and self-renewal. Nonetheless, the need for serum during culture of mouse ES cells in
the presence of recombinant LIF implies that additional signaling molecules are
important for maintenance of pluripotency and self-renewal and directing gene
expression.
Bone morphogenetic proteins (BMP) are known to influence the maintenance of
ES cells in culture (Okita and Yamanaka, 2006). These proteins bind to type 1 and type 2
receptor tyrosine kinases and induce the heterodimerization of Smad transcription factors,
which translocate to the nucleus to regulate target gene expression. BMP4 has been
reported to cooperate with LIF in order to maintain mouse ES cells in culture (Ying et al.,
2003). LIF and BMP4 are sufficient to maintain ES cells grown without a mitotically
inactivated MEF feeder population and serum: BMP4 is known to signal through
activation of the inhibitor of differentiation (Id) genes, and overexpression of Id proteins
substitutes for BMP4 in culture. As in the case of LIF, the role of BMP4 is not conserved
between mouse and human, and BMP4 induces mesodermal and ectodermal
differentiation of human ES cells (Schuldiner et al., 2000). In contrast, inhibition of
BMP4 signaling in combination with bFGF leads to self-renewal in the absence of serum
or mitotically inactivated MEF feeder cells (Xu et al., 2005). BMP4, like LIF, has
distinct functions in human and mouse ES cells and serves as an important link between
the external environment and the transcriptional state of the ES cell.
The Wnt signaling pathway is a highly conserved pathway involved in development
and has been demonstrated to play a key role in ES cell identity (Wang and Wynshaw-
Boris, 2004). The canonical Wnt pathway activates 8-catenin, which translocates to the
nucleus and, in conjunction with TCF/LEF transcription factors, activates gene
expression (Giles, 2003). Both human and mouse embryonic stem cells are known to
express components of this pathway (Walsh and Andrews, 2003; Wang et al., 2004), and
MEF feeder cells express Wnt ligands (Sato et al., 2004). Human embryonic stem cells
treated with a drug that activates the canonical Wnt pathway remain undifferentiated in a
feeder-free system (Sato et al., 2004). Mouse embryonic stem cells have an active Wnt
pathway that is downregulated upon their differentiation (Sato et al., 2004) and cells with
activating mutations in the Wnt pathway show reduced differentiation potential and
remain undifferentiated longer than their wild type counterparts upon removal of self-
renewal medium (Kielman et al., 2002). Nonetheless, while numerous studies have
implicated Wnt signaling in the maintenance of ES cell identity (Hao et al., 2006;
Miyabayashi et al., 2007; Ogawa et al., 2006; Singla et al., 2006; Takao et al., 2007),
several studies have shown a role for Wnt signaling in differentiation (Lindsley et al.,
2006; Otero et al., 2004). This dual function of Wnt signaling in ES cells may be due to
crosstalk between Wnt signaling and other pathways that are active in ES cells under
different conditions (Okita and Yamanaka, 2006).
The Activin/Nodal signaling pathway has also been shown to contribute to
embryonic stem cell pluripotency (Valdimarsdottir and Mummery, 2005). Activin and
Nodal are part of the TGFB superfamily, which includes ligands that play critical roles in
a number of developmental processes. Activin/Nodal signaling through Smad2/3
activation and subsequent translocation to the nucleus is necessary to maintain expression
of Oct4 and Nanog, two key markers of pluripotency, in human ES cells (James et al.,
2005). Inhibition of this pathway induces differentiation and loss of Nanog and Oct4
expression. The role of Activin/Nodal in murine ES cells is less clear, but the pathway
appears to be active as phosphorylated Smad2/3 is observed in the nucleus. In blastocyst
outgrowths, Oct4 expression is lost upon treatment with an inhibitor of Activin/Nodal
signaling. Thus, it appears that this pathway contributes to pluripotency and self-renewal
in both human and mouse ES cells. However, while the importance of Activin/Nodal
signaling in ES cells has been demonstrated, it remains unclear how this signaling
pathway impacts specific genes to create gene expression programs that promote
pluripotency and self-renewal.
A number of other signaling pathways are also important for ES cell identity,
including PI3K and ERK (Burdon et al., 1999; Jirmanova et al., 2002; Paling et al.,
2004). Moreover, it is likely that these pathways function in combination with other
pathways, posing a challenge to researchers who are best equipped to study them in
isolation (Hayward et al., 2008; Hurlbut et al., 2007; Okita and Yamanaka, 2006;
Sundaram, 2005). For example, it is known that LIF induces signaling pathways that are
STAT3-independent. LIF activates the Ras/ERK signaling pathway through the effector
protein SHP2 (Schiemann et al., 1997). Myc has not only been shown to be a target of
the LIF signaling cascade, but it is also known to be degraded by GSK3[3, indicating that
Myc is regulated by both LIF and Wnt (Sears et al., 2000). Crosstalk between signaling
pathways explains why a ligand may promote a particular state under one set of
conditions and an alternative state under separate conditions. It will be important to
develop reagents and culture conditions that permit pathways to be studied both in
isolation and in combination. As ES cell culture conditions trend away from the use of
serum and mitotically inactivated MEF feeders, it will become simpler to assay the effect
of a particular signaling molecule (Adewumi et al., 2007; Bongso and Tan, 2005; Findikli
et al., 2006; Loring and Rao, 2006; Mannello and Tonti, 2007).
An important challenge to understanding how signaling pathways impact ES cell
identity is to identify the downstream transcriptional targets of these pathways. This
effort will involve defining the complete set of terminal components for each pathway
and the target genes that they regulate. This understanding will reveal the mechanisms
through which these pathways directly impact the ES cell transcriptional program to
modify cell state.
Transcriptional Regulatory Circuitry
Transcriptional regulatory circuitry describes the interactions between
transcriptional regulatory components, such as transcription factors, chromatin regulators
and terminal signaling components, and their target genes (Alon, 2007). This circuitry
can respond to biological inputs to alter gene expression programs and thereby governs
cell state. The goal of my thesis work has been to define the ES cell transcriptional
regulatory circuitry and reveal how this circuitry controls ES cell identity. This effort has
involved integrating the impact that transcription factors, chromatin regulators and
signaling pathways have on the ES cell transcriptome using genomics approaches. The
transcriptional regulatory circuitry that is produced from such an analysis is a model for
how the cell maintains a stable cell state but allows for adaptive changes, such as
differentiation, based on inputs from the environment (Figure 2).
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Figure 2. Model of transcriptional regulatory circuitry. Transcription factors, chromatin
regulators and signal transduction pathways collaborate to regulate the expression of
target genes and control cell state.
Thus, an understanding of the transcriptional regulatory circuitry will allow us to
understand the gene expression changes that enable an organism to execute coordinated
developmental events. Transcriptional regulatory circuitry provides the framework
through which cells can specify over 200 lineages from an identical mammalian genome
(Boiani and Scholer, 2005). These networks enable cells to generate complex organisms
from a single totipotent zygote. As pluripotent cells differentiate, they restrict their
potential. Yet, with the exception of plasma cells in the mammalian immune system, this
change in potential is not mediated by genomic changes (Alt et al., 1992). Rather, stable
expression states are defined by the transcriptional regulatory circuitry that governs the
cell and is modified throughout development (Ferrell, 2002). Jacob and Monod first
suggested that gene regulatory circuits are wired in order to maintain changes in cell state
during differentiation (Monod and Jacob, 1961). This assertion was precocious given the
limited understanding of eukaryotic gene regulation at that point. Nonetheless, it is
becoming clear that transcriptional networks are designed to create stable cell states that
can respond to inputs and are key to understanding cellular identity (Alon, 2007).
Analysis of transcriptional regulatory circuitry for a number of organisms has
revealed several network motifs that are conserved between species and play a functional
role in the regulation of cell state (Alon, 2007). Autoregulation involves a gene
regulating its own expression. This type of regulation can be positive or negative, with
the former characterized by rapid response and minimal cell-cell variation and the latter
displaying slow response time and enhanced cell-cell variation (Alon, 2007).
Mathematical and experimental modeling of the regulatory motifs confirms these
tendencies. Feedforward loops are an additional common regulatory motif that enable a
cell to modulate response time to a stimulus (Mangan et al., 2003; Mangan and Alon,
2003; Mangan et al., 2006; Alon, 2007). Feedforward loops involve two transcription
factors (X, Y) that regulate a shared gene target (Z) and X also regulates the gene
encoding Y (Figure 3)(Mangan et al., 2003). These loops come in two varieties, coherent
and incoherent, and can have positive or negative connections, such that there are 8 types
of feedforward loops (Mangan et al., 2003). These different types are used by cells when
response time to stimulation or loss of stimulation needs to be tightly controlled.
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Figure 3. Adapted from Alon, 2007. Eight types of feedforward loops (FFL) exist.
Coherent FFLs are such that the outcome of X signaling through Y to modify Z is
identical to the direct impact of X on Z. Incoherent FFLs have conflicting outputs when
X signals through Y compared to directly to Z.
Single-input modules are another type of regulatory mechanism used by cells. These
modules involve a single transcription factor regulating a large set of genes with a shared
function. This particular type of module is useful for inducing differentiation by
temporal expression changes at target genes. Each of the above mechanisms permits a
cell to respond to inputs with temporal and genetic specificity. Developmental regulatory
circuitry can also involve additional motifs, such as dense overlapping regulons, feedback
loops and transcription cascades, that allow for integrated and combinatorial signal
response (Alon, 2007). These mechanisms reveal the complex genetic structures that
cells have evolved to be able to adapt to changes in cell state induced by environmental
stimuli and differentiation. Defining the specific modules used by ES cells will reveal
the mechanisms by which cell state is balanced between pluripotency and differentiation.
A clear understanding of the transcriptional regulatory circuitry that governs ES
cell identity and pluripotency will also enable the manipulation of pluripotent cells for the
purposes of regenerative medicine (Boiani and Scholer, 2005). By clearly defining the
nature of the transcriptional circuitry that governs ES cells, it will be possible to perturb it
in a targeted way to induce specific differentiation programs. Models for transcriptional
regulatory circuitry provide for this in two ways. First, they reveal the regulatory motifs
that ES cells use to balance between pluripotency and differentiation. For example, if a
single-input module for Oct4 includes transcriptionally active genes encoding other
pluripotency regulators, then removal of Oct4 may induce silencing of these regulators to
permit differentiation. Alternatively, if Oct4 does not associate with the promoters of
pluripotency regulators, then disrupting its expression is less likely to effect their
expression. A second way the transcriptional regulatory circuitry is instructive for
reprogramming is by identifying molecular targets. Identification of the transcriptional
cascade that is downstream from Oct4 will reveal the set of genes whose regulation is key
for pluripotency and self-renewal. This will generate a set of testable hypotheses to
direct investigations of the role of Oct4 target genes in controlling ES cell identity.
Modulating these genes may allow for the induction of distinct genetic programs.
It is clear that a mechanistic and molecular understanding of the transcriptional
regulatory circuitry will afford scientists the tools necessary to manipulate pluripotent
cells for the purposes of regenerative medicine. Such manipulations have been
accomplished in some instances and reveal that pluripotent cells have empirically
demonstrated potential to be useful in human medicine for treatment of diseases such as
Parkinson's disease, sickle cell anemia and muscular dystrophy (Cho et al., 2008; Darabi
et al., 2008; Hanna et al., 2007; Redmond et al., 2007; Takagi et al., 2005). The
tremendous efforts to understand ES cell identity that are described in this chapter
indicate that we are fast approaching an era of regenerative medicine. The achievements
that have brought us to this threshold support James Thomson's original aspiration for
human ES cells-that they enable scientists to develop lifelong treatments for severe
human disease.
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My contributions to this work
The effort to profile transcription factors in human ES cells was initiated in the
summer of 2004, shortly after I joined the Young lab. I was involved in this collaborative
project from the beginning, participating in the many discussions during which we
evaluated the best factors and cell types to use for these genome-wide experiments.
Laurie Boyer's efforts to map binding events for the transcription factors Oct4, Sox2 and
Nanog in ES cells were chosen for these genome-wide experiments because of their
success experimentally and their value to the ES cell community. My contributions to
this project span from the experimental effort to the analysis and writing of the results.
My initial efforts were to help improve the technical aspects of the lab's ChIP-
chip protocol to adapt it for the purpose of genome-wide profiling of mammalian cells.
Towards this end, I helped to scale the experimental method to enable genome-wide
profiling of a key set of transcription factors in ES cells. I was a critical player in the
effort to obtain binding data for the three factors described in this chapter, from the initial
effort to amplify the material to hybridizing it to a set of microarrays representing
approximately 18,000 annotated human promoters.
Upon obtaining high-quality genome-wide binding data for Oct4, Sox2 and
Nanog, I was a key participant in analyzing these data. I was principally responsible for
inspecting binding plots to determine the parameters and quality of binding events for the
different ChIP samples, as well as their overlap. I also was responsible for generating
many of the figures in the paper. Since much of the writing advanced simultaneously
with the analysis, I was very involved with Laurie Boyer during the organizing and
editing stages of the manuscript.
Summary
The transcription factors Oct4, Sox2, and Nanog have essential roles in early
development and are required for the propagation of undifferentiated embryonic stem
(ES) cells in culture. To gain insights into transcriptional regulation of human ES cells,
we have identified Oct4, Sox2, and Nanog target genes using genome-scale location
analysis. We found, surprisingly, that Oct4, Sox2, and Nanog co-occupy a substantial
portion of their target genes. These target genes frequently encode transcription factors,
many of which are developmentally important homeodomain proteins. Our data also
indicates that Oct4, Sox2, and Nanog collaborate to form regulatory circuitry in ES cells
consisting of autoregulatory and feedforward loops. These results provide new insights
into the transcriptional regulation of stem cells and reveal how Oct4, Sox2, and Nanog
contribute to pluripotency and self-renewal.
Introduction
Mammalian development requires the specification of over 200 unique cell types
from a single totipotent cell. Embryonic stem (ES) cells are derived from the inner cell
mass (ICM) of the developing blastocyst and can be propagated in culture in an
undifferentiated state while maintaining the capacity to generate any cell type in the
body. As such, the recent derivation of human ES cells provides a unique opportunity to
study early development and is thought to hold great promise for regenerative medicine
(Pera and Trounson, 2004; Reubinoff et al., 2000; Thomson et al., 1998). An
understanding of the transcriptional regulatory circuitry that is responsible for
pluripotency and self-renewal in human ES cells is fundamental to understanding human
development and realizing the therapeutic potential of these cells.
Homeodomain transcription factors are evolutionarily conserved and play key
roles in cell fate specification in many organisms (Hombria and Lovegrove, 2003). Two
such factors, Oct4 and Nanog, are essential regulators of early development and ES cell
identity (Chambers et al., 2003; Hay et al., 2004; Matin et al., 2004; Mitsui et al., 2003;
Nichols et al., 1998; Zaehres et al., 2005). Several genetic studies in mouse suggest that
these regulators have distinct roles, but may function in related pathways to maintain the
developmental potential of these cells (Chambers, 2004). For example, disruption of
OCT4 and NANOG results in the inappropriate differentiation of ICM and ES cells to
trophectoderm and extra-embryonic endoderm, respectively (Chambers et al., 2003;
Mitsui et al., 2003; Nichols et al., 1998). However, functional over-expression of Oct4 in
ES cells leads to a phenotype that is similar to loss of Nanog function (Chambers et al.,
2003; Mitsui et al., 2003; Nichols et al., 1998; Niwa et al., 2000). Thus, knowledge of
the set of genes regulated by these two transcription factors might reveal why
manipulation of Oct4 and Nanog results in these phenotypic consequences.
Oct4 is known to interact with other transcription factors to activate and repress
gene expression in mouse ES cells (Pesce and Scholer, 2001). For example, Oct4, a
member of the POU (Pit/Oct/Unc) class of homeodomain proteins, can heterodimerize
with the HMG-box transcription factor, Sox2, to affect the expression of several genes in
mouse ES cells (Botquin et al., 1998; Nishimoto et al., 1999; Yuan et al., 1995). The
cooperative interaction of POU homeodomain and HMG factors is thought to be a
fundamental mechanism for the developmental control of gene expression (Dailey and
Basilico, 2001). The extent to which ES cell gene regulation is accomplished by Oct4
through an Oct4/Sox2 complex and whether Nanog has a role in this process is unknown.
Oct4, Sox2, and Nanog are thought to be central to the transcriptional regulatory
hierarchy that specifies ES cell identity because of their unique expression patterns and
their essential roles during early development (Avilion et al., 2003; Chambers et al.,
2003; Hart et al., 2004; Lee et al., 2004; Mitsui et al., 2003; Nichols et al., 1998; Sch6ler
et al., 1990). Studies in a broad range of eukaryotes have shown that transcriptional
regulators that have key roles in cellular processes frequently regulate other regulators
associated with that process (Guenther et al., 2005; Lee et al., 2002; Odom et al., 2004).
It is likely that the key stem cell regulators bind and regulate genes encoding other
transcriptional regulators, which in turn determine the developmental potential of these
cells, but we currently lack substantial knowledge of the regulatory circuitry of ES cells
and other vertebrate cells.
To further our understanding of the means by which Oct4, Sox2, and Nanog
control the pluripotency and self-renewal of human ES cells, we have used genome-scale
location analysis (chromatin immunoprecipitation coupled with DNA microarrays) to
identify the target genes of all three regulators in vivo. The results reveal that Oct4,
Sox2, and Nanog co-occupy the promoters of a large population of genes, that many of
these target genes encode developmentally important homeodomain transcription factors,
and that these regulators contribute to specialized regulatory circuits in ES cells.
Results and Discussion
Oct4 promoter occupancy in human ES cells
DNA sequences occupied by Oct4 in human H9 ES cells (NIH code WA09;
Appendix A) were identified in a replicate set of experiments using chromatin-
immunoprecipitation (ChIP) combined with DNA microarrays (Figure IA and Appendix
A). For this purpose, DNA microarrays were designed that contain 60-mer
oligonucleotide probes covering the region from -8kb to +2kb relative to the transcript
start sites for 17,917 annotated human genes. Although some transcription factors are
known to regulate genes from distances greater than 8kb, 98% of known binding sites for
human transcription factors occur within 8kb of target genes (Appendix A Figure S l).
The sites occupied by Oct4 were identified as peaks of ChIP-enriched DNA that span
closely neighboring probes (Figure IB). Oct4 was associated with 623 (3%) of the
promoter regions for known protein-coding genes and 5 (3%) of the promoters for known
miRNA genes in human ES cells (Appendix A Table S2).
Figure 1
2
0 2 21
C 215
Human embryonic
stem cells
Promoter Arrays Scatter plot Promoters bound by
400,000 features (ChiP/reference) Oct4
B
166484030 1634745C0
Chromosomal Position
GALNT3(pdp5IW6 N>y9
5
35L 
113717900 113727300
Chromosomal Position
KCNN2iKCNiN 'a,, y
SI I
3
7823130 73-1352
Chromosomal Position
NANOG
"i~
3
537376203 53741003
Chromosomal Position
DKKI666446 6
1466361681u~
8222JG-C 832943CO
Chromosomal Position
RASGRF2
re ts3 d6 2ý
5737120 57361500
Chromosomal Position
HOP
Odd 7,,6 1)
1J~
5!
Figure 1. Genome-wide ChIP-Chip in human embryonic stem cells.
A. DNA segments bound by transcriptional regulators were identified using chromatin-
immunoprecipitation (ChIP) and identified with DNA microarrays containing 60-mer
oligonucleotide probes covering the region from -8kb to +2kb for 17,917 annotated
transcription start sites for human genes. ES cell growth and quality control, ChIP
protocol, DNA microarray probe design and data analysis methods are described in detail
in Experimental Procedures and Appendix A.
B. Examples of Oct4 bound regions. Plots display unprocessed ChIP-enrichment ratios
for all probes within a genomic region. Genes are shown to scale below plots (exons and
introns are represented by thick vertical and horizontal lines, respectively), and the
genomic region represented is indicated beneath the plot. The transcription start site and
transcript direction are denoted by arrows.
Two lines of evidence suggested that this protein-DNA interaction dataset is of
high quality. First, the genes occupied by Oct4 in our analysis included many previously
identified or supposed target genes in mouse ES cells or genes whose transcripts are
highly enriched in ES cells, including POU5F1/OCT4, SOX2, NANOG, LEFTY2/EBAF,
CDX2, HANDI, DPPA4, GJAI/CONNEXIN43, FOXOIA, TDGFI and ZIC3 (Abeyta et
al., 2004; Brandenberger et al., 2004; Catena et al., 2004; Kuroda et al., 2005; Niwa,
2001; Okumura-Nakanishi et al., 2005; Rodda et al., 2005; Sato et al., 2003; Wei et al.,
2005) (Appendix A Table S2). Second, we have used improved protocols and DNA
microarray technology in these experiments (Appendix A) that should reduce false
positive rates relative to those obtained in previous genome-scale experiments (Odom et
al., 2004). By using this new technology with yeast transcription factors, where
considerable prior knowledge of transcription factor binding sites has been established,
we estimated that this platform has a false positive rate of <1% and a false negative rate
of 20% (Appendix A).
Oct4, Sox2, and Nanog co-occupy many target genes
We next identified protein-coding and miRNA genes targeted by the stem cell
regulators Sox2 and Nanog using location analysis. Sox2 and Nanog were found
associated with 1271 (7%) and 1687 (9%), respectively, of the promoter regions for
known protein-coding genes in human ES cells (Appendix A Table S2 - S4). It was
immediately evident that many of the target genes were shared by Oct4, Sox2, and Nanog
(Figure 2A). Examples of protein-coding genes that are co-occupied by the three
regulators are shown in Figure 2B (Appendix A Table S5). Control experiments showed
that the set of promoters bound by the cell cycle transcription factor E2F4 in these human
ES cells did not overlap substantially with those bound by the three stem cell regulators
(Appendix A Table S2 and S6). We found that Oct4, Sox2 and Nanog together occupy at
least 353 genes in human ES cells.
Previous studies have shown that Sox2 and Oct4 can interact cooperatively to
synergistically activate transcription of target genes in murine ES cells and that this
activity is dependent upon the juxtaposition of Oct4 and Sox2 binding sites (Ambrosetti
et al., 1997; Remenyi et al., 2004). Our results revealed that approximately half of the
genes occupied by Oct4 were also bound by Sox2 in human ES cells (Figure 2A;
Appendix A Table S2). It was surprising, however, to find that >90% of promoter
regions bound by both Oct4 and Sox2 were also occupied by Nanog. Furthermore, we
found that Oct4, Sox2, and Nanog binding sites occured in close proximity at nearly all
of the genes that they co-occupied (Figure 2C). These data suggest that Oct4, Sox2 and
Nanog function together to regulate a significant proportion of their target genes in
human ES cells.
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Figure 2. Oct4, Sox2 and Nanog target genes in human ES cells.
A. Venn diagram representing the overlap of Oct4, Sox2, and Nanog promoter bound
regions.
B. Representative examples of protein-coding genes co-occupied by Oct4, Sox2, and
Nanog. Plots display unprocessed ChIP enrichment ratios for all probes within a
genomic region. Genes are shown to scale relative to their chromosomal position. Exons
and introns are represented by thick vertical and horizontal lines, respectively. The start
and direction of transcription are denoted by arrows. Green, red, and purple lines
represent Nanog, Sox2, and Oct4 bound regions, respectively.
C. Oct4, Sox2, and Nanog bind in close proximity. The distances between the midpoint
of bound regions for pairs of transcription factors was calculated for the 353 regions
bound by all three transcription factors. Negative and positive values indicate whether
the first factor is upstream or downstream of the second factor in relation to the gene.
The frequency of different distances between the bound regions is plotted as a histogram.
A class of small non-coding RNAs known as microRNAs (miRNA) play vital
roles in gene regulation and recent studies indicate that more than a third of mammalian
protein-coding genes are conserved miRNA targets (Bartel, 2004; Lewis et al., 2005). ES
cells lacking the machinery that processes miRNA transcripts are unable to differentiate
(Kanellopoulou et al., 2005). Moreover, recent evidence indicates that microRNAs play
an important role in organismal development through regulation of gene expression
(Pasquinelli et al., 2005). Oct4, Sox2, and Nanog were found associated with 14 miRNA
genes and co-occupied the promoters of at least two miRNA genes, mir- 137 and mir-301
(Table 1). Our results suggest that miRNA genes which have been implicated in
developmental processes are likely regulated by Oct4, Sox2 and Nanog in human ES
cells and are important components of the transcriptional regulatory circuitry in these
cells.
Table 1. miRNA Loci Near Oct4, Sox2 and
Nanog Bound Regions
Transcription Factor
miRNA Oct4 Sox2 Nanog
mir-7-1 +
mir-10a +
mir-22 + +
mir-32 + +
mir-128a +
mir-135b + +
mir-137 + + +
mir-196a- +
mir-196b +
mir-204 + +
mir-205 + +
mir-301 + + +
mir-361 +
mir-448 +
Proximal binding of Oct4, Sox2 and Nanog to
miRNAs from the RFAM database.
Transcription factors bound are indicated by a
"r+".
ES cell transcription factors occupy active and inactive genes
Oct4 and Sox2 are known to be involved in both gene activation and repression in
vivo (Botquin et al., 1998; Nishimoto et al., 1999; Yuan et al., 1995), so we sought to
identify the transcriptional state of genes occupied by the stem cell regulators. To this
end, the set of genes bound by Oct4, Sox2, and Nanog were compared to gene expression
datasets generated from multiple ES cell lines (Abeyta et al., 2004; Brandenberger et al.,
2004; Sato et al., 2003; Wei et al., 2005) to identify transcriptionally active and inactive
genes (Appendix A Table S2). The results showed that one or more of the stem cell
transcription factors occupied 1303 actively transcribed genes and 957 inactive genes.
The importance of Oct4, Sox2, and Nanog for early development and ES cell
identity led us to focus additional analyses on the set of 353 genes that are co-occupied
by these regulators in human ES cells (Table S5). We first identified transcriptionally
active genes. Transcripts were consistently detected in ES cells for approximately half of
the genes co-bound by Oct4, Sox2, and Nanog. Among these active genes, several
encoding transcription factors (e.g. POU5FI/OCT4, SOX2, NANOG, STAT3, ZIC3) and
components of the Tgf-P3 (e.g. TDGFI, LEFTY2/EBAF) and Wnt (e.g. DKK I, FRAT2)
signaling pathways were notable targets. Recent studies have shown that Tgf-3 and Wnt
signaling play a role in pluripotency and self-renewal in both mouse and human ES cells
(James et al., 2005; Sato et al., 2004). These observations suggest that Oct4, Sox2, and
Nanog promote pluripotency and self-renewal through positive regulation of their own
genes and genes encoding components of these key signaling pathways.
Among transcriptionally inactive genes co-occupied by Oct4, Sox2, and Nanog,
we noted a striking enrichment for transcription factor genes (p<10-18; Appendix A Table
S7), many of which have been implicated in developmental processes. These included
genes that specify transcription factors important for differentiation into extra-embryonic,
endodermal, mesodermal, and ectodermal lineages (e.g. ESX 11, HOXB I, MEIS 1, PAX6,
LHX5, LBX1, MYF5, ONECUTI) (Appendix A Table S5). Moreover, nearly half of the
transcription factor genes that were bound by the three regulators and transcriptionally
inactive encoded developmentally important homeodomain proteins (Table 2). These
results demonstrate that Oct4, Sox2, and Nanog occupy a set of repressed genes that are
key to developmental processes.
Table 2. Examples of Inactive Homeodomain Genes Co-occupied by Oct4, Sox2,
and Nanog
Gene Symbol Entrez Gene Gene Name
AT-binding transcription factor I
distal-less homeo box 1
distal-less homeo box 4
distal-less homeo box 5
engrailed homolog I
extraembryonic, spermatogenesis, homeobox 1-like
gastrulation brain homeobox 2
goosecoid
homeodomain-only protein
homeo box B I
homeo box B3
homeo box C4
insulin promoter factor 2
ISLI transcription factor, LIM/homeodomain (islet-
1)
transcription factor similar to D. melanogaster
homeodomain protein lady bird late
LIM homeobox 2
LIM homeobox 5
myeloid ecotropic
(mouse)
NK2 transcription
(Drosophila)
NK2 transcription
(Drosophila)
viral integration site I homolog
factor related, locus 2
factor related, locus 3
one cut domain, family member I
orthopedia homolog (Drosophila)
orthodenticle homolog 1(Drosophila)
paired box gene 6
thyroid transcription factor 1
ATBFI
DLX1
DLX4
DLX5
ENI
ESX I L
GBX2
GSC
HOP
HOXB I
HOXB3
HOXC4
IPF2
ISLI
LBX1
LHX2
LHX5
MEIS I
NKX2-2
NKX2-3
ONECUT 1
OTP
OTX 1
PAX6
TITFI
ID
463
1745
1748
1749
2019
80712
2637
145258
84525
3211
3213
3221
3651
3670
10660
9355
64211
4211
4821
159296
3175
23440
5013
5080
7080
To determine which of the Oct4, Sox2, and Nanog bound genes were
preferentially expressed in ES cells, we compared expression datasets (Abeyta et al.,
2004; Sato et al., 2003) from ES cells and a compendium of differentiated tissues and cell
types (Su et al., 2004) (Figure 3; Appendix A). It was notable that DPPA4, TDGFI,
OCT4, NANOG, and LEFTY2 were at the top of the rank order list of genes that are
bound and preferentially expressed in ES cells (Figure 3A). All five of these genes have
been implicated in pluripotency (James et al., 2005; Mitsui et al., 2003; Chambers et al.,
2003; Nichols et al., 1998; Bortvin et al., 2003). Moreover, several genes that encode
developmentally important homeodomain proteins such as DLX5, HOXB 1, LHX5,
TITFI, LBX1, and HOP were at the bottom of this list, indicating that they are
preferentially repressed in ES cells.
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Figure 3. Expression of Oct4, Sox2, and Nanog co-occupied genes.
A. Affymetrix expression data for ES cells was compared to a compendium of
expression data from 158 experiments representing 79 other differentiated tissues and cell
types (Appendix A). Ratios were generated by comparing gene expression in ES cells to
the median level of gene expression across all datasets for each individual gene. Genes
were ordered by relative expression in ES cells and the results were clustered by
expression experiment using hierarchical clustering. Each gene is represented as a
separate row and individual expression experiments are in separate columns. Red
indicates higher expression in ES cells relative to differentiated cells. Green indicates
lower expression in ES cells relative to differentiated cells. Examples of bound genes
that are at the top and bottom of the rank order list are shown.
B. Relative levels of gene expression in H9 ES cells compared to differentiated cells were
generated and converted to log2 ratios. The distribution of these fold changes was
calculated to derive a profile for different sets of genes. Data are shown for the
distribution of expression changes between H9 ES cells and differentiated tissues for
transcription factor genes that are not occupied by Oct4, Sox2 or Nanog (solid black line)
and transcription factor genes occupied by all three (dotted line). The change in relative
expression is indicated on the x axis and the numbers of genes in each bin are indicated
on the y axes (left axis for unoccupied genes, right axis for occupied genes). The shift in
distribution of expression changes for genes occupied by Oct4, Sox2 and Nanog is
significant (p-value < 0.001 using a two-sampled Kolmogorov-Smirnov test), consistent
with the model that Oct4, Sox2 and Nanog are contributing to the regulation of these
genes.
The observation that Oct4, Sox2, and Nanog bound to transcriptionally active
genes that have roles in pluripotency and transcriptionally inactive genes that promote
development suggests that these binding events are regulatory. Two additional lines of
evidence indicated that many of the binding events identified in this study contribute to
regulation of their target genes. First, some of the genes identified here (e.g., OCT4,
SOX2, and NANOG) were previously shown to be regulated by Oct4 and Sox2 in mouse
ES cells (Catena et al., 2004; Kuroda et al., 2005, Okumura-Nakanishi et al., 2005;
Rodda et al., 2005). Second, we further explored the hypothesis that bound genes are
regulated by these transcription factors by taking advantage of the fact that Oct4 and
Nanog are expressed in ES cells but their expression is rapidly downregulated upon
differentiation. We compared the expression of Oct4, Sox2 and Nanog occupied genes in
human ES cells with expression patterns in 79 differentiated cell types (Su et al., 2004)
(Appendix A) and focused the analysis on transcription factor genes because these were
the dominant functional class targeted by the ES cell regulators (Figure 3B). We
expected that for any set of genes that there would be a characteristic change in
expression levels between ES cells and differentiated cells. If Oct4, Sox2 and Nanog do
not regulate the genes they occupy, then these genes should have the same general
expression profile as the control population. We found, however, a significant shift in the
distribution of expression changes for genes occupied by Oct4, Sox2 and Nanog (p-value
< 0.001). Taken together, these data support the model that Oct4, Sox2 and Nanog
functionally regulate the genes they occupy and suggest that loss of these regulators upon
differentiation results in increased expression of genes necessary for development and
reduced expression of a set of genes required for the maintenance of stem cell identity.
Our results suggest that Oct4, Sox2, and Nanog contribute to pluripotency and
self-renewal by activating their own genes and genes encoding components of key
signaling pathways and by repressing genes that are key to developmental processes. It is
presently unclear how the three key regulators can activate some genes and repress
others. It is likely that the activity of these key transcription factors is further controlled
by additional cofactors, the precise levels of Oct4, Sox2, and Nanog, and by post-
translational modifications.
Core transcriptional regulatory circuitry in ES cells
In order to identify regulatory network motifs associated with Oct4, Sox2 and
Nanog, we assumed that regulator binding to a gene implies regulatory control and used
algorithms that were previously devised to discover such regulatory circuits in yeast (Lee
et al., 2002). The simplest units of commonly used transcriptional regulatory network
architecture, or network motifs, provide specific regulatory capacities such as positive
and negative feedback loops to control the levels of their components (Lee et al., 2002;
Milo et al., 2002; Shen-Orr et al., 2002).
Our data indicated that Oct4, Sox2 and Nanog form feedforward loops that
involve at least 353 protein coding and 2 miRNA genes (Figure 4A). Feedforward loop
motifs contain a regulator that controls a second regulator, and have the additional feature
that both regulators bind a common target gene. The feedforward loop has multiple
regulatory capacities that may be especially useful for stem cells. When both regulators
are positive, the feedforward loop can provide consistent activity that is relatively
insensitive to transient changes in input (Mangan et al., 2003; Shen-Orr et al., 2002). If
the regulators have positive and negative functions, the feedforward loop can act as a
switch that enables a rapid response to inputs by providing a time-sensitive delay where
the downstream regulator acts to counter the effects of the upstream regulator in a
delayed fashion (Mangan and Alon, 2003; Mangan et al., 2003). In ES cells, both
regulatory capacities could be useful for maintaining the pluripotent state while retaining
the ability to react appropriately to differentiation signals. Previous studies have shown
that feedforward loop architecture has been highly favored during the evolution of
transcriptional regulatory networks in less complex eukaryotes (Lee et al., 2002; Ma et
al., 2004; Milo et al., 2002; Resendis-Antonio et al., 2005; Shen-Orr et al., 2002). Our
data suggest that feedforward regulation is an important feature of human ES cells as
well.
Our results also showed that Oct4, Sox2, and Nanog together bound to the
promoters of their own genes, forming interconnected autoregulatory loops (Figure 4B;
see also Appendix A, Figure S2). Transcriptional regulation of Oct4, Sox2, and Nanog
by the Oct4-Sox2 complex was recently described in murine ES cells (Catena et al.,
2004; Kuroda et al., 2005; Okumura-Nakanishi et al., 2005; Rodda et al., 2005). Our data
indicate that this autoregulatory loop is conserved in human ES cells and more
importantly, that Nanog is a component of the regulatory apparatus at these genes. Thus,
it is likely that the expression and function of these three key stem cell factors are
inextricably linked to one another. Autoregulation is thought to provide several
advantages, including reduced response time to environmental stimuli and increased
stability of gene expression (McAdams and Arkin, 1997; Rosenfeld et al., 2002; Shen-
Orr et al., 2002; Thieffry et al., 1998).
Figure 4
Figure 4. Transcriptional regulatory motifs in human ES cells
A. Shown here is an example of feed-forward transcriptional regulatory circuitry in
human ES cells. Regulators are represented by blue circles; gene promoters are
represented by red rectangles. Binding of a regulator to a promoter is indicated by a solid
arrow. Genes encoding regulators are linked to their respective regulators by dashed
arrows. B. The interconnected autoregulatory loop formed by Oct4, Sox2, and Nanog.
The autoregulatory and feedforward circuitry described here may provide
regulatory mechanisms by which stem cell identity can be robustly maintained, yet
permit cells to respond appropriately to developmental cues. Modifying Oct4 and Nanog
levels and function can change the developmental potential of murine ES cells (Avilion et
al., 2003; Chambers et al., 2003; Mitsui et al., 2003; Nichols et al., 1998; Niwa et al.,
2000) and this might be interpreted as being a consequence of perturbing independent
regulatory pathways under the control of these two regulators. Our results argue that the
levels and functions of these key stem cell regulators are tightly linked at both target
genes and at their own promoters and thus provide an additional framework for
interpreting the genetic studies. Changes in the relative stoichiometry of these factors
would disturb the autoregulatory and feedforward circuitry, producing changes in global
gene regulation and thus cell fate.
Expanded transcriptional regulatory circuitry
An initial model for ES cell transcriptional regulatory circuitry was constructed
by identifying Oct4, Sox2, and Nanog target genes that encode transcription factors and
chromatin regulators, and integrating knowledge of the functions of these downstream
regulators in both human and mouse based on the available expression studies and
literature (Figure 5). The model includes a subset of active and a subset of repressed
target genes based on the extensive expression characterization of the 353 co-bound
genes as described earlier. The active targets include genes encoding components of
chromatin remodeling and histone modifying complexes (e.g. SMARCADI, MYST3,
and SET), which may have general roles in transcriptional regulation and genes encoding
transcription factors (e.g. REST, SKIL, HESXI, STAT3) which themselves are known to
regulate specific genes. For instance, the REST protein has recently been shown to be
present at high levels in ES cells and is required for the coordinate expression of a
number of genes during neurogenesis, in part through repression of neuronal genes in the
inappropriate cell type (Ballas et al., 2005). Previous studies have proposed that Nanog
may function through the Tgf-13 pathway in ES cells (Chambers, 2004). Our model
suggests that this occurs through direct regulation of key components of this pathway
(e.g. TDFG 1, LEFTY2/EBAF) and through regulation of at least one transcription factor,
SKIL, which controls the activity of downstream components of this pathway (SMAD2,
SMAD4) (He et al., 2003). Our data also reveal that Oct4, Sox2, and Nanog co-occupy
STAT3, a key regulator of self-renewal in mouse ES cells (Chambers, 2004), suggesting
that Stat3 may also play a role in human ES cells.
The model described in Figure 5 also depicts a subset of the genes bound by Oct4,
Sox2, and Nanog that are inactive and that encode transcription factors that have key
roles in differentiation and development. These include regulators with demonstrated
roles in development of all embryonic lineages. This initial model for ES cell
transcriptional regulatory circuitry is consistent with previous genetic studies in mice that
suggest that Oct4 and Nanog maintain pluripotency through repression of differentiation
programs (Chambers et al., 2003; Mitsui et al., 2003; Niwa et al., 2000). This model also
provides a mechanistic framework for understanding how this is accomplished through
regulation of specific sets of genes that control cell fate specification.
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Figure 5. Core transcriptional regulatory network in human ES cells.
A model for the core transcriptional regulatory network was constructed by identifying
Oct4, Sox2, and Nanog target genes that encode transcription factors and chromatin
regulators, and integrating knowledge of the functions of these downstream regulators
based on comparison to multiple expression datasets (Appendix A) and to the literature.
A subset of active and inactive genes co-occupied by the three factors in human ES cells
is shown here. Regulators are represented by blue circles; gene promoters are represented
by red rectangles; grey boxes represent putative downstream target genes. Positive
regulation was assumed if the target gene was expressed whereas negative regulation was
assumed if the target gene was not transcribed.
Conclusions
Discovering how gene expression programs are controlled in living cells promises
to improve our understanding of cell biology, development and human health.
Identifying the target genes for key transcriptional regulators of human stem cells is a
first critical step in the process of understanding these transcriptional regulatory networks
and learning how they control cell identity. Mapping Oct4, Sox2, and Nanog to their
binding sites within known promoters has revealed that these regulators collaborate to
form regulatory circuitry in ES cells consisting of specialized autoregulatory and
feedforward loops. Continued advances in our ability to culture and genetically
manipulate human ES cells will allow us to test and manipulate this circuitry.
Identification of the targets of additional transcription factors and chromatin regulators
using the approaches described here should allow investigators to produce a more
comprehensive map of transcriptional regulatory circuitry in these cells. Connecting
signaling pathways to this circuit map may reveal how these pluripotent cells can be
stimulated to differentiate into different cell types or how to reprogram differentiated
cells back to a pluripotent state.
Experimental Procedures
Growth Conditions for Human Embryonic Stem Cells
Human embryonic stem (ES) cells were obtained from WiCell (Madison, WI;
NIH Code WA09). Detailed protocol information on human ES cell growth conditions
and culture reagents are available at http://www.mcb.harvard.edu/melton/hues. Briefly,
passage 34 cells were grown in KO-DMEM medium supplemented with serum
replacement, basic fibroblast growth factor (bFGF), recombinant human leukemia
inhibitory factor (LIF) and a human plasma protein fraction. In order to minimize any
MEF contribution in our analysis, H9 cells were cultured on a low density of irradiated
murine embryonic fibroblasts (ICR MEFs) resulting in a ratio of approximately >8:1 H9
cell to MEF. The culture of H9 on low-density MEFs had no adverse affects on cell
morphology, growth rate, or undifferentiated status as compared to cells grown under
typical conditions. In addition, immunohistochemistry for pluripotency markers (e.g.
Oct4, SSEA-3) indicated that H9 cells grown on a minimal feeder layer maintained the
ability to generate derivates of ectoderm, mesoderm, and endoderm upon differentiation
(Appendix A Figures S3 and S4).
Antibodies
The Nanog (AF1997) and Sox2 (AF2018) antibodies used in this study were
immunoaffinity purified against the human proteins and shown to recognize their target
proteins in Western blots and by immunocytochemistry (R&D Systems Minneapolis,
MN). Multiple Oct4 antibodies directed against different portions of the protein, some of
which were immunoaffinity purified (AF1759 R&D Systems, sc-8628 Santa Cruz, sc-
9081 Santa Cruz) were used in this study and have been shown to recognize their target
protein in Western blots and by immunocytochemistry. The E2F4 antibody used in this
study was obtained from Santa Cruz (sc-1082) and has been shown to recognize E2F4-
responsive genes identified in previous ChIP studies (Table S2) (Ren et al., 2002;
Weinmann et al., 2002).
Chromatin Immunoprecipitation
Protocols describing all materials and methods can be downloaded from
http://jura.wi.mit.edu/young/hESRegulation/. Human embryonic stem cells were grown
to a final count of 5x10 7 - lx 108 cells for each location analysis reaction. Cells were
chemically crosslinked by the addition of one-tenth volume of fresh 11% formaldehyde
solution for 15 minutes at room temperature. Cells were rinsed twice with IxPBS and
harvested using a silicon scraper and flash frozen in liquid nitrogen and stored at -800 C
prior to use. Cells were resuspended, lysed in lysis buffers and sonicated to solubilize
and shear crosslinked DNA. Sonication conditions vary depending on cells, culture
conditions, crosslinking and equipment. We used a Misonix Sonicator 3000 and
sonicated at power 7 for 10 x 30 second pulses (90 second pause between pulses) at 40 C
while samples were immersed in an ice bath. The resulting whole cell extract was
incubated overnight at 40 C with 100 pl of Dynal Protein G magnetic beads that had been
preincubated with 10 /g of the appropriate antibody. Beads were washed 5 times with
RIPA buffer and I time with TE containing 50 mM NaCI. Bound complexes were eluted
from the beads by heating at 650 C with occasional vortexing and crosslinking was
reversed by overnight incubation at 650 C. Whole cell extract DNA (reserved from the
sonication step) was also treated for crosslink reversal. Immunoprecipitated DNA and
whole cell extract DNA were then purified by treatment with RNAseA, proteinase K and
multiple phenol:chloroform:isoamyl alcohol extractions. Purified DNA was blunted and
ligated to linker and amplified using a two-stage PCR protocol. Amplified DNA was
labeled and purified using Invitrogen Bioprime random primer labeling kits
(immunoenriched DNA was labeled with Cy5 fluorophore, whole cell extract DNA was
labeled with Cy3 fluorophore). Labeled DNA was combined (5 - 6 pig each of
immunoenriched and whole cell extract DNA) and hybridized to arrays in Agilent
hybridization chambers for 40 hours at 400 C. Arrays were then washed and scanned
(Appendix A).
Array Design and Data Extraction
The design of the 10-slide oligo-based promoter arrays used in this study and data
extraction methods are described in detail in Appendix A. Arrays were manufactured by
Agilent Technologies (www.agilent.com). All microarray data is available at
ArrayExpress under the following accession designation E-WMIT-5.
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My contributions to this work
The effort to profile chromatin regulators and RNA polymerase in ES cells was
initiated in the summer of 2004. I was involved in this collaborative project from its
inception, participating in the experimental efforts and the data analysis. I worked with
Tony Lee to help improve the technical aspects of the lab's ChIP-chip protocol to adapt it
for the purpose of genome-wide profiling. Towards this end, I helped to develop a high-
throughput protocol for mammalian ChIP-chip (Appendix B; Lee et al., 2006). My
principle contributions were developing the techniques necessary to hybridize 115
microarrays for individual experiments with minimal experimental variability. I was also
responsible for helping lead the efforts to amplify, label and hybridize the three ChIP
samples described in this chapter.
Upon obtaining high-quality genome-wide binding data for Suzl2 and RNA
Polymerase, I contributed to the analysis by inspecting binding plots to determine the
parameters and quality of binding events for the different ChIP samples. Part of this
effort included identifying patterns of binding in order to understand the role of Suzl2 at
its target genes. I also provided edits to the manuscript and contributed to figures of
binding plot data.
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Summary
Polycomb group proteins are essential for early development in metazoans but
their contributions to human development are not yet well understood. We have mapped
the Polycomb Repressive Complex 2 (PRC2) subunit Suzl2 across the entire non-repeat
portion of the genome in human embryonic stem (ES) cells. We found that Suzl2 is
distributed across large portions of over two hundred genes encoding key developmental
regulators. These genes are occupied by nucleosomes trimethylated at histone H3K27,
are transcriptionally repressed, and contain some of the most highly conserved non-
coding elements in the vertebrate genome. We found that preferential activation of PRC2
target genes occurs during differentiation of ES cells into other cell types. The ES cell
transcriptional regulators Oct4, Sox2 and Nanog co-occupied a significant subset of these
genes, further supporting a link between repression of developmental regulators and stem
cell pluripotency. These results indicate that PRC2 occupies a special set of
developmental genes in ES cells that must be repressed to maintain pluripotency and that
are poised for activation during ES cell differentiation.
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Introduction
Embryonic stem (ES) cells are a unique self-renewing cell type that can give rise
to the ectodermal, endodermal, and mesodermal germ layers during embryogenesis.
Human ES cells, which can be propagated in culture in an undifferentiated state but
selectively induced to differentiate into many specialized cell types, are thought to hold
great promise for regenerative medicine (Thomson et al., 1998; Reubinoff et al., 2000;
Mayhall et al., 2004; Pera and Trounson, 2004). The gene expression program of ES
cells must allow these cells to maintain a pluripotent state but also allow for
differentiation into more specialized states when signaled to do so. How the gene
expression program of ES cells is regulated to accomplish this is not well understood but
may be key to realizing the therapeutic potential of ES cells and further understanding
early development.
Among regulators of development, the Polycomb group proteins (PcG) are of
special interest. These regulators were first described in Drosophila, where they repress
the homeotic genes controlling segment identity in the developing embryo (Lewis, 1978;
Denell and Frederick, 1983; Simon et al., 1992; Orlando and Paro, 1995; Pirrotta, 1998;
Kennison, 2004). The initial repression of these genes is carried out by DNA-binding
transcriptional repressors, and PcG proteins modify chromatin to maintain these genes in
a repressed state (Duncan, 1986; Bender et al., 1987; Strutt et al., 1997; Horard et al.,
2000; Hodgson et al., 2001; Mulholland et al., 2003).
The PcG proteins form multiple Polycomb Repressive Complexes (PRCs), the
components of which are conserved from Drosophila to humans (Franke et al., 1992;
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Shao et al., 1999; Birve et al., 2001; Tie et al., 2001; Cao et al., 2002; Czermin et al.,
2002; Kuzmichev et al., 2002; Levine et al., 2002). The PRCs are brought to the site of
initial repression and act through epigenetic modification of chromatin structure to
promote gene silencing (Pirrotta, 1998; Levine et al., 2004; Lund and van Lohuizen,
2004; Ringrose and Paro, 2004). PRC2 catalyzes histone H3 lysine-27 (H3K27)
methylation and this enzymatic activity is required for PRC2-mediated gene silencing
(Cao et al., 2002; Czermin et al., 2002; Kuzmichev et al., 2002; Muller et al., 2002).
H3K27 methylation is thought to provide a binding surface for PRCI, which facilitates
oligomerization, condensation of chromatin structure and inhibition of chromatin
remodeling activity in order to maintain silencing (Shao et al., 1999; Francis et al., 2001;
Cao et al., 2002; Czermin et al., 2002).
Components of PRC2 are essential for the earliest stages of vertebrate
development (Faust et al., 1998; O'Carroll et al., 2001; Pasini et al., 2004). PRC2 and its
related complexes PRC3 and PRC4 contain the core components Ezh2, Suz12 and Eed
(Kuzmichev et al., 2004; Kuzmichev et al., 2005). Ezh2 is a H3K27 methyltransferase
and Suzl2 (Suppressor of zeste 12) is required for this activity (Cao and Zhang, 2004;
Pasini et al., 2004). ES cell lines cannot be established from Ezh2-deficient blastocysts
(O'Carroll et al., 2001), suggesting that PRC2 is involved in regulating pluripotency and
self-renewal. Although the PRCs are known to repress individual Hox genes (van der
Lugt et al., 1996; Akasaka et al., 2001; Wang et al., 2002; Cao and Zhang, 2004), it is not
clear how these important PcG regulators contribute to early development in vertebrates.
Because the nature of PRC2 target genes in ES cells might reveal why PRC2 is
essential for early embryonic development, pluripotency and self-renewal, we have
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mapped the sites occupied by the Suz12 subunit throughout the genome in human ES
cells. This genome-wide map reveals that PRC2 is associated with a remarkable cadre of
genes encoding key regulators of developmental processes that are repressed in ES cells.
The genes occupied by PRC2 contain nucleosomes that are trimethylated at histone H3
lysine-27 (H3K27me3), a modification catalyzed by PRC2 and associated with the
repressed chromatin state. Both PRC2 and nucleosomes with histone H3K27me3 occupy
surprisingly large genomic domains around these developmental regulators and are
frequently associated with highly conserved non-coding sequence elements previously
identified by comparative genomic methods. The transcription factors Oct4, Sox2 and
Nanog, which are also key regulators of ES cell pluripotency and self-renewal, occupy a
significant subset of these genes. Thus, the model of epigenetic regulation of homeotic
genes extends to a large set of developmental regulators whose repression in ES cells
appears to be key to pluripotency. We suggest that PRC2 functions in ES cells to repress
developmental genes that are preferentially activated during differentiation.
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Results and Discussion
Mapping genome occupancy in ES cells
We mapped the location of both RNA polymerase II and the Suzl2 subunit of
PRC2 genome-wide in human ES cells (Figure 1). The initiating form of RNA
polymerase II was mapped to test the accuracy of the method and provide a reference for
comparison with sites occupied by PRC2. The Suz12 subunit of PRC2 is critical for the
function of the complex and was selected for these genome-wide experiments. Human
ES cells (H9, NIH code WA09) were cultured as described previously, analyzed by
immunohistochemistry for characteristic stem cell markers, tested for their ability to
generate cell types from all three germ layers upon differentiation into embryoid bodies
and shown to form teratomas in immunocompromised mice (Appendix C; Figures S l-
S3).
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Figure 1. Genome-wide ChIP-Chip in human embryonic stem cells
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Figure 1. Genome-wide ChIP-Chip in human embryonic stem cells.
a. DNA segments bound by the initiation form of RNA polymerase II or Suz12 were
isolated using chromatin-immunoprecipitation (ChIP) and identified with DNA
microarrays containing over 4.6 million unique 60-mer oligonucleotide probes spanning
the entire non-repeat portion of the human genome. ES cell growth and quality control,
the antibodies, ChIP protocol, DNA microarray probe design and data analysis methods
are described in detail in Appendix C.
b. Examples of RNA polymerase II ChIP signals from genome-wide ChIP-Chip. The
plots show unprocessed enrichment ratios (blue) for all probes within a genomic region
(ChIP vs. whole genomic DNA). Chromosomal positions are from NCBI build 35 of the
human genome. Genes are shown to scale below plots (exons are represented by vertical
bars). The start and direction of transcription are noted by arrows.
c. Examples of Suzl2 ChIP signals from genome-wide ChIP-Chip. The plots show
unprocessed enrichment ratios (green) for all probes within a genomic region (ChIP vs.
whole genomic DNA). Chromosomal positions, genes and notations are as described in
b.
d. Chart showing percentage of all annotated genes bound by RNA polymerase II (blue),
Suzl2 (green), both (yellow) or neither (grey).
e. Distribution of the distance between bound probes and the closest transcription start
sites from RefSeq, Ensembl, MGC, UCSC Known Genes and H-Inv databases for Suzl2
(green line) and RNA polymerase II (blue line). The number of bound probes is given as
the percentage of total probes and is calculated for 400 bp intervals from the start site.
The null-distribution of the distance between all probes and the closest transcription is
shown as a black line.
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DNA sequences bound by RNA polymerase II were identified in replicate
chromatin-immunoprecipitation (ChIP) experiments using DNA microarrays that contain
over 4.6 million unique 60-mer oligonucleotide probes spanning the entire non-repeat
portion of the human genome (Figure 1 and Appendix C). To obtain a probabilistic
assessment of binding events genome-wide, an algorithm was implemented that
incorporates information from multiple probes representing contiguous regions of the
genome and threshold criteria were established to identify a dataset with minimal false
positives and false negatives (Appendix C). RNA polymerase II was associated with the
promoters of 7,106 of the approximately 22,500 annotated human genes, indicating that
one-third of protein-coding genes are prepared to be transcribed in ES cells. Three lines
of evidence suggest this dataset is high quality. First, eighty-seven percent of the RNA
polymerase II sites occurred at promoters of known or predicted genes. Additionally,
previously reported expression experiments in ES cells detected transcripts for 88% of
the genes bound by RNA polymerase II. Finally, independent analysis using gene-
specific PCR (Appendix C) indicated that the frequency of false positives was
approximately 4% and the frequency of false negatives was approximately 30% in this
dataset. A detailed analysis of the RNA polymerase II dataset can be found in Appendix
C (Tables S 1-S6 and Figures S4 and S5).
The sites occupied by Suzl2 were then mapped throughout the entire non-repeat
genome in H9 ES cells using the same approach described for RNA polymerase II
(Figure IC). Suzl2 was associated with the promoters of 1,893 of the approximately
22,500 annotated human genes, indicating that -8% of protein-coding genes are occupied
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by Suzl2 in ES cells (Appendix C; Tables S7 and S8). Independent site-specific analysis
indicated that the frequency of false positives was approximately 3% and the frequency
of false negatives was approximately 27% in this dataset.
Comparison of the genes occupied by Suzl2 with those occupied by RNA
polymerase II revealed that the two sets were largely exclusive (Figure ID; Appendix C;
Table S8). There were, however, genes where Suzl2 and RNA polymerase II co-
occupied promoters. At these genes, PRC complexes may fail to block assembly of the
preinitiation complex (Dellino et al., 2004) consistent with the observation that Polycomb
group proteins can associate with components of the general transcription apparatus
(Breiling et al., 2001; Saurin et al., 2001).
It was notable that, like RNA polymerase II, the vast majority of Suzl2 bound
sequences were found at gene promoters (Figure 1E). 95% of the Suzl2 bound regions
were found within 1 kb of known or predicted transcription start sites (Appendix C; Table
S7). This suggests that Suzl2 functions in human ES cells primarily at promoters rather
than at distal regulatory elements.
Global transcriptional repression by PRC2
PRC2 is composed of three core subunits, Suz12, Eed and Ezh2, and has been
shown to mediate histone H3K27 methylation at specific genes in vivo (Cao et al., 2002;
Czermin et al., 2002; Kuzmichev et al., 2002; Muller et al., 2002; Cao and Zhang, 2004;
Kirmizis et al., 2004). To confirm that Suzl2 is associated with active PRC2 at target
genes, we used chromatin immunoprecipitation with antibodies against Eed and the
histone H3K27me3 mark and analyzed the results with promoter microarrays. We found
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that Eed and the histone H3K27me3 mark co-occurred with Suzl2 at most genes (Figure
2A; Appendix C, Figure S6), as shown for NeuroDI in Figure 2B.
Genetic and biochemical studies at selected genes indicate that PRC2-mediated
H3K27 methylation represses gene expression, but it has not been established if it acts as
a repressor genome-wide. If genes occupied by Suzl2 are repressed by PRC2, then
transcripts from these genes should generally be present at lower levels in ES cells than
in differentiated cell types. To test this idea, we compared the expression levels of PRC2-
occupied genes in four different ES cell lines with the expression level of these genes in
79 differentiated human cell and tissue types (Sato et al., 2003; Abeyta et al., 2004; Su et
al., 2004). We found that PRC2 occupied genes were generally underexpressed in ES
cells relative to other cell types (Figure 2C). A small fraction of the genes occupied by
PRC2 were overexpressed in ES cells (Figure 2C) and these tended to show limited
Suz12 occupancy (Appendix C). These results are consistent with the model that PRC2-
mediated histone H3K27 methylation promotes gene silencing at the majority of its target
genes throughout the genome in ES cells.
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Figure 2. Suz12 is associated with Eed, histone H3K27me3
modification and transcriptional repression in ES cells
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Figure 2. Suzl2 is associated with Eed, histone H3K27me3 modification and
transcriptional repression in ES cells.
a. Venn diagram showing the overlap of genes bound by Suzl2 at high-confidence, genes
bound by Eed at high-confidence and genes trimethylated at H3K27 at high-confidence.
The data are from promoter microarrays that contain probes tiling -8 kb and +2 kb around
transcription start. 72% of the genes bound by Suzl2 at high-confidence are also bound
by Eed at high-confidence; others are bound by Eed at lower confidence (Figure S6).
b. Suzl2 (top), Eed (middle) and H3K27me3 (bottom) occupancy at NeuroDl. The plots
show unprocessed enrichment ratios for all probes within this genomic region (Suz12
ChIP vs. whole genomic DNA, Eed ChIP vs whole genomic DNA and H3K27me3 ChIP
vs. total H3 ChIP). Chromosomal positions are from NCBI build 35 of the human
genome. NeuroDI is shown to scale below plots (exons are represented by vertical bars).
The start and direction of transcription are noted by arrows.
c. Relative expression levels of 604 genes occupied by PRC2 and trimethylated at H3K27
in ES cells. Comparisons were made across 4 ES cell lines and 79 differentiated cell
types. Each row corresponds to a single gene that is bound by Suz12, associated with Eed
and H3K27me3 and for which Affymetrix expression data is available. Each column
corresponds to a single expression microarray. ES cells are in the following order; HI,
H9, HSF6, HSFI. For each gene, expression is shown relative to the average expression
level of that gene across all samples, with shades of red indicating higher than average
expression and green lower than average expression according to the scale on the right.
Cell types are grouped by tissue or organ function and genes are ranked according the
significance of their relative level of gene expression in ES cells.
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Key developmental regulators are targets of PRC2
Examination of the targets of Suz12 revealed that they were remarkably enriched
for genes that control development and transcription (Figure 3 and examples in Figure
IC) and that Suzl2 tended to occupy large domains at these genes (Figure 4). Although
only 8% of all annotated genes were occupied by Suzl2, -50% of those encoding
transcription factors associated with developmental processes were occupied by Suz 12.
By comparison, RNA polymerase II preferentially occupied genes involved in a broad
spectrum of cell proliferation functions such as nucleic acid metabolism, protein
synthesis and cell cycle (Figure 3A and examples in Figure IB; Appendix C, Table S 10).
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Figure 3. Cellular functions of genes occupied by Suzl2
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Figure 3. Cellular functions of genes occupied by Suzl2
a. Genes bound by Suzl2 or RNA polymerase II were compared to biological process
gene ontology categories; highly represented categories are shown. Ontology terms are
shown on the y-axis; p-values for the significance of enrichment are graphed along the x-
axis (Suzl2 in green, RNA polymerase II in blue).
b. Selected examples of developmental transcription factor families bound by Suz12.
Suzl2 is represented by the green oval; individual transcription factors are represented by
circles and grouped by family as indicated. Examples of transcription factors with
defined roles in development are labeled. Transcription factor families include
homeobox protein (HOX: all Hox genes except HOXAI lS), basic helix-loop-helix
domain containing, class B (BHLHB: BHLHB1/OLIG2, BHLHB2, BHLHB3, BHLHB4,
BHLHB5, BHLHB6/OLIG 1, BHLHB7/OLIG3), Hox co-factors (MEIS/EVX: MEIS 1,
MEIS2, MEIS3, EVXI), distal-less homeobox (DLX: DLX1, DLX2, DLX3, DLX4,
DLX5, DLX6), Forkhead box (FOX: FOXA , FOXA2, FOXB 1, FOXC2, FOXD1,
FOXD2, FOXD3, FOXEl, FOXF1, FOXG1B, FOXJI, FOXL1, FOXL2, FOXP2,
FOXP4), NEUROD (NEURODI, NEUROD2, NEUROD3/NEUROG1), GATA binding
protein (GATA: GATA2, GATA3, GATA4, GATA5, GATA6), runt related transcription
factor (RUNX: RUNXI, RUNX2, RUNX3), paired box and paired-like (PAX 1, PAX3,
PAX5, PAX6, PAX7, PAX8, PAX9, PRRX I, PRRXL1, PITX I, PITX2, PHOX2A,
PHOX2B), LIM homeobox (LHX: LHX 1, LHX2, LHX4, LHX5, LHX6, LHX8, LHX9,
LMX1A, LMX IB, ISLI, ISL2), sine oculis homeobox homolog (SIX: SIXI, SIX2, SIX3,
SIX5, SIX6), NK transcription factor related (NKX: NKX2-2, NKX2-6, NKX2-8,
NKX6-1, NKX6-2), SRY box (SOX: SOX3, SOX6, SOX8, SOX9, SOX12, SOX14,
SOX 17, SOX21), POU domain containing, classes 3 and 4 (POU: POU3FI, POU3F2,
POU3F4, POU4FI, POU4F2, POU4F3), early B-cell factor (EBF: EBF, EBF2, EBF3),
atonal homolog (ATOH: ATOH I, ATOH4/NEUROG2, ATOH5/NEUROG3, ATOH7,
ATOH8), hairy and enhancer of split protein (HES: HES2, HES3, HES4, HES7),
myogenic basic domain (MYO: MYODI, MYF6), T-box (TBX: TBXI, TBX2, TBX3,
TBX4, TBX5, TBX 15, TBX18, TBX20, TBX21, T), caudal type homeobox (CDX2,
CDX4), and iroquois homeobox protein (IRX: IRX 1, IRX2, IRX3, IRX4, IRX5, IRX6).
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Figure 4. Suzl2 occupies large portions of genes encoding
transcription factors with roles in development
- Transcnption
- Signaling
~30
020
0O
0
100
Size of Suzl 2 bound region
31820000
Chromosomal position
TBX5
(T-box 5)
31760000
Chromosomal position
PAX6
WPaired box Weoe 61
26800000 27150000
Chromosomal position
HoxA | I Evxl HoxB i| I
5 16 16
0-0
Chromosomal position Chromosomal position
HoxC HoxD
122
12
41
i
!
I t
Figure 4. Suzl2 occupies large portions of genes encoding transcription factors with
roles in development
a. The fraction of Suzl2 target genes associated with different sizes of binding domains.
Genes are grouped into four categories according to their function: Signaling,
Adhesion/migration, Transcription and Other.
b. Examples of Suzl2 (green) and RNA polymerase II (blue) binding at the genes
encoding developmental regulators TBX5 and PAX6. The plots show unprocessed
enrichment ratios for all probes within a genomic region (ChIP vs. whole genomic DNA).
Genes are shown to scale below plots (exons are represented by vertical bars). The start
and direction of transcription are noted by arrows.
c. Binding profiles of Suzl2 (green) and RNA polymerase II (blue) across -500 kb
regions encompassing Hox clusters A-D. Unprocessed enrichment ratios for all probes
within a genomic region are shown (ChIP vs. whole genomic DNA). Approximate Hox
cluster region sizes are indicated within black bars.
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It was striking that Suz12 occupied many families of genes that control
development and transcription (Figure 3B; Appendix C, Figure S7 and Table S 11).
These included 39 of 40 of the homeotic genes found in the Hox clusters and the majority
of homeodomain genes. Suz12-bound homeodomain genes included almost all members
of the DLX, IRX, LHX and PAX gene families, which regulate early developmental steps
in neurogenesis, hematopoiesis, axial patterning, tissue patterning, organogenesis and
cell-fate specification. Suz12 also occupied promoters for large subsets of the FOX,
SOX and TBX gene families. The forkhead family of FOX genes is involved in axial
patterning and tissue development from all three germ layers (Carlsson and Mahlapuu,
2002; Lehmann et al., 2003). Mutations in members of the SOX gene family alter cell-
fate specification and differentiation and are linked to several developmental diseases
(Schepers et al., 2002). The TBX family of genes regulates a wide variety of
developmental processes such as gastrulation, early pattern formation, organogenesis and
limb formation (Logan, 2003; Showell et al., 2004). Thus, the genes preferentially bound
by Suzl2 have functions that, when expressed, promote differentiation. This is likely to
explain, at least in part, why PRC2 is essential for early development and ES cell
pluripotency.
A remarkable feature of Suzl2 binding at most genes encoding developmental
regulators was the extensive span over which the regulator occupied the locus (Figure 4;
Appendix C, Figure S8). For the majority (72%) of bound sites across the genome,
Suzl2 occupied a small region in a promoter region similar in size to those bound by
RNA polymerase II (Figure 1). For the remaining bound regions, Suzl2 occupancy
encompassed large domains spanning 2-35 kb and extending from the promoter into the
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gene. A large portion of genes encoding developmental regulators (72%) exhibited these
extended regions of Suzl2 binding. In some cases, binding encompassed multiple
contiguous genes. For instance, Suzl2 binding extended -100 kb across the entire HoxA,
HoxB, HoxC and HoxD clusters but did not bind to adjacent genomic sequences, yielding
a highly defined spatial pattern (Figure 4B). In contrast, clusters of unrelated genes, such
as the interleukin 1-beta cluster, were not similarly bound by Suzl2. Thus, genes
encoding developmental regulators showed an unusual tendency to be occupied by Suzl2
over much or all of their transcribed regions.
PRC2 and highly conserved elements
Previous studies have noted that many highly conserved non-coding elements of
vertebrate genomes are associated with genes encoding developmental regulators
(Bejerano et al., 2004; Siepel et al., 2005; Woolfe et al., 2005). Given Suzl2's strong
association with this class of genes, we investigated the possibility that Suzl2 bound
regions are associated with these highly conserved elements. Inspection of individual
genes suggested that Suzl2 occupancy was associated with regions of sequence
conservation (Figure 5A). Eight percent of the approximately 1,400 highly conserved
non-coding DNA elements described by Woolfe and colleagues (Woolfe et al., 2005)
were found to be associated with the Suz12-bound developmental regulators (p-value 10
14). Using entries from the PhastCons database of conserved elements (Siepel et al.,
2005), we found that Suzl2 occupancy of highly conserved elements was highly
significant (using highly conserved elements with a LoD conservation score of 100 or
better, the p-value for significances was less than 1085). Since PRC2 has not been shown
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to directly bind DNA sequences, we expect that specific DNA-binding proteins occupy
the highly conserved DNA sequences and may associate with PRC2, which spreads and
occupies adjacent chromatin. Thus, the peaks of Suzl2 occupancy might not be expected
to precisely colocate with the highly conserved elements, even if these elements are
associated with PRC2 recruitment.
Remarkably, the degree of the association between Suz12 binding and conserved
sequences increases when considering sequences with an increasing degree of
conservation (Figure 5B). By comparison, RNA polymerase II showed no such
enrichment. These results suggest that the subset of highly conserved non-coding
elements at genes encoding developmental regulators may be associated with PcG
mediated silencing of these regulators.
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Figure 5. Suz12 binding is associated with highly conserved regions
I17
13
9
5
21530M0 213M500-
II I IIIII I
- NKX2-2
Suz12
Occupancy
Chr postion
Highly Conserved
Regrons
Gene (NKX2-21
Suzl2
Occuparcy
Chr. posaon
Highly Consenrve
Regions
Gene
200 400 600 800+
Conservation score
127
Figure 5. Suzl2 binding is associated with highly conserved regions
a. Suzl2 occupancy (green) and conserved elements are shown at NKX2-2 and adjacent
genomic regions. The plots show unprocessed enrichment ratios for all probes within this
genomic region (Suzl2 ChIP vs. whole genomic DNA). Conserved elements (red) with
LoD scores > 160 derived from the PhastCons program (Siepel et al., 2005) are shown to
scale above the plot. Genes are shown to scale below plots (exons are represented by
vertical bars). A higher resolution view is also shown below.
b. Enrichment of conserved non-coding elements within Suz12 (green) and RNA
polymerase II (blue) bound regions. The maximum non-exonic PhastCons conservation
score was determined for each bound region. For comparison, the same parameter was
determined using a randomized set of genomic regions with the same size distribution.
The graph displays the ratio of the number of bound regions with that score versus the
number of randomized genomic regions with that score.
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Signaling genes are among PRC2 targets
The targets of Suzl2 were also enriched for genes that encode components of
signaling pathways (Figure 3A and Table S 12). Current studies suggest that the
transforming growth factor-beta (TGFP), bone morphogenic protein (BMP), wingless-
type MMTV integration site (Wnt), and fibroblast growth factor (FGF) signaling
pathways that are required for gastrulation and lineage differentiation in the embryo are
also essential for self-renewal and differentiation of ES cells in culture (Loebel et al.,
2003; Molofsky et al., 2004; Mishra et al., 2005; Varga and Wrana, 2005). We noted that
Suzl2 occupied the promoters of multiple components of these pathways. Although
most of these genes were occupied by Suzl2 over a small portion of their promoters, a
few were more notable because Suz 12 occupied large portions of their genes and these
loci contained highly conserved elements, as observed for the developmental regulators.
This group contained members of the Wnt family (WNT 1, WNT2, WNT6) as well as
components of the TGFP3 superfamily (BMP2, GDF6). Recent studies have shown that
Wnt signaling plays a role in pluripotency and self-renewal in both mouse and human ES
cells (Sato et al., 2004) and our results suggest that it is important to maintain specific
family members in a repressed state in ES cells.
Activation of PRC2 target genes during differentiation
PRC2 is associated with an important set of developmental regulators that must be
silent in ES cells but activated during differentiation. This observation suggests that
PRC2 ultimately functions to repress occupied genes in ES cells and that these genes may
be especially poised for transcriptional activation during ES cell differentiation. We
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reasoned that if this model is correct, genes bound by Suzl2 should be preferentially
activated upon ES cell differentiation or in cells that lack Suz12. Furthermore, in
differentiated cells, Suzl2 might continue to be observed at silent genes but must be
removed from genes whose expression is essential for that cell type.
We first examined gene expression in ES cells stimulated to undergo
differentiation (Sato et al., 2003). We found that genes occupied by Suzl2 were more
likely to be activated during ES cell differentiation than genes that were not occupied by
Suzl2 (Figure 6A; Appendix C, Table S 13), indicating that Suzl2-occupied genes show
preferential activation during differentiation under these conditions. This effect was
particularly striking at the set of developmental regulators (Figure 6B). Suzl2 occupied
most (83%) of the developmental regulators that were induced more than 10-fold during
ES cell differentiation.
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Figure 6. Suz12 occupies genes poised for expression during
differentiation
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Figure 6. Preferential activation of PRC2 target genes during ES cell differentiation.
a. Fold enrichment in the number of genes induced or repressed during ES cell
differentiation. The change in gene expression is given as the log(2) transformed ratio of
the signals in differentiated cells versus pluripotent cells. The two lines show genes
transcriptionally inactive in ES cells (absence of RNA polymerase II) and bound by
Suzl2 (green) and genes transcriptionally inactive in ES cells and repressed by other
means (blue). In both cases, fold enrichment is calculated against the total population of
genes.
b. Expression changes of genes encoding developmental regulators during ES cell
differentiation. Expression ratio (differentiated / pluripotent) is represented by color, with
shades of red indicating upregulation and shades of green downregulation according to
the scale shown above. Genes are ordered according to change in gene expression, with
genes exhibiting higher expression in pluripotent ES cells to the left and genes exhibiting
higher expression in differentiated cells to the right. Genes bound by Suzl2 in
undifferentiated ES cells are indicated by blue lines in the lower panel.
c. Fold enrichment in the number of genes induced or repressed in Suz12-deficient mouse
cells. The change in gene expression is given as the log(2) transformed ratio of the
signals in Suz12-deficient cells versus wild-type ES cells. The two lines show genes
transcriptionally inactive in human ES cells (absence of RNA polymerase II) and bound
by Suzl2 (green) and genes transcriptionally inactive in human ES cells and repressed by
other means (blue). In both cases, fold enrichment is calculated against the total
population of genes.
d. Gene expression ratios (log base 2) of Suz 12 target genes in differentiated human H1
ES cells relative to pluripotent H1 ES cells (x-axis) and in Suz12-deficient mouse cells
relative to wild-type mouse ES cells (y-axis).
e. Suzl2 binding profiles across the gene encoding muscle regulator MYODI in H9
human ES cells (green) and primary human skeletal myotubes (grey). The plots show
unprocessed enrichment ratios for all probes within a genomic region (ChIP vs. whole
genomic DNA). Genes are shown to scale below plots (exons are represented by vertical
bars). The start and direction of transcription are noted by arrows.
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f. Suzl2 binding profiles across the gene encoding LHX9 in H9 human ES cells (green)
and primary human skeletal myotubes (grey). The plots show unprocessed enrichment
ratios for all probes within a genomic region (ChIP vs. whole genomic DNA). Genes are
shown to scale below plots (exons are represented by vertical bars). The start and
direction of transcription are noted by arrows.
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We next examined the expression of Suzl2 target genes in Suz 12-deficient cell
lines derived from homozygous mutant blastocysts (Appendix C). We reasoned that
genes bound by Suzl2 in human ES cells have orthologs in mice that should be
upregulated in Suzl2-deficient mouse cells, although we expected the overlap in these
sets of genes to be imperfect because of potential differences between human and mouse
ES cells, the possible repression of PRC2 target genes by additional mechanisms,
pleotropic effects of the Suz 12 knockout on genes downstream of Suz 12-target genes,
and the false positive and negative rates in both binding and expression analysis.
Differences in gene expression between Suzl2 homozygous mutant cells and wild-type
ES cells were measured using gene expression microarrays and the human Suzl2 binding
data mapped to orthologous mouse genes using Homologene (Wheeler et al., 2006).
Among the orthologs in this comparison, we found that a significant portion of the genes
bound by Suzl2 in human ES cells were upregulated in Suz12-deficient mouse cells (p =
6x10-4); these genes are listed in Table S14. The genes occupied by Suzl2 in human ES
cells were more likely to be activated in Suz12-deficient mouse cells than genes that were
not occupied by Suz12 (Figure 6C). Furthermore, we found that the Suzl2 target genes
that were induced upon human ES cell differentiation were generally also induced upon
loss of Suzl2 in mouse cells (Figure 6D). Genes that were activated during ES cell
differentiation and in Suz 12-deficient cells included the transcriptional regulators
GATA2, GATA3, GATA6, HAND 1, MEIS2 and SOX 17, the signaling proteins
WNT5A, DKK I (dickkopf homolog 1), DKK2, EFNA I (ephrin A 1), EFNB 1, EPHA4
(ephrin receptor A4) and EPHB3 and the cell cycle inhibitor CDKN IA. These data
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indicate that Suzl2 is necessary to fully repress the genes that are occupied by PRC2 in
wild-type ES cells.
If PRC2 functions to repress genes in ES cells that are activated during
differentiation, then in differentiated tissues Suzl2 occupancy should be diminished at
genes encoding developmental regulators that have a role in specifying the identity of
that tissue, similar to results seen with Ezh2 at specific genes in mouse (Caretti et al.,
2004). To test this, we designed an array focused on the promoters of developmental
regulators and used ChIP-Chip to investigate Suzl2 occupancy at these promoters in
primary differentiated muscle cells. The results demonstrated that genes encoding key
regulators of muscle differentiation, including MyoD, displayed greatly diminished
Suzl2 occupancy when compared to ES cells (Figure 6E). MyoD is a master regulator
for muscle differentiation (Berkes and Tapscott, 2005; Tapscott, 2005), and the gene
encoding this transcription factor displayed no significant Suzl2 occupancy when
compared to the levels of Suzl2 occupancy observed in ES cells. Genes encoding other
transcriptional regulators that play a central role in muscle development, such as Pax3
and Pax7 (Brand-Saberi, 2005), showed reduced levels of Suzl2 occupancy in muscle
cells relative to ES cells (Appendix C, Figure S 11). In contrast, other developmental
regulators important for differentiation of non-muscle tissues remained occupied by
Suzl2 in differentiated muscle cells (Figure 6F and Table S 15). These data support a
model where Suzl2 binding in ES cells represses key developmental regulators that are
later expressed during differentiation.
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Targets of PRC2 are shared with key ES cell regulators
The transcription factors Oct4, Sox2 and Nanog have essential roles in early
development and are required for the propagation of undifferentiated ES cells in culture
(Nichols et al., 1998; Avilion et al., 2003; Chambers et al., 2003; Mitsui et al., 2003). We
recently reported that these transcription factors occupied promoters for many important
developmental regulators in human ES cells (Boyer et al., 2005). This led us to compare
the set of genes encoding developmental regulators and occupied by Oct4, Sox2 and
Nanog with those occupied by PRC2 (Figure 7; Appendix C). We found that each of the
three DNA-binding transcription factors occupied approximately one-third of these
PRC2-occupied developmental genes (Figure 7A, Table S 11). Remarkably, we found
that the subset of genes encoding developmental regulators that were occupied by Oct4,
Sox2 and Nanog and repressed in the regulatory circuitry highlighted in Boyer et al. were
almost all occupied by PRC2 (Figure 7B). These included transcription factors known to
be important for differentiation into extra-embryonic, endodermal, mesodermal, and
ectodermal lineages (e.g., ESXIL, ONECUT 1I, HANDI, HOXBl). As expected, active
genes encoding ES cell transcription factors (e.g., ZIC3, STAT3, OCT4, NANOG) were
occupied by Oct4, Sox2, Nanog and RNA polymerase II, but not PRC2 (Figure 7B).
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Figure 7. Suz12 is localized to genes also bound by
ES cell transcriptional regulators
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Figure 7. Suzl2 is localized to genes also bound by ES cell transcriptional
regulators.
a. Transcriptional regulatory network model of developmental regulators governed by
Oct4, Sox2, Nanog, RNA polymerase II and Suzl2 in human ES cells. The ES cell
transcription factors each bound to approximately one-third of the PRC2-occupied,
developmental genes. Developmental regulators were selected based on gene ontology.
Regulators are represented by dark blue circles; RNA polymerase II is represented by a
light blue circle; Suz12 is represented by a green circle; gene promoters for
developmental regulators are represented by small red circles.
b. Suzl2 occupies a set of repressed developmental regulators also bound by Oct4, Sox2
and Nanog in human ES cells. Genes annotated as bound by Oct4, Sox2 and Nanog
previously and identified as active or repressed based on expression data (Boyer et al.,
2005) were tested to see if they were bound by Suzl2 or RNA polymerase II. Ten of
eleven previously identified active genes were found to be bound by RNA polymerase II
at known promoters while eleven of twelve previously identified repressed genes were
bound by Suzl2. Regulators are represented by dark blue circles; RNA polymerase II is
represented by a light blue circle; Suz12 is represented by a green circle; gene promoters
are represented by red rectangles.
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The observation that Oct4, Sox2 and Nanog are bound to a significant subset of
developmental genes occupied by PRC2 supports a link between repression of
developmental regulators and stem cell pluripotency. Like PRC2, Oct4 and Nanog have
been shown to be important for early development and ES cell identity. It is possible,
therefore, that inappropriate regulation of developmental regulators that are common
targets of Oct4, Nanog and PRC2 contributes to the inability to establish ES cell lines in
OCT4, NANOG and EZH2 mutants (Nichols et al., 1998; O'Carroll et al., 2001;
Chambers et al., 2003; Mitsui et al., 2003).
139
Conclusion
We have mapped the sites occupied by Suzl2 throughout the genome to gain
insights into how PRC2 contributes to pluripotency in human embryonic stem cells. ES
cells proliferate in an undifferentiated state yet remain poised to respond to development
cues. Genes encoding the transcriptional regulators that promote differentiation must
therefore be repressed in ES cells but activated upon receiving signals to differentiate.
We found that PRC2 occupies large domains at genes encoding a key set of repressed
developmental regulators that are preferentially activated upon cellular differentiation,
thus implicating this complex directly in the maintenance of the pluripotent state.
Transcription factors and chromatin regulators contribute to the transcriptional
regulatory circuitry responsible for pluripotency and self-renewal in human ES cells.
Understanding this circuitry is fundamental to understanding human development and
realizing the therapeutic potential of these cells. In this context, we find it exciting that
the outlines of the core transcriptional regulatory circuitry of human ES cells are
emerging. The transcription factors Oct4, Sox2, and Nanog are associated with actively
transcribed genes that contribute to growth and self-renewal (Boyer et al., 2005). These
factors also occupy genes encoding key developmental regulators that are
transcriptionally repressed, due at least in part to their association with PRC2 and
nucleosomes modified at histone H3K27me3. Further study of transcription factors and
chromatin regulators genome-wide will allow investigators to produce a more
comprehensive map of transcriptional regulatory circuitry in ES cells and to test models
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that emerge from the circuitry. This information may provide insights into approaches by
which pluripotent cells can be stimulated to differentiate into different cell types.
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Methods
See Appendix C.
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Tcf3 is an Integral Component of the Core Regulatory Circuitry of Embryonic Stem
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My contributions to this work
Following the initial characterization of the core transcriptional regulatory
circuitry of ES cells, I became interested in understanding how signaling pathways
impact this circuitry. I felt that exploring this topic would be essential for understanding
both how to cells maintain pluripotency in culture and how to direct cells to differentiate
towards particular lineages. With this in mind, I worked with Megan Cole and Jamie
Newman to explore the role of Wnt signaling in ES cells. We were interested in
characterizing the role of Wnt in ES cells by understanding the target genes for this
pathway.
I was highly involved in every aspect of this project. Megan, Jamie and I each
contributed equally to the conceptualization of the project, the experimental design,
executing the experiments, analyzing the data and writing the manuscript. To make our
experimental efforts maximally efficient, we divided the experimental space. My
responsibility was generating an ES cell line deficient in Tcf3 and analyzing the gene
expression profile for these cells. I was also involved in much of the growing and
manipulating of the ES cells that is described in this paper.
I was involved in analyzing both the genome-wide ChIP-chip data and expression
data and exploring possible connections between Wnt signaling, Tcf3 and the core
regulatory circuitry of ES cells. I contributed to each figure in the paper and the writing
of the text.
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Summary
Embryonic stem cells have a unique regulatory circuitry, largely controlled by the
transcription factors Oct4, Sox2 and Nanog, which generates a gene expression program
necessary for pluripotency and self-renewal (Boyer et al., 2005; Loh et al., 2006;
Chambers et al., 2003; Mitsui et al., 2003; Nichols et al., 1998). How external signals
connect to this regulatory circuitry to influence embryonic stem cell fate is not known.
We report here that a terminal component of the canonical Wnt pathway in embryonic
stem cells, the transcription factor Tcf3, co-occupies promoters throughout the genome in
association with the pluripotency regulators Oct4 and Nanog. Thus Tcf3 is an integral
component of the core regulatory circuitry of ES cells, which includes an autoregulatory
loop involving the pluripotency regulators. Both Tcf3 depletion and Wnt pathway
activation cause increased expression of Oct4, Nanog and other pluripotency factors and
produce ES cells that are refractory to differentiation. Our results suggest that the Wnt
pathway, through Tcf3, brings developmental signals directly to the core regulatory
circuitry of ES cells to influence the balance between pluripotency and differentiation.
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Introduction
Embryonic stem (ES) cells provide a unique opportunity to study early
development and hold great promise for regenerative medicine (Thomson et al., 1998;
Reubinoff et al., 2000; Pera and Trounson, 2004). ES cells are derived from the inner
cell mass of the developing blastocyst and can be propagated in culture in an
undifferentiated state while maintaining the capacity to generate any cell type in the
body. Discovering how signaling pathways and transcriptional regulatory circuitry
contribute to self-renewal and pluripotency is essential for understanding early
development and realizing the therapeutic potential of ES cells.
A model for the core transcriptional regulatory circuitry of ES cells has emerged
from studying the target genes of the ES cell transcription factors Oct4, Sox2 and Nanog
(Boyer et al., 2005; Loh et al., 2006). These master regulators occupy the promoters of
active genes encoding transcription factors, signal transduction components and
chromatin modifying enzymes that promote ES cell self-renewal. They also occupy the
promoters of a large set of developmental transcription factors that are silent in ES cells,
but whose expression is associated with lineage commitment and cellular differentiation.
Polycomb Repressive Complexes co-occupy the genes encoding these developmental
transcription factors to help maintain a silent transcriptional state in ES cells (Boyer et al.,
2006; Lee et al., 2006; Wilkinson et al., 2006; Rajaskhar and Begemann, 2007; Stock et
al., 2007).
External signals can promote ES cell pluripotency or cause these cells to
differentiate, but precisely how these pathways are connected to the ES cell regulatory
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network has not been determined. These signals are produced by the stem cell niche in
the developing blastocyst or, for cultured ES cells, can be produced by added factors or
serum to maintain stem cell identity or promote differentiation. Recent studies have
demonstrated the importance of several signaling pathways in maintaining or modifying
ES cell state, including the Activin/Nodal, Notch, BMP4 and Wnt pathways (Rao et al.,
2004; Kristensen et al., 2005; Friel et al., 2005; Boiani and Scholer, 2005;
Valdimarsdottir and Mummery, 2005; Dreesen and Brivanlou, 2007; Pan and Thomson,
2007). By understanding how these signaling pathways influence the gene expression
program of ES cells, it should be possible to discover how they contribute to embryonic
stem cell identity or promote specific differentiation programs.
The Wnt/j3-catenin signaling pathway has multiple roles in embryonic stem cell
biology, development and disease (Logan and Nusse, 2004; Reya and Clevers, 2005;
Clevers, 2006). Several studies have shown that activation of the Wnt pathway can cause
ES cells to remain pluripotent under conditions that induce differentiation (Kielman et al.,
2002; Sato et al., 2004; Singla et al., 2006; Hao et al., 2006; Ogawa et al., 2006;
Miyabashi et al., 2007; Takao et al., 2007), while other studies have shown that the Wnt
pathway has an important role in directing differentiation of ES cells (Otero et al., 2004;
Lindsley et al., 2006). Recent studies have shown that T Cell Factor-3 (Tcf3), a terminal
component of the Wnt pathway, acts to repress the Nanog gene in ES cells (Pereira et al.,
2006), providing an important clue for at least one mechanism by which the Wnt pathway
regulates stem cell state. Nonetheless, we have an incomplete understanding of how the
pathway exerts its effects, in part because few target genes have been identified for its
terminal components in ES cells.
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Stimulation of the canonical Wnt signaling pathway causes the transcriptional co-
activator 3-catenin to translocate to the nucleus, where it interacts with constitutively
DNA-bound Tcf/Lef proteins to activate target genes (Behrens et al., 1996; Brantjes et
al., 2001; Cadigan, 2002). Tcf3, a member of the Tcf/Lef family, is highly expressed in
murine embryonic stem (mES) cells and is critical for early embryonic development
(Korinek et al., 1998; Merrill et al., 2004; Pereira et al., 2006). To determine how the
Wnt pathway is connected to the gene expression program of ES cells, we have
determined the genome-wide binding profile of Tcf3 and examined how perturbations of
the pathway affect the gene expression program. Remarkably, the genome-wide data
reveal that Tcf3 co-occupies the ES cell genome with the pluripotency transcription
factors Oct4 and Nanog. These and other results reveal that the Wnt pathway brings
developmental signals directly to the core regulatory circuitry of ES cells, which consists
of the pluripotency transcription factors and Tcf3, together with their mutual target genes.
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Results
Identification of Tcf3 Binding Sites Genome-wide
To determine how the Wnt pathway regulates the gene expression program of
murine embryonic stem cells, we first identified genes occupied by Tcf3. Murine
embryonic stem cells were grown under standard conditions (Appendix D Fig. S 1) and
DNA sequences occupied by Tcf3 were identified using chromatin immunoprecipitation
(ChIP) combined with DNA microarrays (ChIP-Chip). For this purpose, DNA
microarrays were designed with 60-mer oligonucleotide probes tiling the entire non-
repeat portion of the mouse genome. The results revealed that Tcf3 occupies over 1000
murine promoters (Appendix D Table S 1), including those of the known Wnt targets
Axin2 and Myc (Fig. IA)(He et al., 1998; Yan et al., 2001; Jho et al., 2002).
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Figure 1
Tcf3, Oct4 and Nanog co-occupy the genome in mouse ES cells.
(A). Tcf3 binds to known target genes. Examples of previously known Tcf3 bound
regions are displayed as unprocessed ChIP-enrichment ratios for all probes within the
chromosomal region indicated beneath the plot. The gene is depicted below the plot, and
the TSS and direction are denoted by an arrow.
(B). Tcf3, Oct4 and Nanog display nearly identical binding profiles. Analysis of ChIP-
chip data from genes bound by Tcf3, Oct4, or Nanog reveals that the three factors bind to
similar genomic regions at all promoters. Regions from -8kb to +2kb around each TSS
were divided into bins of 250bp. The raw enrichment ratio for the probe closest to the
center of the bin was used. If there was no probe within 250bp of the bin center then no
value was assigned. For genes with multiple promoters, each promoter was used for
analysis. The analysis was performed on 3764 genes, which represents 4086 promoters.
Promoters are organized according to the distance between the maximum Tcf3 binding
ratio and the TSS.
(C). Tcf3, Oct4 and Nanog bind in close proximity at target genes. Plots display
unprocessed ChIP-enrichment ratios for all probes within the chromosomal region
indicated beneath the plot. The gene is depicted below the plot, and the TSS and
direction are denoted by an arrow.
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Tcf3 Co-occupies the Genome with ES Cell Master Regulators
Inspection of the genes occupied by Tcf3 revealed a large set that were previously
shown to be bound by the homeodomain transcription factor Oct4 (Boyer et al., 2005;
Loh et al., 2006), which is an essential regulator of early development and ES cell
identity (Nichols et al., 1998; Hay et al., 2004). To examine the overlap of gene targets
more precisely, we carried out ChIP-Chip experiments with antibodies directed against
Oct4 in mES cells and used the same genome-wide microarray platform employed in the
Tcf3 experiment. Remarkably, the binding profiles of Tcf3 and Oct4 revealed that they
bind the same genomic regions and display identical spatial distribution patterns with
regards to transcription start sites (Fig. IB; Appendix D Fig. S2). These results identified
a set of 1224 genes that are co-occupied by Tcf3 and Oct4 at high confidence (Appendix
D Table S1) and suggested that the Wnt pathway connects directly to genes regulated by
Oct4 through Tcf3.
Previous studies in human embryonic stem cells have shown that Oct4 shares
target genes with the transcription factors Nanog and Sox2 (Boyer et al., 2005),
suggesting that Tcf3-occupied genes in murine ES cells should also be occupied by
Nanog and Sox2. Additional genome-wide ChIP-Chip experiments with antibodies
directed against Nanog revealed that it does indeed bind the same sites occupied by Oct4
and Tcf3 (Fig. 1 B,C and 2, Appendix D Fig. S2). The fact that Oct4 and Sox2 form
heterodimers in ES cells (Dailey and Bascilico, 2001; Okumura-Nakanishi et al., 2005)
and frequently co-occupy promoters in human ES cells (Boyer et al., 2005) makes it
likely that Tcf3 co-occupies much of the genome with Oct4, Nanog and Sox2.
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Figure 2
Tcf3, Oct4 and Nanog bind the promoters of Tcf3, Oct4, Sox2 and Nanog. Plots display
unprocessed ChIP-enrichment ratios for all probes within the chromosomal region
indicated beneath the plot. The gene is depicted below the plot, and the TSS and
direction are denoted by an arrow.
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The observation that Tcf3 co-occupies much of the genome with the ES cell
pluripotency transcription factors has a number of implications for the regulatory
circuitry of these cells. Tcf3 binds its own promoter as well as the promoters of genes
encoding Oct4, Sox2 and Nanog (Fig. 2). Thus Tcf3 is an integral component of an
interconnected autoregulatory loop, where all four transcription factors together occupy
each of their own promoters (Fig. 3A). This feature of ES cell regulatory circuitry was
previously described for Oct4, Sox2 and Nanog alone (Boyer et al., 2005) and has been
postulated to be a common regulatory motif for master regulators of cell state (Chambers
et al., 2003; Okumura-Nakanishi et al., 2005; Rodda et al., 2005; Odom et al., 2004;
Odom et al., 2006). Autoregulation is thought to provide several advantages to the control
of cell state, including reduced response time to environmental stimuli and increased
stability of gene expression (McAdams et al., 1997; Rosenfeld et al., 2002; Shenn-Orr et
al., 2002; Thieffry et al., 1998). It is also notable that Tcf3 and the pluripotency
transcription factors together occupy genes encoding many Wnt pathway components
(Appendix D Fig. S3), suggesting that this transcription factor regulates much of its own
signaling pathway apparatus together with the pluripotency factors.
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Figure 3
Tcf3 is an integral component of the core regulatory circuitry of ES cells.
(A). Tcf3 forms an interconnected autoregulatory loop with Oct4, Sox2 and Nanog.
Proteins are represented by ovals and genes by rectangles.
(B). Model showing a key portion of the regulatory circuitry of murine embryonic stem
cells where Oct4, Sox2, Nanog and Tcf3 occupy both active and silent genes. The
evidence that Oct4, Nanog and Tcf3 occupy these genes is described here; Sox2
occupancy is inferred from previous studies in human ES cells (Boyer et al., 2005).
Evidence that the transcriptionally silent genes are occupied by Polycomb Repressive
Complexes is from Boyer et al. (2006) and unpublished data and that these genes have
stalled RNA polymerases is from Guenther et al. (2007) and Stock et al. (2007). Proteins
are represented by ovals and genes by rectangles.
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A model for the core regulatory circuitry of ES cells has been proposed in which
the genes bound by the master regulators Oct4, Sox2 and Nanog fall into two classes:
transcriptionally active genes encoding transcription factors, signaling components and
other products that support the stem cell state, and transcriptionally inactive genes,
consisting mostly of developmental regulators, where Polycomb is bound and RNA
polymerase II is recruited, but transcription is stalled (Boyer et al., 2005; Boyer et al.,
2006; Lee et al., 2006; Guenther et al., 2007; Stock et al., 2007; Zeitlinger et al., 2007).
Our results reveal that Tcf3, together with the pluripotency regulators, is associated with
both classes of genes, and thus provide a modified model of the core regulatory circuitry
of ES cells (Fig. 3B). The association of Tcf3 with the set of genes encoding key
transcription factors, signaling pathway components, and developmental regulators
suggests that the Wnt signaling pathway contributes to the regulation of these genes,
thereby impacting embryonic stem cell pluripotency and self-renewal.
Expression Analysis of Tcf3 Knockdown in mES Cells
Genes bound by Tcf/Lef proteins are thought to be repressed in the absence of
Wnt/3-catenin signaling and to be activated upon Wnt pathway stimulation (Behrens et
al., 1996; Brantjes et al., 2001; Miyabayashi et al., 2007; Daniels et al., 2005; Cavallo et
al., 1998). Murine ES cells have low endogenous Wnt activity in standard culture
conditions and the Wnt pathway can be further stimulated in culture (Dravid et al., 2005;
Yamaguchi et al., 2005; Lindsley et al., 2006; Ogawa K et al., 2006; Anton et al., 2007;
Takao et al., 2007) (Appendix D Fig. S4). Thus it is unclear whether Tcf3-occupied
genes are being repressed or activated at the low level of Wnt activity characteristic of
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standard ES cell culture conditions. To investigate whether the effect of Tcf3 occupancy
is to repress or to activate genes, RNAi constructs were used to deplete Tcf3 mRNA in
mES cells in two independent experiments (Appendix D Fig. S5) and changes in global
mRNA levels were assayed with DNA microarrays (Fig. 4A). The ~3.5% of mouse
genes whose mRNA levels changed by at least two-fold were significantly enriched for
Tcf3 targets relative to genes whose expression was unaltered by the Tcf3 knockdown (p
value < 2 x 10-'0; Appendix D Fig. S6; Appendix D Table S2). The genes whose
expression increased upon loss of Tcf3 included those encoding the master regulators
Oct4, Sox2 and Nanog, other genes involved in pluripotency such as Lefty2 and Nodal,
and the Wnt pathway component Dkkl (Fig. 4A). The fact that upregulated genes are
strongly enriched for Tcf3 binding suggests that Tcf3 mainly acts to repress genes. Upon
loss of Tcf3, target genes are no longer repressed and can now be activated by other
factors (such as Oct4, Sox2 and Nanog) present at their promoters.
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Figure 4
Knockdown of Tcf3 and activation of the Wnt pathway in mES cells reveals a role for
Tcf3 in repression of target genes and a role in regulating pluripotency.
(A). Tcf3 knockdown results in up-regulation of target genes. The effect of Tcf3
knockdown on gene expression was measured by hybridization of labeled RNA prepared
from Tcf3 knockdown cells against RNA prepared from cells infected with non-silencing
control lentivirus at 48 hours post infection. A heat map of biological replicate datasets
of expression changes was generated where genes are ordered according to average
expression change. Tcf3 target genes have a higher average expression change than the
average for all genes upon knockdown of Tcf3.
(B). Wnt conditioned media (CM) results in up-regulation of Tcf3 target genes. The
effect of Wnt activation on gene expression was measured by hybridization of labeled
RNA prepared from mES cells grown in Wnt CM against RNA prepared from cells
grown in mock CM. A heat map of biological replicate datasets of expression change
upon addition of Wnt conditioned media where genes are ordered according to average
expression change of replicates. Tcf3 target genes have a higher average expression
change than the average for all genes upon addition of Wnt CM.
(C). Tcf3 knockdown results in increased expression of Oct4, Sox2 and Nanog. Real-time
PCR demonstrates that Oct4, Sox2 and Nanog have increased expression upon
knockdown of Tcf3. Values are normalized to Gapdh transcript levels, and fold change is
relative to cells transfected with a non-silencing hairpin. (D). Tcf3 knockdown results in
increased staining for Oct4 and Nanog. Immunofluorecence was performed on mES cells
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grown one passage off of feeders that were either infected with Tcf3 knockdown
lentivirus or infected with non-silencing control lentivirus. Cells were fixed with 4%
paraformaldehyde 96 hours post-infection. Cells were stained with Oct4, Nanog and
DAPI. Images for Oct4 and Nanog staining were taken at 40x magnification and an
exposure time of 300 msec. Tcf3 KD I and 2 represent different knockdown hairpin
constructs. Tcf3 KD 2 is the virus also used in panels 4A,C,E,F.
(E). Tcf3 knockdown results in a significant increase of Oct4 staining. Quantification of
Oct4 staining was performed in cells infected with Tcf3 or Gfp knockdown virus.
(F). Tcf3 knockdown cells proliferate over more passages in the absence of LIF. Relative
cell numbers of ES cells transfected with Tcf3 or control virus through multiple passages
off of feeders in the presence or absence of LIF. Identical cell numbers were initially
plated and cells were split 1:12 every 2-3 days. Cells were counted at each passage and
values for cells grown in the absence of LIF were normalized to cells grown in the
presence of LIF.
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While expression of Tcf3 target genes was often up-regulated upon loss of Tcf3,
the expression of a substantial number of Tcf3-bound genes remained unchanged, and a
relatively small number of Tcf3-bound genes showed reduced expression (Fig. 4A).
Nearly half of the genes occupied by Tcf3, Oct4 and Nanog are co-occupied by
Polycomb Repressive Complexes (Boyer et al., 2006; Lee et al., 2006; Wilkinson et al.,
2006; Rajaskhar and Begemann, 2007), and their transcriptional state would not be
expected to change as Polycomb would prevent elongation of transcripts at these genes
(Stock et al., 2007). Indeed, we find that expression of genes occupied by Tcf3 and
Polycomb do not show a significant expression change upon loss of Tcf3 (p value > 0.4).
There were some Tcf3 target genes whose expression was down-regulated upon loss of
Tcf3; because mES cells have a low level of Wnt pathway activation, it is possible that
sufficient b-catenin enters the nucleus in order to associate with and activate this subset
of genes. Indeed, we find that some amount of p-catenin does associate with Tcf3 and
Oct4 as 1-catenin can be detected in crosslinked chromatin extracts immunoprecipitated
for either Tcf3 or Oct4 (Appendix D Fig. S7). It is also possible that the loss of
expression of this set of Tcf3 target genes is a secondary consequence of the knockdown.
The repressive activity of Tcf3 appears to be its dominant function for most genes under
these conditions, as the set of Tcf3 bound genes were found to have a significantly higher
increase in expression upon knockdown compared to all genes (Fig. 4A; p value <
7 x 10-5).
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Expression Analysis of Wnt Pathway Activation in mES Cells
We next studied the effect of increased stimulation of the Wnt pathway on Tcf3
target genes in murine ES cells. Cells were treated with Wnt3a conditioned media in two
independent experiments, and changes in global mRNA levels were assayed with DNA
microarrays (Fig. 4B). The <1% of mouse genes whose mRNA levels changed by at
least two-fold in the Wnt treated cells were significantly enriched for Tcf3 targets relative
to genes whose expression was unaltered by the addition of Wnt (p value < 1.5 x 10-5;
Appendix D Fig. S8; Appendix D Table S3). The genes whose expression most
increased encode the pluripotency factors Oct4 and Nanog, Wnt pathway components
such as Wnt8a and Dkkl, and known Wnt targets such as Brachury (Fig. 4B). These
results are consistent with a model where Tcf3 acts to partially repress many of its target
genes under standard mES cell culture conditions, yet contributes to increased expression
of its target genes under conditions of increased Wnt stimulation. We would therefore
expect a correlation between genes up-regulated upon loss of Tcf3 and genes up-
regulated upon Wnt stimulation. Indeed, we do find these gene sets to be significantly
correlated (p value < 1 x 108; Appendix D Fig. S9). Although a significant portion of
Tcf3 target genes undergo expression changes upon Wnt stimulation, it is possible that a
second class of Tcf3 target genes are regulated independently of Wnt signaling and
therefore are uninfluenced by changes in pathway activation (Yi and Merrill, 2007). In
fact, several studies have shown a (3-catenin independent role for Tcf3 (Kim et al., 2000;
Merrill et al., 2001; Roel et al., 2002). It should also be noted that ES cells express other
mammalian Tcf/Lef proteins and that these factors may also mediate the functional
consequences of Wnt signaling (Pereira et al., 2006).
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Influence of Tcf3 and Wnt on Pluripotency Regulators and ES Cell State
Evidence that Tcf3 is an integral component of the core transcriptional circuitry of
ES cells that functions to partially repress transcription of pluripotency genes led us to
examine whether Tcf3 knockdown enhances features of ES cells associated with
pluripotency and self-renewal. Quantitative real-time PCR analysis demonstrated that
Tcf3 knockdown in mES cells results in higher transcript levels for the pluripotency
genes Oct4, Sox2 and Nanog (Fig. 4C). Upregulation of Nanog upon Tcf3 depletion
confirms a previous report that Tcf3 acts to repress this gene under normal ES cell
growth conditions(Pereira et al., 2006). Thus the results of the Tcf3 knockdown
experiment indicate that under normal conditions Tcf3 functions to reduce expression of
the three pluripotency regulators.
We next measured the levels of Oct4 and Nanog proteins in ES cells subjected to
Tcf3 knockdown. The results of immunofluorescence experiments show that there are
substantial increases in the levels of Oct4 and Nanog transcription factors in the nucleus
of such cells (Fig. 4D). There is a significant increase of Oct4 in Tcf3 knockdown cells
compared to control cells based on quantitative measurements of staining intensity using
Cellomics software (Fig. 4E). Remarkably, Tcf3 knockdown mES cells display enhanced
proliferation and Oct4 staining in the absence of feeders and LIF compared to control
cells, supporting previous results (Fig. 4F; Appendix D Fig. S 10)(Pereira et al., 2006).
Previous studies have demonstrated that activation of the Wnt/3-catenin pathway can
have similar effects on ES cell pluripotency (Sato et al., 2003; Singla et al., 2006; Hao et
al., 2006) and we also find that cells treated with Wnt conditioned media show increased
staining of Oct4 (Appendix D Fig. S 11). The observation that Tcf3 knockdown and Wnt
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stimulation have similar functional consequences is consistent with the expression data
described above for ES cells subjected to Tcf3 knockdown and ES cells treated with
Wnt3a CM. These studies demonstrate the functional importance of Tcf3 occupancy and
Wnt pathway activation for a subset of target genes that includes the pluripotency
regulators.
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Discussion
It is fundamentally important to determine how signaling pathways control ES
cell pluripotency and differentiation and how these pathways connect to discrete sets of
target genes to affect such states. We have found that a terminal component of the Wnt
signaling pathway, the transcription factor Tcf3, is physically associated with the same
genomic sites as the pluripotency regulators Oct4 and Nanog in murine embryonic stem
cells. This result reveals that the Wnt pathway is physically connected to the core
regulatory circuitry of these cells. This core circuitry consists of two key features: an
interconnected autoregulatory loop and the set of target genes that are mutually bound by
the pluripotency transcription factors and Tcf3.
The genome-wide datasets we report here enhance our knowledge of the targets of
Oct4, Nanog and Tcf3. These new datasets were generated using the same protocols and
genome-wide tiling microarrays in ES cells grown under identical conditions, allowing
more reliable conclusions about the overlap of these factors throughout the genome;
previous datasets for these factors came from different murine ES cells grown in different
settings, using different chromatin IP analysis platforms, and these data were not always
genome-wide (Boyer et al., 2005; Boyer et al., 2006; Loh et al., 2006). The new data
reveal, for example, the remarkable extent to which Oct4 and Nanog binding overlap
throughout the ES cell genome and the striking association of Tcf3 with those sites (Fig.
1B). The new data also provide a revised model for the core regulatory circuitry of
murine ES cells, which incorporates Tcf3 and high confidence target genes of key ES cell
regulators (Fig. 3).
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The revised model of core regulatory circuitry extends our knowledge of how
extracellular signals from the Wnt pathway contribute to stem cell state. Pereira et al.
(2006) demonstrated that Tcf3 binds the Nanog promoter and represses its mRNA
expression in mES cells. Our data confirm Tcf3 binding and function at Nanog and
extend our knowledge of Tcf3 targets to the other well-characterized pluripotency
regulators Oct4 and Sox2, as well as most of their target genes. Pereira et al. (2006)
proposed a model wherein Tcf3-mediated control of Nanog levels allows stem cells to
balance the creation of lineage-committed and undifferentiated cells. Our results also
support this model, but argue that Tcf3 contributes to the balance through its functions in
the core regulatory circuitry described here.
Our results suggest that the Wnt pathway, through Tcf3, influences the balance
between pluripotency and differentiation in ES cells, as modeled in Figure 5. Under
standard culture conditions, where there is a low-level of Wnt activation, ES cells are
poised between the pluripotent state and any of a number of differentiated states. It is
well established that Oct4, Sox2 and Nanog act to promote the pluripotent state, as
depicted in the model where the influence of these factors is shown by an arrow. Under
standard culture conditions, Tcf3 may exist in an activating or repressive complex, but is
predominantly in a repressive complex promoting differentiation. The loss of Tcf3 in
Tcf3 knockdown cells, would, in this model, favor pluripotency. Wnt stimulation
converts the repressive complex to an activating complex and thus promotes
pluripotency. Our results suggest that the Wnt pathway, through Tcf3, influences the
balance between pluripotency and differentiation by bringing developmental signals
directly to the core regulatory circuitry of ES cells. The observation that the Wnt
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pathway can be manipulated to affect the balance between pluripotency and
differentiation suggests that perturbation of this pathway may impact the efficiency of
reprogramming somatic cells into pluripotent stem cells.
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Figure 5
Model depicting the influence of Wnt pathway components on pluripotency and
differentiation in ES cells. ES cells are poised between the pluripotent state and any of a
number of differentiated states. Oct4, Sox2 and Nanog act to promote the pluripotent
state (depicted by an arrow). Tcf3 can exist in an activating complex with 3-catenin or a
repressive complex with Groucho (Reya and Clevers, 2005). Under standard growth
conditions, the Wnt pathway is only active at low levels (Dravid et al., 2005; Yamaguchi
et al., 2005; Lindsley et al., 2006; Ogawa K et al., 2006; Anton et al., 2007; Takao et al.,
2007)(Appendix D Fig. S4). Therefore Tcf3 is mainly in a repressive complex promoting
differentiation (depicted by a thick arrow), although some Tcf3 associates with P-catenin
to activate target genes and promote pluripotency (depicted by a thin arrow). In Tcf3
knockdown cells, there is no influence from Tcf3 on cell state. Thus the balance is tipped
towards maintaining pluripotency. Upon Wnt stimulation, the balance again tips towards
maintaining pluripotency as more Tcf3 associates with P-catenin in an activating
complex (depicted by a thick arrow). This model is not meant to imply that Wnt or Tcf3
are themselves pluripotency factors, but rather that they can influence cell state in the
presence of other pluripotency factors, such as Oct4, Sox2 and Nanog.
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Materials and methods
Mouse embryonic stem cell culture conditions
V6.5 murine ES cells were grown on irradiated murine embryonic fibroblasts
(MEFs) unless otherwise stated. Cells were grown under mES cell conditions as
previously described in Boyer et al. (2005). Briefly, cells were grown on 0.2%
gelatinized tissue culture plates in DMEM-KO (Invitrogen 10829-018) supplemented
with 15 % fetal bovine serum (Hyclone, Characterized SH3007103), 1000 Units/mL
leukemia inhibitory factor (LIF) (ESGRO ESG 1106), 100piM nonessential amino acids
(Invitrogen 11140-050 ), 2mM L-glutamine (Invitrogen 25030-081 ),100 Units/mL
pennicillin and 100 p/g/mL streptomycin (Invitrogen 15140-122), and 8 nL/ml 2-
mercaptoethanol (Sigma M7522).
Genome-wide location analysis
Chromatin immunoprecipitation protocol
Protocols describing ChIP methods were downloaded from
http://jura.wi.mit.edu/young public/hESregulation/ChIP.html with slight modifications.
Briefly, 10" mES cells were grown for one passage off of feeders and then crosslinked
using formaldehyde. Cells were resuspended, lysed in lysis buffer and sonicated to
solubilize and sheer crosslinked DNA. Triton X-100 and SDS were added to the lysate
after sonication to final concentrations of 1% and 0. 1% respectively. The resulting whole
cell extract was incubated at 40 C overnight with 100 uL of Dynal Protein G magnetic
beads that had been preincubated with 10 ug of the appropriate antibody overnight. After
16-18 hours, beads were washed with the following 4 buffers for 4 minutes per buffer:
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low salt buffer (20mM Tris pH 8.1, 150mM NaCI, 2mM EDTA, 1% Triton X-100, 0.1%
SDS), high salt buffer (20mM Tris pH 8.1, 500mM NaCI, 2mM EDTA, 1% Triton X-
100, 0.1% SDS), LiCI buffer (10mM Tris pH 8.1, 250mM LiCI, ImM EDTA, 1%
deoxycholate, 1% NP-40), and TE+ 50mM NaCI. Bound complexes were eluted from
the beads in elution buffer by heating at 650 C with occasional vortexing, and crosslinks
were reversed by overnight incubation at 650 C.
ChIP Antibodies
Cell extracts were immunoprecipitated using antibodies against Tcf3 (Santa Cruz
sc-8635), Oct4 (Santa Cruz sc-8628) or Nanog (Bethyl Labs bl 11662).
Array Design
The murine 244k whole genome array was purchased from Agilent Technology
(www.agilent.com). The array consists of 25 slides each containing -244,000 60mer
oligos (slide ID 15310-3, 15317, 15319-21, 15323, 15325, 15327-30, 15332-7, 15339-41,
15343-44) covering the entire non-repeat portion of the mouse genome at a density of
about I oligo per 250bp.
Data Normalization and Analysis
Data normalization and analyses were performed as previously described in Boyer et al.
(2005).
Tcf3 Knockdown
Lentiviral Production
Lentivirus was produced according to Open Biosystems Trans-lentiviralTM shRNA
Packaging System (TLP4614). The shRNA constructs targeting murine Tcf3 were
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designed using an siRNA rules based algorithm consisting of sequence, specificity and
position scoring for optimal hairpins that consist of a 21 base stem and a 6 base loop
(RMM4534-NM-009332). Five hairpin constructs were used to produce virus targeting
Tcf3. A negative control virus was made from the pLKO. 1 empty vector (RHS4080).
Lentiviral Infection of mES Cells
Murine V6.5 ES cells were plated at approximately 30% confluence on the day of
infection. Cells were seeded in 2x mES media with 6 ug/ml of polybrene (Sigma H9268-
O1G) and Tcf3 knockdown or control (pLKO. 1) virus was immediately added. After 24
hours, infection media was removed and replaced with mES media with 2 ug/ml of
Puromycin (Sigma P8833). RNA was harvested at 48 hours after infection.
Knockdown Efficiency
Knockdown efficiency was measured using real-time PCR to measure levels of
Tcf3 mRNA (Appendix D Fig. S5).
RNA Isolation, Real-time PCR and Analysis of Transcript Levels
To determine transcript levels by RT-PCR, RNA was isolated from approximately
106 - 10 7 mES cells using TRIzol reagent following the protocol for cells grown in
monolayer (Invitrogen 15596-026). Samples were treated with Dnase I (Invitrogen
18068-015) and cDNA was prepared using SuperScript III reverse transcriptase kit
(Invitrogen 180808-051) using oligo dT primed first strand synthesis. Real-time PCR
was carried out on the 7000 ABI Detection System using Taqman probes for the
housekeeping gene Gapdh (Applied Biosystems Mm99999915_gl) as a control and
genes of interest (Applied Biosystems; Tcf3 Mm00493456_m I, Oct4 Mm00658129_gH,
Sox2 Mm00488369_s 1, Nanog Mm02384862_g 1).
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Expression Arrays
Genomic expression analysis was measured using Agilent Whole Mouse Genome
Microarrays (Agilent G4122F). 2 ug of RNA was labeled for each sample using the
Two-color Low RNA Input Linear Amplification Kit PLUS (Agilent 5188-5340). RNA
from the treated sample (either Tcf3 KD cells or cells treated with Wnt3a conditioned
media) were labeled with Cy5 and RNA from control cells (infected with empty-vector
virus or a mock conditioned media control, respectively) were labeled with Cy3. Labeled
cRNA was hybridized overnight at 650 C. Slides were washed according to the Agilent
protocol and scanned on an Agilent DNA microarray scanner BA. Data was analyzed
using Agilent Feature Extraction Version 9.5.3 with default settings recommended by
Agilent. Flagged and low-intensity spots were then removed and spots representing a
single gene were averaged.
Wnt Pathway Activation
Wnt pathway activity in mES cells was stimulated using Wnt3a conditioned
media (ATCC CRL-2647) and mock conditioned media (ATCC CRL-2648) was used as
a control. Preparation of conditioned medias was performed as per protocol provided
with the cells. Conditioned media was diluted with mES media at a ratio of 1:1.
Immunohistochemical Analysis
Mouse ES cells were crosslinked for 10 minutes at room temperature with 4%
paraformaldehyde. Cells were permeabilized with 0.2% Triton X-100 for 10 minutes and
stained for Oct4 (Santa Cruz, sc-5279; 1:200 dilution), Nanog (Abcam, ab1603; 1:250
dilution), and DAPI Nucleic Acid Stain (Invitrogen D1306; 1:10000 dilution) overnight
at 40C. After several washes cells were incubated for 2 hours at room temperature with
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goat-anti mouse conjugated Alexa Fluor 488 (Invitrogen 1:200 dilution) or goat-anti
rabbit conjugated Alexa Fluor 568 (Invitrogen 1:200 dilution).
Quantitative Image Acquisition and Data Analysis
Image acquisition and data analysis was performed essentially as described in
Moffat et al. (2006). Five days post infection cells were fixed and stained with Oct4 and
Hoechst 33342 (1:1000 dilution). Stained cells were imaged on an Arrayscan HCS
Reader (Cellomics) using the standard acquisition camera mode (10x objective, 9 fields).
Hoechst was used as the focus channel and intra-well focusing was done every 3 fields.
The Apotome feature was applied to acquire all images. Objects selected for analysis
were identified based on the Hoechst staining intensity using the Target Activation
Protocol and the Isodata Threshold method. Parameters were established requiring that
individual objects pass an intensity and size threshold. The Object Segmentation Assay
Parameter was adjusted for maximal resolution. Following object selection the average
Oct4 intensity was determined and then a mean value for each well was calculated. All
wells used for subsequent analysis contained at least 5000 selected objects.
Accession Numbers
All microarray data from this study are available at ArrayExpress at the EBI
(http://www.ebi.ac.uk/arrayexpress) under the accession designation E-TABM-409.
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Chapter 5
Conclusions
191
A comprehensive understanding of the transcriptional regulatory circuitry that
governs ES cells is of great value. It can enable these cells to be modulated to undergo
directed differentiation and permit differentiated cells to be reprogrammed towards a
pluripotent state. Two outstanding issues remain in understanding the transcriptional
regulatory circuitry of ES cells. First, a number of factors and signaling pathways are
known to have genetic importance for ES cells and should be integrated into this
circuitry. Secondly, it is important to understand the nature of the connections between
components within this circuitry and the combinatorial aspects of these factors. This
latter effort will require integrating theories of circuitry into our understanding of the
model, as well as defining new tests to evaluate the circuitry itself. I will briefly review
additional components that should be integrated into the circuitry and then discuss how to
approach understanding the combinatorial aspects of the network. Finally, I want to
describe how the ES cell community is uniquely poised to revolutionize regenerative
medicine through stem-cell based therapies given the understanding of pluripotency and
differentiation that has evolved in recent years.
Integrating into the transcriptional regulatory circuitry the additional transcription
factors and signaling pathways that impact ES cell pluripotency is important for
understanding the full repertoire of ES cell components that contribute to the balance
between maintaining pluripotency and initiating differentiation. The set of factors that
should be integrated into the transcriptional regulatory circuitry were described in chapter
I and include FoxD3, Zic3, Pem, c-Myc, Klf4, Gata6 and Cdx2 (Boiani and Scholer,
2005; Fan et al., 1999; Hanna et al., 2002; Li et al., 2005; Lim et al., 2007; Nakatake et
al., 2006; Takahashi and Yamanaka, 2006). Signaling pathways that can impact ES cell
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identity include LIF/gpl30, BMP4, Activin/Nodal, PI3K and ERK (Okita and Yamanaka,
2006; Valdimarsdottir and Mummery, 2005). Additionally, the Notch signaling pathway
plays a key role in differentiation of ES cells (Fox et al., 2008; Lowell et al., 2006; Nemir
et al., 2006; Noggle et al., 2006; Schmitt et al., 2004; Schroeder et al., 2006). Since
transcriptional regulatory circuitry governs cell state and ES cells are poised to
differentiate, it will be important to understand how pro-differentiation factors and
signaling pathways impact the core regulatory circuitry. For example, Tcf3 is a factor
that is crucial for maintaining the balance between pluripotency and differentiation in ES
cells since it functions to repress pluripotency regulators in ES cells (Cole et al., 2008). It
is important to have the ES cell poised to differentiate, and pro-differentiation factors and
pathways must be active in ES cells in order to permit differentiation. By integrating the
entire set of factors and pathways that regulate ES cells into the transcriptional regulatory
circuitry, we will be able to better understand how the ES cell is poised for
differentiation. Perhaps more importantly, understanding how factors that promote
differentiation modify the transcriptional regulatory circuitry may permit the
manipulation of ES cells down specific lineages, a necessary step for the therapeutic
potential of these cells to be fully developed.
In addition to the transcription factors and signaling pathways that impact ES cell
identity, miRNAs have also been shown to play a key role in governing ES cell identity
and are known targets of the pluripotency regulators (Boyer et al., 2005; Ivey et al., 2008;
Li et al., 2008). Mice deficient in Dicer, a component necessary for miRNA processing,
die at E7.5 and are incapable of producing ES cells (Bernstein et al., 2003; Li and
Gregory, 2008). ES cells deficient in Dicer are incapable of differentiating
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(Kanellopoulou et al., 2005). These studies suggest that miRNAs play a critical role in
ES cell identity. Tissue-specific miRNAs can be isolated that confer lineage specificity
during differentiation of ES cells. This has been shown for miR-1 and miR-133, which
confer muscle-specific differentiation of ES cells (Ivey et al., 2008). Efforts to
characterize the miRNA profile of human and mouse ES cells have revealed the bulk of
miRNAs present in an ES cell are encoded on genomic miRNA clusters (Calabrese et al.,
2007; Suh et al., 2004). Since miRNAs are predicted to fine-tune gene expression in
cells, it is likely that these miRNAs impact the transcriptional regulatory circuitry that
balances ES cells between pluripotency and differentiation. Further analysis of the
miRNAs that are active in ES cells and upregulated in differentiated cell types will reveal
the subsets that contribute to different cell states. It will also be important to integrate the
miRNA targets into the transcriptional regulatory circuitry to understand how they impact
ES cell state.
While many of the factors that may be important for ES cell identity are already
characterized, it is likely that there are many unidentified factors and signaling pathways
that impact ES cells. Differential gene expression can be used to identify factors that are
upregulated in ES cells relative to other tissues that are likely to play a key role in ES cell
identity. Genetic screens can also be conducted in order to further identify factors
contributing to pluripotency and differentiation. It has been reported that screening
factors implicated in ES cells by loss-of-function techniques using shRNAs can identify
previously uncharacterized factors important for ES cell identity (Ivanova et al., 2006).
Gain-of-function studies have also been used to identify factors whose overexpression is
capable of maintaining ES cell self-renewal and pluripotency (Pritsker et al., 2006).
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Additionally, it is possible to screen miRNAs for their role in ES cells. Finally, the
identification of small molecules that can activate or inhibit signaling pathways will
further reveal the role of signaling pathways on ES cells (Schugar et al., 2008; Schuldiner
et al., 2000). These types of studies will be important for revealing the complete set of
factors and pathways involved in ES cell identity and identifying an additional set of
components that can be integrated into the transcriptional regulatory circuitry.
In addition to understanding the genomic targets of transcription factors, signaling
pathways and miRNAs, it will be important to understand their combinatorial behavior.
It is well characterized that POU and SOX domain proteins such as Oct4 and Sox2
interact to regulate gene expression (Rem6nyi et al., 2004). Studies of transcriptional
activation at promoters over the last two decades have revealed that many factors
assemble at the transcriptional start site in order to regulate gene expression. New
approaches to understand how multiple factors interact to govern regulation of gene
expression will need to be developed to interpret the transcriptional outcome at target
genes. As the transcriptional regulatory circuitry becomes further elucidated, it can be
coupled to gene expression analyses in order to predict the combinatorial effect of
different sets of factors at their target promoters.
Clarifying the role of signaling pathways on the transcriptional regulatory
circuitry of ES cells will need to be particularly sensitive to combinatorial effects. The
view that signaling pathways act in parallel to process information is becoming
increasingly contested. It is clear, for example, that Wnt and Notch interact to regulate
expression of target genes, and crosstalk is reported between Wnt and BMP4 (Hayward et
al., 2008; Okita and Yamanaka, 2006). As the effect of different signaling pathways are
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explored, it will be important to consider these combinatorial effects. Cell culture
conditions will need to be improved so that all factors present in culture are known.
Serum and feeder-dependent cultures will need to be replaced with medium that includes
the necessary growth factors. Moreover, mapping of the downstream target genes for
different signaling pathways to identify targets shared between different pathways is
important. This will also allow signaling pathways to be integrated into the
transcriptional regulatory circuitry.
A better understanding of how signaling pathways connect to the ES cell genome
and impact pluripotency and self-renewal will be useful for developing tools to
differentiate ES cells down specific developmental lineages. For example, it has been
demonstrated that under certain conditions, Notch signaling promotes neural
development of ES cells (Lowell et al., 2006). The identification of which signaling
pathways promote which developmental pathways will be crucial for directing lineage
differentiation and establish tools for promoting differentiation of ES cells for therapeutic
purposes. Furthermore, signaling pathways may be useful for reprogramming of somatic
cells. It may be possible to treat differentiated somatic cells with a set of signaling
ligands to promote reprogramming towards a stem cell state. Since it has been shown
that Wnt signaling leads to the upregulation of Oct4 and Nanog, Wnt may be a candidate
factor for reprogramming somatic cells through the manipulation of signal transduction
pathways. Screening combinations of ligands to identify a set that can reprogram ES
cells will be important for exploring the possibility of reprogramming through signaling
pathways. These external ligands could then substitute for genetic manipulation that is
currently the best method for reprogramming (Yamanaka, 2007).
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In order to direct differentiation of ES cells down specific lineages, it will be
essential to upregulate the set of lineage specific developmental regulators. The
repression of developmental regulators is a key mechanism that ES cells use to maintain
pluripotency (Boyer et al., 2005; Lee et al., 2006). An outstanding question that pertains
to the manipulation of ES cell fate is how these cells are able to upregulate a subset of the
repressed developmental regulators to initiate development down a particular lineage. It
is known that RNA polymerase II is paused at these developmental regulators, indicating
that they are poised to be transcribed, and that this poised state is controlled by Polycomb
Repressor Complex-mediated ubiquitination of H2A (Guenther et al., 2007; Stock et al.,
2007). It will be essential to identify the signals that connect to particular subsets of
developmental regulators to release poised polymerase and initiate gene expression.
Since the isolation of ES cells over 25 years ago, much has been learned about the
molecular mechanisms that govern pluripotency and differentiation. ES cells have served
as an ideal candidate system for the study of how transcriptional regulation governs cell
state. The latter effort has revealed the mechanisms that the cells use to maintain the
balance between pluripotency and differentiation. As more and more components are
integrated into this circuitry, it will further elucidate the mechanisms the cell uses to
achieve this balance. Efforts to understand how particular network motifs contribute to
this balance, such as autoregulatory and feedforward loops, will reveal the switches that
cells use to signal the cell to differentiate. Ideally, as the components of the circuitry
become clearer, it will also become evident what modifications need to be made to the
cell to promote specific differentiation program. Efforts to understand ES cells have
allowed their fate to be directed and for differentiated cells to be directed towards a
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pluripotent fate. These remarkable achievements are the results of tremendous effort in
the research community to understand ES cells and are inspired by the hope that these
cells will revolutionize regenerative medicine and aid the treatment of disease during the
2 1s' century and beyond.
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SuDplementarv Data and Tables
All supplementary data and Tables S I-S7 can be found at the following website:
http://www.cell.com/cgi/content/full/ 122/6/947/DC l/
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Figure S1. Distribution of Transcription Factor Binding Sites and Transcriptional
Regulatory Elements Relative to Transcription Start Sites
A Human transcription factor binding sites(TRANSFAC, n=1459)
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A. Distribution of transcription factor binding sites from TRANSFAC from -8kb to
+3kb around the transcription start site.
B. Distribution of functional regulatory elements from the TRRD (database of
transcriptional regulatory regions, http://www.bionet.nsc.ru/trrd/34/) from -8kb to +3kb
around the transcription start site.
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Figure S2. Oct4, Sox2, and Nanog Cooccupy Each of Their Promoters
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Plots display unprocessed ChIP enrichment ratios for all probes within a genomic region.
Genes are shown to scale relative to their chromosomal position. Exons and introns are
represented by thick vertical and horizontal lines, respectively. The start and direction of
transcription are denoted by arrows. Green, red, and purple lines represent Nanog, Sox2,
and Oct4 bound regions, respectively.
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Figure S3. Immunuohistochemical Analysis of Pluripotency Markers
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Human ES cells were analyzed by immunohistochemistry for the characteristic
pluripotency markers Oct4 and SSEA-3. For reference, nuclei were stained with DAPI.
Our analysis indicated that >>80% of the colonies were positive for Oct4 and SSEA-3.
Alkaline phosphatase activity was also strongly detected in hES cells.
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Figure S4. H9 Cells Maintain Differentiation Potential in Teratoma Assay
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Teratomas were analyzed for the presence of markers for ectoderm (Tuj 1), mesoderm
(MF20) and endoderm (AFP). For reference, nuclei are stained with DAPI. Antibody
reactivity was detected for derivatives of all three germ layers confirming that the human
embryonic stem cells used in our analysis have maintained differentiation potential.
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Figure S5. Control Chromatin Immunoprecipitations
A IgG in Human ES cells
12
WCE (1g2)
B Oct4 in HepG2 cells
WCE 0og92)
A. Oct4, Sox2, and Nanog targets were not enriched using preimmune sera in human ES
cells. ChIP was carried out using rabbit or goat IgG to assess antibody specificity.
Labeled IP material and control DNA were hybridized to self-printed promoter arrays.
Background subtracted normalized log2 intensities are plotted. Red lines represent
enrichment / exclusion p-values of <10-3. Example shown is for the goat IgG control
experiment.
B. Potential antibody cross-reactivity with other family members was assessed by
performing ChIP experiments in HepG2 cells. Data were analyzed as above. Example
shown for Oct4 (sc-908 1) in HepG2.
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Figure S6. Oct4 and Sox2 Binding to UTF1 and FGF4
134929600 134937000
Chromosomal Position
UTF1
(undifferentiated embryonic cell transcription)
69302000 69292000
Chromosomal Position
FGF4
(fibroblast growth factor 4)
Plots display unprocessed ChIP enrichment ratios for all probes within a genomic region.
Genes are shown to scale relative to their chromosomal position. Exons and introns are
represented by thick vertical and horizontal lines, respectively. The start and direction of
transcription are denoted by arrows. Green, red, and purple lines represent Nanog, Sox2,
and Oct4 bound regions, respectively.
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Figure S7. Distribution of Oct4, Sox2, and Nanog Bound Regions Relative to
Transciption Start Sites
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Distance from transcription start site
Histogram of the distance between transcription factor bound regions and the nearest
transcription start site. Green, red, and purple lines represent Nanog, Sox2, and Oct4
bound regions, respectively. A distance of 0 refers to bound regions that overlap a
transcription start site.
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Appendix B
Chromatin Immunoprecipitation and Microarray-based Analysis of Protein Location
Published as: Lee TI, Johnstone SE and Young RA (2006). "Chromatin
immunoprecipitation and microarray-based analysis of protein location." Nat Protoc 1(2):
729-48.
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Chromatin immunoprecipitation and
microarray-based analysis of protein location
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Genome-wide location analysis, also known as ChIP-Chip, combines chromatin immunoprecipitation and DNA microarray analysis to
identify protein-DNA interactions that occur in living cells. Protein-DNA interactions are captured in vivo by chemical crosslinking. Cell
lysis, DNA fragmentation and immunoaffinity purification of the desired protein will co-purify DNA fragments that are associated with
that protein. The enriched DNA population is then labeled, combined with a differentially labeled reference sample and applied to DNA
microarrays to detect enriched signals. Various computational and bioinformatic approaches are then applied to normalize the enriched
and reference channels, to connect signals to the portions of the genome that are represented on the DNA microarrays, to provide
confidence metrics and to generate maps of protein-genome occupancy. Here, we describe the experimental protocols that we use from
crosslinking of cells to hybridization of labeled material, together with insights into the aspects of these protocols that influence the
results. These protocols require approximately 1 week to complete once sufficient numbers of cells have been obtained, and have been
used to produce robust, high-quality ChIP-chip results in many different cell and tissue types.
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ize the enriched and reference channels, to calculate the degree of
enrichment and confidence metrics for each feature, to incorporate
the information gained from having multiple probes representing
contiguous regions of the genome and to generate maps of protein-
genome occupancy.
Applications of ChIP-Chip
The range of applications for ChIP-Chip is broad but still expand-
ing. The method has recently been used to investigate DNA-bind-
ing transcription factors and the networks formed by these factors
(reviewed in refs. 15-18), the distributions of chromatin-modify-
ing machinery, histones, histone variants and histone modifications
(reviewed in refs. 16, 19), factors involved in DNA replication, DNA
repair and DNA methylation (reviewed in refs. 20-22), and the
linkage between transcription and nuclear-export machinery 23- 25.
Immunoprecipitation has been coupled with microarrays to identify
interactions between proteins and RNA26- 30 and ChIP has recently
been used to study RNA-binding proteins that become associated
with the genome through their interactions with RNA31. We antic-
ipate that many new biological insights will emerge from protein-
DNA and protein-RNA interactions that are identified using ChIP.
Limitations of ChIP-Chip
There are several features of ChIP-Chip that currently limit its utili-
ty and make it a challenging technique32-34. The primary limitation
is the quality of antibodies that are available for a protein of interest.
The antibody, ideally, has high avidity and specificity for an epitope
that is accessible in the crosslinked chromatin. Because this is not
always the case, the investigator must be cautious about interpret-
ing the lack of detection as reflecting the absence of an interaction.
A second limitation is that a substantial number of cells (107-108)
are generally needed to obtain a robust result. With current meth-
ods, using fewer cells can reduce signals, leading to an underesti-
mation of protein-DNA interactions. High-quality, whole-genome
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INTRODUCTION
Chromatin immunoprecipitation (ChIP) has become a widely used
method for studying how proteins interact with the genome. The
ChIP technique identifies physical interactions between proteins
and DNA that occur within living cellsl- 3 and ChIP can provide a
whole-genome view of protein-DNA interactions when combined
with DNA microarray analysis4- '4. Our goal here is to share our
ChIP-Chip protocol, suggest useful quality-control tests, identify
the most likely sources of trouble and suggest solutions to problems
with experiments. The protocol presented here has been in use for
several years and has been used by many different individuals using
a broad range of different mammalian cell types and tissues.
Overview of the ChIP-Chip technique
In a typical experiment (Figure 1), protein-DNA interactions
are first captured in vivo by treating cells with a small, reversible
crosslinker that is capable of rapidly diffusing into cells. After cell
lysis, the DNA is fragmented and protein-DNA complexes can be
enriched by immunoaffinity capture of the desired protein. As the
DNA is fragmented prior to the capture, the DNA fragments that
are most proximal to the binding event are enriched. Often, an
aliquot of the input DNA is saved prior to immunoprecipitation
for use as a reference sample. The crosslinks for both the enriched
and input DNA are then reversed, and the DNA is purified away
from RNA and protein components. The enrichment relative to
a reference sample can then be measured by one of several tech-
niques, such as PCR, comparative sequencing or DNA microarray
analysis. For most DNA microarray experiments, the enriched and
reference samples must be amplified first to provide sufficient
material. In this protocol, the ends of the DNA are blunted and
ligated to small DNA linkers that are subsequently used in priming
PCR. This ligation-mediated PCR (LM-PCR) results in expanded
pools of the enriched and reference DNA that are then differentially
labeled and hybridized to the microarrays. The arrays are washed
and then scanned. Various algorithms are then used to normal-
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DNA microarray platforms are expensive. As array manufacturers
continue to make improvements in designs and manufacturing,
more cost-effective experiments will be possible. Finally, the experi-
mental process is long and can be challenging to troubleshoot.
Experimental design
Background. The sections below describe several issues that we
have found to be critical to consider in the early stages of planning
and designing ChIP-Chip experiments.
Antibodies. ChIP-Chip is highly dependent on the antibody
used for the immunoprecipitation. As individual antibodies
can perform differently in the ChIP assay, it is helpful to screen
a wide variety of available antibodies before launching a full-
scale ChIP-Chip experiment. We generally start with antibod-
ies, for which there is previous evidence for use in ChIP, or we
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use a variety of polyclonal and monoclonal antibodies from
several sources.
The most reliable way to test the antibodies is to use them in
small-scale ChIPs and to test for enrichment at a gene-specific level,
although this approach depends entirely on the number of known
binding sites, the strength of the evidence for the binding event
and the comparability with your specific cell type, growth condi-
tions and treatments. For small-scale ChIPs, we prepare material as
described below, but instead of using all the material for a single
reaction, we will split it into five to ten aliquots and use each aliquot
in an immunoprecipitation. This lower amount of material seems
adequate for gene-specific analysis, but does not usually work for
microarray analysis. If no binding sites are known, it is much more
difficult to screen for a useful antibody. Western blot analysis may
be informative but is unreliable, as the antibody may recognize the
denatured protein in a western blot but may still fail to recognize
the native form in vivo.
If there are no antibodies for a specific protein, it is possible to
use epitope-tagged versions of proteins, provided the tagged version
does not radically affect protein function. We have used myc, TAP
and FLAG epitope-tagged versions of various proteins with success.
Reference samples. Chromatin immunoprecipitation is an
enrichment relative to a reference and not an absolute measure-
ment, thus the choice of reference sample can be an important ele-
ment of experimental design. Although it is most common to use
unenriched, genomic DNA as the reference, it is sometimes more
useful to hybridize an immunoprecipitation of one factor against
an immunoprecipitation of a second factor to capture subtle effects.
For instance, this approach can be useful when studying histone
modifications. An immunoprecipitation against a core histone sub-
unit is used as the reference to normalize the signal of the modifi-
cation against the amount of histone. This can help to determine
whether a perceived gain or loss of the modification is due to actual
changes in modification or due to changes in histone density.
Replicates. ChIP-Chip, like many other forms of genome-
wide analysis, requires the use of replicate samples to account for
experimental noise that is inherent to high-throughput approach-
es and biological complexity due to the many factors influencing
protein and nucleic-acid interactions. In particular, biological
replicates (independently grown and treated pools of cells or tis-
sue) or replicates with different antibodies against the same fac-
tor are valuable. The number of replicates needed depends on the
noise that is inherent in the platform and the type of analysis to be
performed, but triplicate experiments are preferred and duplicate
experiments should be considered to be the minimum require-
ment whenever feasible.
Experimental controls. The use of a positive control and nega-
tive control for the experiment can be useful, both for trouble-
shooting and for calibrating the analysis. The positive control
should be a high-quality antibody against a protein that is likely
to be present in any cell type. For example, in mammalian cells,
we regularly use antibodies against the ubiquitous cell-cycle regu-
lator E2F4. The most common negative control is an immunopre-
cipitation using a non-specific antibody that matches the isotype
of the experimental antibody.
Choice of arrays. There are a number of options available for
array hybridization, including self-printed oligonucleotide or PCR
amplicon arrays, and commercial arrays and services. The choice
of array platform ultimately depends on the need to balance per-
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Figure 1 I A sample timeline for the ChIP-Chip protocol. Individual
steps are shown in white boxes. Steps that are typically performed on
the same day are grouped by day, which is indicated in gray boxes. IP,
immunoprecipitation; LM-PCR, ligation-mediated PCR.
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formance, ease of use, resolution, cost of arrays and investment
in equipment, and will vary from lab to lab. Due to the variety of
options, a fully detailed protocol for our specific hybridization,
washing, scanning and analysis steps is unlikely to be generally use-
ful. However, we have included the relevant details for hybridiza-
tion and washing and offer general guidelines that we try to follow
for scanning and data analysis. This protocol was developed based
on our work with both self-printed PCR amplicon arrays and com-
mercially available oligonucleotide arrays, and reflects our most
recent experience with oligonucleotide arrays1 3,14,35,36 . A number
of useful ChIP-Chip protocols have been published that describe
protocols similar to this one, but which cover more specific aspects
of dealing with different array platforms 37- 44
Normalization controls on the array. As ChIP measures
enrichment in one sample compared with another, it is essential to
define an appropriate baseline for a particular experiment - one
that reflects the signal from the background of all sequences from
the whole genome and reflects lack of enrichment in the immu-
noprecipitation. This requirement can affect the sets of controls
that are needed on the array. When there are a small number of
features expected to show enrichment, the enrichment ratios of
the majority of features can serve to represent the baseline level;
the large size of this latter set strengthens the statistical signifi-
cance of the enrichment. In other situations, for example, when
examining RNA polymerase II binding at promoter regions using
arrays focused only on promoter regions, we found that it was
more difficult to determine the baseline enrichment that repre-
sented'no binding'. RNA polymerase II bound at a relatively high
fraction of probes, making it more difficult to distinguish bound
and unbound probes with as high a degree of statistical signifi-
cance. In these cases, we found it useful to have a set of control
probes designed against 'gene deserts', genomic regions that are
devoid of known open reading frames and for which there is no
evidence of noncoding transcripts. We assumed that these control
probes would be generally unenriched for RNA polymerase II and
could therefore serve as a normalization baseline. Similarly, we
use control probes to subtract out a baseline level of non-specific
hybridization signal and, for multislide arrays, control probes to
normalize between slides.
Data analysis and bioinformatics. The ChIP-Chip analysis gen-
erates a large amount of data that requires some investment in sta-
tistical, computational and bioinformatics infrastructure.
Statistical analysis is required to account for experimental
noise that is inherent to high-throughput approaches, but more
importantly, to deal with the biological complexity of protein and
nucleic-acid interactions. We expect that a protein of interest will
be distributed across many different sites in a single cell in a man-
ner that is dependent on protein concentration, its affinities for
each site and other variables such as the presence of proteins that
compete for similar sites. As a result, the output of ChIP-Chip is
a distribution of enrichment ratios representing DNA or RNA
occupancy, as opposed to two distinct sets of 'bound' and 'not
bound' Statistical methods are needed to identify the statistically
significant set of enrichment ratios, to provide a measure of con-
fidence at the level of individual probe features and to incorporate
data from multiple features to build models for binding that are
both sensitive and specific. As there are a wide variety of options
for statistical analysis 7,12,45- 51 and the needs of individual labs
will vary, a fully detailed description of our analysis methods is
unlikely to be generally useful. However, we have included a basic
outline of the approach that we have used in the past.
The volume and complexity of the data from ChIP-Chip analysis
may require access to resources that are capable of creating or adapt-
ing programming code to manipulate and analyze the data. Even
if most of the early steps are handled by a commercially available
analysis package, there is almost always a need for additional analy-
ses that need to be customized in some way. The capacity to handle
and display the data using common programming languages, such
as Visual Basic, MATLAB, Perl, R, Java or Python, is highly useful.
Along these lines, the need to be able to map ChIP-Chip data back
to genomic location and genomic features often requires the devel-
opment ofbioinformatics resources, such as access to genome anno-
tation and transcription-factor databases, and the ability to handle
and cross-reference genome-wide expression data. Commonly used
databases include the UCSC Genome Browser (http://genome.
ucsc.edu/); the NCBI databases (http://www.ncbi.nlm.nih.gov/),
particularly RefSeq, Gene and GEO datasets; the EMBL-EBI data-
bases (http://www.ebi.ac.uk/services/); GO functional annotation
(http://www.geneontology.org/); and TRANSFAC (http://www.
gene-regulation.com/pub/databases.html).
Protocol Tips
Background. The sections below describe a few key steps of the
protocol for which we have some experience with variables that are
particularly critical to the success of the experiment. The steps are
presented in order, with those most likely to cause problems being
presented first.
Sonication. Sonication is the most variable step in the process
and will vary greatly depending on cell type, cell culture conditions
used, quantity of cells, volume of sonication, degree of crosslink-
ing and specifics of the sonicator being used. As a result, conditions
must usually be optimized for each situation. Sonication fulfills two
roles, solubilization of chromatin and shearing of chromatin, both
of which are essential for successful ChIP analysis. Solubilization is
achieved relatively easily. However, the degree of shearing requires
more care. Undersonication results in a loss of resolution of bind-
ing events. Smaller DNA fragments allow for more precise localiza-
tion of a specific binding event, as a smaller region of DNA will be
pulled down in the immunoprecipitation. We have also found that
oversonication must be avoided as it results in more noise in the
microarray analysis and difficulty in identifying legitimate targets.
As a guide, most protocols suggest sonication until reaching an
average fragment size (different protocols suggest a value varying
from 350 to 1,000 bp) or until the fragment sizes are within a certain
range. Undersonication relative to these kinds of guidelines is easy
to identify: the size of the reverse crosslinked, purified DNA frag-
ments will be too large. Oversonication is more difficult to quantify.
Most crosslinked material has a physical limit of sonication, and
additional sonication past this point will not result in further visible
shearing but will affect microarray results. Thus, it is possible that
researchers trying to match previously published descriptions that
were optimized for different conditions may inadvertently over-
sonicate their DNA. As an alternative, we suggest sonication using
the lowest power and time settings that result in sheared DNA, of
which at least a quarter of the total DNA is sized from 200 to 600
bp in size, with less emphasis on the average size or overall spread
of fragment sizes. One way to identify these conditions is to run a
small time course of sonications. We will set up a sample of cells, as
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Figure 2 I Results of Number of cycles of sonication
varying degrees of KA n a A 19 iA 9n 9A M
sonication on fragment
size. A total of 2 x 108
crosslinked Jurkat cells
were sonicated using the
following conditions:
Misonix 3000 sonicator
with microtip; power
7; 24 cycles (30 s
sonication, 90 s rest).
Samples were removed at
various times, crosslinks
were reversed and DNA-
purified, and run on a 2%
agarose gel. Lanes with
molecular weights are
Labeled M and lanes with
bp
-1500
-1000
-700
-500
-400
- 300
-200
-100
SUIII",L Ica ClI la a•e
labeled with the number
of cycles of sonication. Sizes of molecular-mass markers are indicated.
Twelve cycles of sonication provide a good degree of sonication. Four cycles
of sonication results in undersonicated DNA. Note that sonication beyond
16 cycles results in little change in fragment size and is Likely to result in
oversonicated material.
described below, with a default power setting but with an extended
time of sonication. We then remove small aliquots (100 tl out of
3.5 ml of material) at discrete time points. After crosslink reversal
and purification, as described in the protocol below, the DNA can
be run on a 2% agarose gel to estimate the degree of sonication. A
sample sonication time course is shown in Figure 2.
Immunoprecipitation conditions. Antibody performance can
be optimized by adjusting a number of variables, but we find that
the simplest, most effective adjustment has been modifying the
amount of salt in the immunoprecipitation. If gene-specific or
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microarray analysis indicates that antibody performance is poor
(two-fold enrichment or less), but a positive control experiment
indicates that the protocol is working well, it may be useful to per-
form a set of small-scale immunoprecipitations over a range of salt
concentrations (typically starting with 0, 50, 100 and 250 mM sodi-
um chloride). Prepare input DNA as described below but use only
one-fifth to one-tenth of the material in an immunoprecipitation.
This small-scale immunoprecipitation usually suffices for gene-
specific analysis, but does not usually work for microarray analysis.
If there is previous evidence indicating specific salt conditions that
are optimal for a particular antibody, we will supplement the lysate
with additional sodium chloride to approximate those conditions.
Washing. Following ChIP, it is possible to overwash the beads.
This usually results in noise in the microarray analysis. In gener-
al, this occurs due to extensive wash times rather than too many
washes. Five washes (as presented below) are adequate for most
antibodies. If signal:noise ratios are low, increasing the number of
washes (as high as 8) may help, although if you suspect low anti-
body affinity, a lower number of washes (as few as 3) may be more
appropriate.
Crosslinking. In practice, we have found that the crosslinking
times and formaldehyde concentrations provided in this proto-
col are generally applicable and have been used successfully with
a variety of proteins in human, mouse, yeast, fruit fly and zebra-
fish model systems. But crosslinking times could theoretically be
optimized for each protein. Insufficient crosslinking can result in
the inability to capture protein-DNA contacts. Over-crosslinking
can actually denature the protein of interest or cause over-aggre-
gation, thus obscuring the epitope. Unfortunately, these problems
are sometimes difficult to diagnose as the primary readout is the
failure to detect enrichment, which could also result in problems at
any number of other steps. One other sign would be unusual ease
or difficulty in obtaining a range of sonicated material when testing
a range of sonication conditions.
* 25x solution Complete Protease Inhibitor Cocktail: I tablet dissolved in 2 ml
of double distilled water (can store up to 12 weeks at -20 OC) (Roche; Cat.
no.: 1 697 498)
* 50% glycerol (Sigma; Cat. no.: G5516)
* 10% Igepal CA-360 (Sigma; Cat. no.: 18896)
* 10% Triton X-100 (Sigma; Cat. no.: T8787)
* I M Tris-HC1, pH 8.0 (Invitrogen/Gibco; Cat. no.: 15568-025)
* 5% Na-Deoxycholate (Sigma; Cat. no.: D5760)
* 5% N-lauroylsarcosine (Fluka; Cat. no.: 61743) A CRITICAL An ultrapure
version of this reagent is not required for lysis steps, but is required for
hybridizations. Lower grades can leave fluorescent residue on slides.
* 5 M LiCI (Sigma; Cat. no.: L7026)
* 10% SDS (Invitrogen/Gibco; Cat. no.: 15553-035)
* 10 mg ml - ' RNAseA (Sigma; Cat. no.: R6513)
* Proteinase K solution (Invitrogen; Cat. no.: 25530-049)
* Phenol:chloroform:isoamyl alcohol (Fluka; Cat. no.: 77617) A CRITICAL
If this solution is old or is at low pH, there will be degradation of DNA.
! CAUTION Phenol is toxic when in contact with skin or if swallowed; causes
burns; and is irritating to eyes, the respiratory system and skin. Chloroform
is harmful by inhalation or if swallowed; is irritating to skin; and is
potentially carcinogenic. Isoamyl alcohol is flammable; and is irritating
to eyes, the respiratory system and skin. The phenol:chloroform:isoamyl
alcohol should be used with appropriate safety measures, such as protective
gloves, glasses and clothing, and adequate ventilation.
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1 M HEPES-KOH, pKa 7.55 (Invitrogen/Gibco; Cat. no.: 15630-080)
* 5 M NaCI (Sigma S-5150)
* 500 mM EDTA (Invitrogen/Gibco; Cat. no: 15575-038)
* 500 mM EGTA (Sigma, Cat no: E3889)
* 37% formaldehyde (J.T. Baker; Cat. no: 2106-01) ! CAUTION Formaldehyde is
flammable; highly toxic by inhalation, contact with skin or if swallowed; causes
burns; and is potentially carcinogenic. Formaldehyde should be used with
appropriate safety measures, such as protective gloves, glasses and clothing, and
adequate ventilation. Formaldehyde waste should be disposed of according to
regulations for hazardous waste.
" 2.5 M glycine (Sigma; Cat. no: G8790)
" 10x Dulbecco's phosphate buffered saline (PBS) (Invitrogen/Gibco; Cat. no.:
14200-075)
* Dynabeads (Dynal) A CRITICAL Although it is possible to use other types
of beads for the immunoprecipitation, we find that Dynabeads give us very
low background and are easy to use. We use Dynabeads that come pre-
coated with secondary antibody (e.g., PanMouse IgG, which is a monoclonal
human anti-mouse IgG) or pre-coated with protein G. The exact type of
bead used will depend on the primary antibody being used)
" Block Solution: Ix PBS, 0.5% bovine serum albumin (BSA) (Sigma; Cat. no:
A7906) A CRITICAL Should be made fresh and kept cold.
* Primary antibody of choice
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The phenol:chloroform:isoamyl alcohol waste should be disposed of
according to regulations for hazardous waste.
* 20 mg m-1' glycogen (Roche; Cat. no.: 901 393)
* 100% ethanol (Aaper)
* 80% ethanol (diluted from 100% ethanol)
* T4 DNA polymerase, 3 U gl-' (New England Biolabs; Cat. no.: M0203S)
* 1Ox NE Buffer 2 (supplied with T4 DNA Polymerase)
* I gg g['l BSA (diluted from 10 mg ml-' stock supplied with T4 DNA
Polymerase)
* 2.5 mM dNTP mix (2.5 mM each dNTP) (GE Healthcare Life Sciences;
Cat. no.: 27-2035-03)
* 3 M sodium acetate (Sigma; Cat. no.: S-7899)
* T4 DNA ligase, 400 U jl (New England Biolabs; Cat. no.: M0202S)
* 5x T4 DNA Ligase buffer (Invitrogen; Cat. no.: 46300-018)
* 40 iM solution oligo oJW102 (MWG Biotech; 5'-GCGGTGACCCGGGAGA
TCTGAATTC-3')
* 40 pM solution oligo oJW103 (MWG Biotech; 5'-GAATTCAGATC-3')
* 15 pM Linker (see REAGENT SETUP)
* 10x ThermoPol buffer (New England Biolabs; Cat. no.: B9004S)
* Double-distilled water
* AmpliTaq polymerase (Applied Biosystems)
* 7.5 M ammonium acetate (Sigma; Cat. no.: A2706)
* BioPrime Array CGH Genomic Labeling System (Invitrogen; Cat. no.: 18095-
011; includes Labeling Module and Purification Module) A CRITICAL We have
experimented with other purification methods, but have found that these kits
gave us the best yield while efficiently removing smaller DNA products. We
have found that these small DNA products increased the background noise at
lower signal intensity levels on our arrays.
* 1 mM Cy3-dUTP (PerkinElmer/NEN; Cat. no.: NEL578)
* 1 mM Cy5-dUTP (PerkinElmer/NEN; Cat. no.: NEL579)
* Formaldehyde Solution (see REAGENT SETUP)
* Lysis Buffer 1 (see REAGENT SETUP)
* Lysis Buffer 2 (see REAGENT SETUP)
* Lysis Buffer 3 (see REAGENT SETUP)
* Wash Buffer (RIPA) (see REAGENT SETUP)
* Elution Buffer: 50 mM Tris-HCl, pH 8.0, 10 mM EDTA, 1.0% SDS
* TE: 10 mM Tris-HCI, pH 8.0, 1 mM EDTA
* TE + NaCl: 10 mM Tris-HCl, pH 8.0, 1 mM EDTA, 50 mM NaCI (keep cold)
* 2x Blunting Mix (See Step 44) A CRITICAL Should be made fresh before use.
* 2x Ligase Mix (See Step 52) A CRITICAL Should be made fresh before use.
Linkers used in this mix should be thawed on ice, used immediately and not
re-used.
* LMPCR Mix A (See Step 58)
* LMPCR Mix B (See Step 58)
* Label Mix (Nucleotide Mix and Klenow are from Invitrogen labeling kit)
(See Step 70)
* The following reagents are specific to our hybridization and washing
protocol; as different laboratories will select different array platforms,
these are intended as a reference: 200 ng pl- ' sheared herring sperm DNA
(Promega; Cat. no.: D1815); 8 jlg l1-h' yeast tRNA (Invitrogen; Cat. no.:
15401-029); 1 pg tLl-' Cot-1 DNA (Invitrogen; Cat. no.: 15279-011; use
species-specific Cot- DNA)
* 1Ox Control Targets (Agilent; Cat. no.: 5185-5976-P) (Reconstitute per
manufacturer's directions. Used in protocol at 0.1 x, not lx as recommended
by manufacturer)
* 500 mM Na-MES, pH 6.9 (Sigma; Cat. no.: M5287) (Adjust pH with 10 N
sodium hydroxide) A CRITICAL MES can go off. As a precaution, make
small batches of the stock solution and use within 3 months. Store in the
dark at 4 *C.
* 100% formamide (Sigma; Cat. no.: F9037) ! CAUTION Formamide is
harmful by inhalation, in contact with skin or if swallowed; and causes
burns. Formamide should be used with appropriate safety measures, such
as protective gloves, glasses and clothing, and adequate ventilation. The
formamide waste should be disposed of according to regulations.
* 100% acetonitrile (J.T. Baker; Cat. no.: 9017-03) ! CAUTION Acetonitrile
is highly flammable; and is toxic by inhalation, in contact with skin or if
swallowed. Acetonitrile should be used with appropriate safety measures,
such as protective gloves, glasses and clothing, and adequate ventilation. The
acetonitrile waste should be disposed of according to regulations.
* Hybridization Control Mix (See Step 80)
* Hybridization Buffer Master Mix (See Step 82) A CRITICAL Should be made
fresh before use.
* 20x SSPE (Invitrogen; Cat. no.: 15591-027)
* Wash I: 6x SSPE, 0.005% N-lauroylsarcosine
* Wash II: 6x SSPE
* Wash III (Stabilization and Drying Buffer; Agilent; Cat. no.: 5185-5979)
! CAUTION This solution contains acetonitrile, which is flammable and
hazardous and should be used in a fume hood.
EQUIPMENT
* Cell strainer, 100 glm nylon (if using tissues) (e.g., BD Falcon)
* Rotator (e.g., Fisher Hematology/Chemistry Mixer)
* Magnetic particle collector (MPC; Dynal)
* Sonicator (e.g., Misonix 3000 sonicator equipped with microtip)
* Phase lock, heavy, pre-dispensed into 2.0 ml microfuge tubes (Eppendorf)
(Although these could be replaced with standard liquid organic solvent
extractions, the ease of use factor makes these ideal)
* NanoDrop ND-1000 spectrophotometer (This is highly useful as it allows
you to assay DNA concentrations and dye incorporations by using low
volumes (1.5 tl) of sample)
* Thermal cycler (e.g., MJ Research PTC-225) (For large-scale set-ups, it is
useful to have a cycler that can handle 96-well plates)
' Swinging bucket centrifuge, variable temperature (e.g., Sorvall Legend RT)
' Rocking platform (e.g., Bellco Rocker Platform)
' Liquid nitrogen and appropriate container
' 65 degree oven (e.g., Techne Hybridiser HD- IB) (Ovens or warm rooms
are preferred for longer incubations as the evenly applied heat limits
condensation forming on tube lids)
REAGENT SETUP
15 pM Linker Mix 250 jl of 1 M Tris-HCl (pH 8.0), 375 pl of 40 gM oJW102
and 375 pl of 40 gM oJW103. Make 50 or 100 pl aliquots in PCR tubes. Place
tubes in thermal cycler. Set up and run the following program: 95 oC for 5
min; 70 'C for 1 min; ramp down to 4 OC (0.4 OC/min); 4 OC Hold. Remove
linkers and store at -20 oC. A CRITICAL Linkers must be thawed on ice and
used immediately. The linkers are labile and will dissociate, causing low-
efficiency ligation. Aliquots of partially used linkers should not be re-frozen
and re-used.
Formaldehyde Solution Should be made fresh. Consists of 50 mM HEPES-
KOH, pH 7.5, 100 mM NaC1, 1 mM EDTA, 0.5 mM EGTA and
11% formaldehyde.
Lysis Buffer 1 Add protease inhibitors just before use, filter and keep cold.
Consists of 50 mM HEPES-KOH, pH 7.5, 140 mM NaCl, I mM EDTA,
10% glycerol, 0.5% NP-40, 0.25% Triton X-100, lx protease inhibitors
Lysis Buffer 2 Add protease inhibitors just before use, filter and keep cold.
Consists of 10 mM Tris-HCI, pH 8.0, 200 mM NaCl, 1 mM EDTA, 0.5 mM
EGTA, lx protease inhibitors
Lysis Buffer 3 Add protease inhibitors just before use, filter and keep cold.
Consists of 10 mM Tris-HCI, pH 8.0, 100 mM NaCl, 1 mM EDTA,
0.5 mM EGTA, 0.1% Na-Deoxycholate, 0.5% N-lauroylsarcosine, lx protease
inhibitors
Wash Buffer (RIPA) Keep cold. Consists of 50 mM HEPES-KOH, pKa 7.55,
500 mM LiCI, 1 mM EDTA, 1.0% NP-40, 0.7% Na-Deoxycholate
EQUIPMENT SETUP
Sonicator We most commonly use a Misonix 3000 sonicator with microtip.
The settings we typically begin with are power setting 7 (-35 W) and 12 cycles
(where each cycle is a 30 s burst of sonication, followed by a 90 s pause). The
range of settings will vary based on cell type, cell number, growth conditions
and crosslinking. For comparison, the range of settings we have used for
specific experiments is: power settings from 6 to 9; cycle number from 8 to 15;
burst times of 20 to 30 s and pause times of 60 to 90 s.
Array scanning As the specifics of scanning depend on the platform chosen
and the scanner available, it is less useful to provide a detailed protocol on
how to scan arrays using any one specific set-up. However, there are a few
guidelines that we have found to be useful for two-color hybridizations. In
selecting scanner settings, the primary variable we change is photomultiplier
tube (PMT) gain, which adjusts the sensitivity of the PMT that converts
photons to a digitized electrical signal for the Cy3 and Cy5 channels.
218
NATURE PROTOCOLS I VOL.1 NO.2 I 2006 I 733
o
o
0
o
0.
a.
CL
CD0-
.(0
:3
z
00
0f
PROTOCOL
A higher PMT gain creates a brighter image. We try to select PMT settings such that the distributions of signal intensities for each channel are similar.
for each of the lasers in a two-color scanner that maximize signal intensity In addition, the settings should not result in a large number of signals that
from features, without creating excessive background signal from the glass exceed, and are therefore thresholded at, the maximum detection range of
surface. Our current array platform has extremely low background signal, the scanner. This can result in loss of detection of enrichment for features
so our main concern is maximizing signal intensity. PMT gains are also set with high signal intensities.
PROCEDURE
Formaldehyde crosslinking cells 0 TIMING Day 1, 1-4 h
11 For formaldehyde-crosslinking of cells, three procedures are described that can be used, depending on whether your cells
are: adherent to culture apparatus (A); growing in suspension (B); or obtained fresh from tissues (C). The procedure given in (C)
has been used with mouse and human tissues. Specifics vary from tissue to tissue, and this extraction procedure will therefore
require some optimization - these steps are, therefore, general guidelines for extracting and crosslinking cells from tissues.
• CAUTION See REAGENTS for precautions when using formaldehyde.
o ? TROUBLESHOOTING
2 (A) For adherent cells:
(i) Use 5 x 107 - 1 x 108 cells for each immunoprecipitation.
So (ii) Add 1/10 volume of fresh 11% Formaldehyde Solution to plates. Swirl briefly.
(iii) Incubate cells with Formaldehyde Solution for 10 min at room temperature.
0 (iv) Add 1/20 volume of 2.5 M glycine to quench formaldehyde.
(v) Rinse cells twice with 10 ml of 1x PBS. Harvest cells using silicon scraper.
(vi) Pool cells in 50 ml conical tubes and spin at 700g for 5 min at 4 'C. Discard supernatant and resuspend pellet in 10 ml of
Sx PBS per 108 cells with gentle inversion (cells may stick to pipettes at this stage).
(vii) Aliquot 5 x 107 - 1 x 108 cells to individual 15 ml conical tubes and spin at 700g for 5 min at 4 *C. Discard supernatants.
S (B) For suspension cells:
(i) Use 5 x 107 - 1 x 108 cells for each immunoprecipitation.
(ii) Add 1/10 volume of fresh 11% Formaldehyde Solution to flasks. Swirl briefly.
2 (iii) Incubate cells with Formaldehyde Solution for 20 min at room temperature.
0 (iv) Add 1/20 volume of 2.5 M glycine to quench formaldehyde.
._ (v) Pool cells in required number of 50 ml conical tubes and spin at 700g for 5 min at 4 oC. Discard supernatant.
. (vi) Resuspend cells in 50 ml of lx PBS with gentle inversion (cells may stick to pipettes at this stage). Spin at 700g for 5 min
at 4 OC to pellet cells. Discard supernatant. Repeat once. Resuspend final cell pellet in 10 ml of lx PBS per 108 cells.
" (vii) Aliquot 5 x 107 - 1 x 108 cells to individual 15 ml conical tubes and spin at 700g for 5 min at 4 OC. Discard supernatants.
. (C) For tissues:
z (i) Harvest tissues. For human tissues, this involves an arrangement to obtain transplant-grade tissue that has been released
Sfor research and will depend on the tissue. Whenever possible, tissues are crosslinked as close to collection as possible and
then shipped. If not possible, tissues are shipped on ice, allowed to recover briefly and then crosslinked and processed as}0 described below. For mouse tissues, this entails euthanizing the mice and then immediately harvesting the desired tissues.S (ii) Mince tissues very finely. Transfer to 50 ml tube and add 2x volume of lx PBS. Add 1/10 volume of fresh 11% Formaldehyde
Solution.
(iii) Incubate cells with Formaldehyde Solution for 10 min at room temperature. Swirl tubes occasionally. Add 1/20 volume of
2.5 M glycine to quench formaldehyde. Immediately place cells on ice.
(iv) Homogenize cells. We typically use douncing or hand-held, mechanical homogenizers. Pass material through a 100-gm
nylon cell strainer.
(v) Pool cells in required number of 50 ml conical tubes and spin at 1,100g for 5 min at 4 OC. Discard supernatant.
(vi) Resuspend cells in 50 ml lx PBS with gentle inversion (cells may stick to pipettes at this stage). Spin at 1,100g for 5 min
at 4 °C to pellet cells. Discard supernatant. Resuspend final cell pellet in 10 ml of 1x PBS per 108 cells.
(vii) Aliquot 5 x 107 - 1 x 108 cells to individual 15 ml conical tubes and spin at 1,350g for 5 min at 4 *C. Discard supernatants.
21 Flash-freeze cells in liquid nitrogen and store pellets at -80 'C.
U PAUSE POINT Once cells are crosslinked, they may be stored frozen at -80 *C indefinitely.
Preparing magnetic beads 0 TIMING Day 2, 7-8 h
31 Add 100 pl of Dynal beads to a 1.5 ml microfuge tube. Set up 1 tube of beads per immunoprecipitation. Add 1 ml Block
Solution.
A CRITICAL STEP Steps 3-9 are all performed at 4 °C.
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41 Collect beads using Dynal MPC. Place tubes in rack. Allow beads to collect on side of tube. This should take approximately
15 s. Invert rack once or twice to help collect all beads. Remove supernatant with aspirator or pipettor.
51 Add 1.5 ml Block Solution and gently resuspend beads. This can be done by removing the tubes from the rack and inverting
the tubes 10-20 times until the beads are evenly resuspended or by removing the magnetic strip from the rack and inverting
the rack, with the tubes still in place - either 10-20 times or until the beads are evenly resuspended. Collect beads as above
(Step 4). Remove supernatant with aspirator or pipettor.
61 Wash beads in 1.5 ml Block Solution, as in Step 5, one more time.
71 Resuspend beads in 250 p•l Block Solution and add 10 pg of antibody. Incubate at 4 °C for a minimum of 6 h, or overnight,
on a rotator.
' U PAUSE POINT This step can be extended to overnight at 4 *C. If so, beads should be prepared starting on Day 1.
o ? TROUBLESHOOTING
0.
E 81 Wash beads three times in 1 ml Block Solution, as described in Step 5.
-I
C 91 Resuspend each aliquot of beads in 100 p• Block Solution.
0
Cell sonication @ TIMING Day 2, 2 h
S 101 Remove frozen cell pellets from -80 0C and resuspend each pellet of-108 cells in 10 ml of Lysis Buffer 1. Rock at 4 oC on
platform rocker for 10 min.
11 Spin at 1,350g for 5 min at 4 OC in a table-top centrifuge. Discard supernatant.
121 Resuspend each pellet in 10 ml of Lysis Buffer 2. Rock gently at room temperature for 10 min.
7
o 131 Pellet nuclei in table-top centrifuge by spinning at 1,350g for 5 min at 4 OC. Discard supernatant.
-. 141 Resuspend each pellet in each tube in 3.5 ml Lysis Buffer 3. Transfer cells to tubes for sonication. We currently prefer to
use the bottom half of a standard polypropylene, 15 ml conical tube for sonication. We cut the tube into two pieces at the 7 ml
0. mark and discard the upper half. Tubes can be covered with parafilm while setting up. You may also wish to save a 50 p.L aliquot
for use as a pre-sonication control.
z
S 151 Using a clamp, position tube so the sonicator probe sits approximately 0.5-1.0 cm above the bottom of the tube. Take care
that the probe is centered and does not contact the sides of the tube.A CRITICAL STEP Probe positioning can affect whether the solution foams or not during sonication. Typically, foaming indicatesSthat the sonicated DNA will be poorly sheared.
? TROUBLESHOOTING
161 Immerse tube in an ice-water bath. This is most easily done by keeping the sonicator probe and tube fixed, placing the bath
on a height-adjustable platform and raising it into position.
171 Sonicate suspension. Samples should be kept in an ice-water bath during sonication. To decrease foaming, initially set
output power to 4 and increase manually to final power during first burst.
A CRITICAL STEP If there is significant foaming, we recommend removing all bubbles by centrifugation at 20,000g followed by
gentle resuspension of all material, leaving no foam bubbles.
? TROUBLESHOOTING
181 Add 1/10 volume of 10% Triton X-100 to sonicated lysate. Split into two 1.5 ml centrifuge tubes. Spin at 20,000g for
10 min at 4 OC to pellet debris.
191 Combine supernatants from the two 1.5 ml centrifuge tubes in a new 15 ml conical tube for immunoprecipitation.
A CRITICAL STEP From here on, keep lysates on ice.
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201 Save 50 pC of cell lysate from each sample as input DNA. Store at -20 0C. At least one input DNA aliquot should be kept per
batch of sonicated lysate. Note that the effects of the sonication and the resulting distribution of fragment sizes can only be
checked at Step 42 after crosslink reversal and purification of DNA.
U PAUSE POINT Lysates can be frozen at -80 oC and used the next day.
Chromatin immunoprecipitation 0 TIMING Day 2, 15 min and overnight incubation
211 Add 100 pt antibody/magnetic bead mix from Step 9 to cell lysates from Step 19. Incubate overnight on rotator at 4 0C.
A CRITICAL STEP Antibody performance can be affected by the amount of salt in the reaction. If there is previous evidence
indicating specific salt conditions that are optimal for a particular antibody, we will supplement the lysate with additional
sodium chloride to approximate those conditions. In this case, the salt concentrations of wash buffers used in Steps 25-26
should also be adjusted.
? TROUBLESHOOTING
o Wash * TIMING Day 3, 2 h
2 221 Set up 1.5 ml microfuge tubes on ice, one tube for each immunoprecipitation. Transfer half of each immunoprecipitation from
a the 15 ml conical tube to its assigned microfuge tube.
A CRITICAL STEP All wash steps are performed at 4 °C. Buffers should be kept cold.
o 231 Collect beads using Dynal MPC. Place tubes in rack. ALLow beads to collect on side of tube. This should take approximately 15 s.
Invert rack once or twice to help collect all beads. Remove supernatant with aspirator or pipettor, changing tips between samples.
C3
C 241 Add second half of immunoprecipitation to tube. Let tubes sit again in magnetic stand to collect the beads. Remove
{ supernatant with aspirator or pipettor, changing tips between samples.
t 251 Add 1 ml Wash Buffer (RIPA) to each tube and gently resuspend beads. This can be done by removing the tubes from the
rack and inverting the tubes 10-20 times or by removing the magnetic strip from the rack and inverting the rack, with tubes still
2 in place - 10-20 times or until the beads are evenly resuspended. Collect beads. Remove supernatant by aspirator or pipettor.
O Repeat this wash four more times, changing tips between washes.
.' ? TROUBLESHOOTING
, 261 Wash once with 1 ml TE + 50 mM NaCI.
" 271 Spin at 960g for 3 min at 4 0C and remove any residual TE buffer.
¢o Elution 0 TIMING Day 3, 30-45 minSm 281 Add 210 p• of Elution Buffer and elute material from beads by incubating tubes in a 65 oC water bath for 15 min. VortexS briefly every 2 min. This incubation can be extended as long as 30 min, which can help improve recovery of the eluate.
291 Spin down beads at 16,000g for 1 min at room temperature.
301 Remove 200 p• of supernatant and transfer to new tube.
E PAUSE POINT Material can be frozen at -20 0C and stored overnight.
Crosslink reversalt TIMING Day 3, 6 h or overnight
311 Reverse crosslink the immunoprecipitation DNA from Step 30 by incubating at 65 0C for a minimum of 6 h. This incubation is
usually done in an oven so that the tube is heated evenly and there is less condensation formed.
? TROUBLESHOOTING
321 Thaw 50 p• of input DNA reserved after sonication (Step 20), add 150 gt (3 volumes) of elution buffer and mix. Reverse
crosslink this input DNA by incubating at 65 0C as in Step 31. From this point, every tube of immunoprecipitation or input DNA is
considered to be a separate tube or sample for later processing steps.
0 PAUSE POINT If the wash was performed early in the day, the crosslink reversal can be stopped after a minimum of 6 h and the
material can be frozen at -20 0C and stored overnight. If the wash was performed later in the day, the crosslink reversal can be
extended up to 15 h and performed overnight with Little effect on the reaction.
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A CRITICAL STEP Longer times of crosslink reversal (18 h or more) usually result in increased noise in the microarray analysis.
? TROUBLESHOOTING
Purification of DNA 0 TIMING Day 4, 6 h
331 Add 200 pl of TE to each tube to dilute SDS in ELution Buffer. We have found that high Levels of SDS can inhibit
RNAse activity.
341 Add 8 p1 of 10 mg ml-1 RNaseA (0.2 mg ml-' final concentration), mix by inverting the tube several times and
incubate at 37 'C for 2 h.
0 PAUSE POINT Material can be frozen at -20 oC and stored overnight.
351 Add 4 p• of 20 mg ml- 1 Proteinase K (0.2 [tg m-1' final concentration) and mix by inverting the tube several times
" and incubate at 55 OC for 2 h.
0
0
2 361 Add 400 gl phenot:chloroform:isoamyl alcohoL (P:C:IA), vortex and separate phases with 2 ml Heavy Phaselock tube
g (follow instructions provided by Eppendorf).
A CRITICAL STEP If the P:C:IA solution is old or is at low pH, there will be degradation of DNA, causing noise in the
microarray analysis and loss of detection of valid targets.
0 ! CAUTION see REAGENTS for precautions when using phenol and chloroform.0
? TROUBLESHOOTING
371 Transfer aqueous layer to new centrifuge tube containing 16 gl of 5M NaCL (200 mM final concentration) and 1.5 pl
of 20 pg pL-1 glycogen (30 gg total).
= 381 Add 800 pl EtOH. Incubate for 30 min at -20 oC.
C.
2 391 Spin at 20,000g for 10 min at 4 OC to pellet DNA. Wash pellets by adding 500 pl of 80% EtOH, vortexing to resuspend(a pellet and spinning again at 20,000g for 5 min at 4 0C.
.. 401 Remove any remaining 80% EtOH. Spin the tubes briefly to collect any remaining liquid and remove liquid with a
pipetteman, avoiding the pellet. Let tubes air dry until pellets are just dry: pellets should still retain a moist appearance.
. Resuspend each pellet in 70 pl of 10 mM Tris-HCL, pH 8.0.
S A CRITICAL STEP Overdrying of these pellets can make them difficult to resuspend, or liable to flake and peel away from
z the side of the tube.
o 7 ?TROUBLESHOOTING
@ 411 Save 15 gL of immunoprecipitation sample for future use. This material can be used to perform gene-specific PCRO confirmation of microarray results.
421 Measure DNA concentration of input DNA with NanoDrop and dilute input DNA to 100 ng iL-1. Run purified input
DNA on a 2% agarose gel to check distribution of fragment sizes and digestion of RNA. The immunoprecipitation DNA will
usually be too dilute to measure or visualize at this point. If possible, this is a good opportunity to check for enrichment
in the immunoprecipitation sample using gene-specific PCR.
E PAUSE POINT Material can be frozen at -80 oC and stored indefinitely.
? TROUBLESHOOTING
T4 polymerase blunting of ends * TIMING Day 4, 2 h
431 Set up 1.5 ml microfuge tubes for each immunoprecipitation and input DNA sample. For each input DNA sample, mix 2 p•(200 ng) input DNA and 53 pl ddH20 in an individual tube. For each immunoprecipitation, aliquot 55 gl into an individual tube.
A CRITICAL STEP Steps 43-45 should be performed on ice, unless otherwise stated.
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441 Make 2x Blunting Master Mix according to the table below:
Component Amount (per reaction) Final amount/concentration
10x NEB buffer 2 11.0 gl[ lx
1 gLg g•-l BSA 5.5 giL 50 igg ml-1
2.5 mM dNTP mix 4.4 git 100 g M each dNTP
T4 DNA polymerase (3 U g -i') 0.5 lt 1.5 U
ddH 20 33.6 1l
TOTAL volume 55.0 jl
451 Add 55 gl of 2x Blunting Master Mix to all tubes. Incubate for 20 min at 12 OC in a water bath that is set up in a 4 *C
cold room.
A CRITICAL STEP The reaction should be kept at 12 0C and promptly removed after incubation. Theoretically, the low
temperature, short reaction time and high concentrations of nucleotides favor the polymerase activity of the T4 DNA
polymerase and not the exonuclease activity, resulting in blunt ends and not 5' overhangs. If no reliable water bath/cold
room set-up exists, set up PCR tubes at Step 43 and use a thermal cycler to incubate reactions at 12 0C. Use of PCR tubes
will require transferring the samples to microfuge tubes for Steps 46-47.
? TROUBLESHOOTING
461 Add 11.5 gl of 3 M sodium acetate and 0.5 gl of 20 glg jl glycogen (10 gg total).
471 Add 120 gl P:C:IA, vortex samples and transfer samples to room temperature Phaselock tubes. Extract once (follow
instructions provided by Eppendorf).
A CRITICAL STEP If the P:C:IA solution is old or is at low pH, there will be degradation of DNA, causing noise in the
microarray analysis and loss of detection of valid targets.
! CAUTION See REAGENTS for precautions when using phenol and chloroform.
? TROUBLESHOOTING
481 Transfer aqueous layer to new centrifuge tube containing 250 til EtOH. Incubate for 30 min at -20 *C.
491 Spin at 20,000g for 10 min at 4 OC to pellet DNA. Wash pellets by adding 500 [l of 80% EtOH, vortexing to resuspend
pellet and spinning again at 20,000g for 5 min at 4 oC.
501 Remove any remaining 80% EtOH. Spin the tubes briefly to collect any remaining liquid and remove liquid with a
pipetteman, avoiding the pellet. Let tubes air dry until pellets are just dry: pellets should still retain a moist appearance.
A CRITICAL STEP Overdrying of these pellets can make them difficult to resuspend, or liable to flake and peel away from
the side of the tube.
? TROUBLESHOOTING
511 Carefully resuspend each pellet in 25 jl H20 with pipetting. Adding the water and then
ice for some time can help. Chill on ice after resuspending.
U PAUSE POINT Material can be frozen at -80 'C and stored indefinitely.
Blunt-end ligation 0 TIMING Day 4, 1 h and overnight incubation; Day 5, 2 h
521 Make 2x Ligase Master Mix according to the table below:
Component Amount (per reaction) Final amount/concentration
5x T4 DNA tigase buffer 10.0 itL lx
15 jiM tinker 6.7 jit 2 iM
T4 DNA ligase (400 U jl -') 0.5 lt 200 U
ddH20 7.8 gji
TOTAL volume 25.0 jit
A CRITICAL STEP Steps 52-57 should be done on ice, unless otherwise stated.
allowing the pellets to sit on
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531 Add 25 plt Ligase Master Mix to 25 plt of sample and incubate for 16 h in a 16 OC water bath.
541 Add 6 p• of 3 M sodium acetate and 130 pl EtOH. Incubate for 30 min at -20 OC.
551 Spin at 20,000g for 10 min at 4 OC to pellet DNA. Wash pellets by adding 500 pL of 80% EtOH, vortexing to resuspend
pellet and spinning again at 20,000g for 5 min at 4 *C.
561 Remove any remaining 80% EtOH. Spin the tubes briefly to collect any remaining Liquid and remove Liquid with a
pipetteman, avoiding the pellet. Pellet may appear as a translucent smear on the side of the tube. Let tubes air dry until
pellets are just dry: pellets should still retain a moist appearance.
A CRITICAL STEP Overdrying of these pellets can make them difficult to resuspend, or Liable to flake and peel away from
the side of the tube.
? TROUBLESHOOTING
571 Carefully resuspend each pellet in 25 pl H2 0 with pipetting. Adding the water and then allowing the pellets to sit on
ice for some time can help. Store on ice after resuspending.
U PAUSE POINT Material can be frozen at -80 °C and stored indefinitely.
Ligation-mediated PCR * TIMING Day 5, 3-6 h
581 Make LMPCR Mix A and LMPCR Mix B according to the tables below. Mixes should be prepared on ice.
LMPCR Mix A
Component Amount (per reaction) Final amount/concentration
10x ThermoPol buffer 4.0 pt 1x
2.5 mM dNTP mix 5.0 glt 250 giM each dNTP
40 iM oJW102 1.25 il 1 iM
oligonucleotide
ddH20 4.75 itl
TOTAL volume 15.0 pL
LMPCR Mix B
Component Amount (per reaction) Final amount/concentration
10x ThermoPol buffer 1.0 gL lx
Taq polymerase (5 U IL-1) 0.5 p1 2.5 U
ddH 20 8.5 jLl
TOTAL volume 10.0 gL
591 Add 15 pl of LMPCR Mix A to each 25 pl sample, on ice. Transfer tubes to the thermal cycler.
601 If an additional expansion step is required to increase the amount of material for LabeLing, follow (A) below. If no
expansion is required, run the program described in (B).
(A) Expansion required
(i) Program the thermocycler as follows:
Cycle Denature Anneal Extend
1 55 OC, 4 min 72 OC, 3 min
2 95 OC, 2 min
3-15 95 OC, 30 s 60 OC, 30 s 72 OC, 1 min
(ii) Start program. Midway through the 55 *C step of cycle 1, add 10 pL Mix B to each tube to hot-start reactions.
If necessary, pause the program so the tubes remain at 55 oC while adding Mix B.
(iii) After the 15-cycle program has finished, remove the samples and add 475 pi of double-distilled water. This diluted
material can then be used as template for subsequent LMPCR reactions (Steps 58-60 (B)). A total of 5 pl of diluted
material should be adequate for a new 50-pt reaction. Adjust the amount of water in the recipes listed above accordingly.
A CRITICAL STEP It is strongly recommended that you do not use this expansion until comfortable with the procedure. It
is important to first calibrate the number of cycles in the first-round PCR to ensure that 15 cycles of amplification are still
in the linear range. We used both real-time PCR and array hybridization of material expanded once with 25 cycles versus
material expanded with the 15/25 protocol to ensure that our results were not affected by the first-round expansion.
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(B) No expansion required
(i) If no expansion step is required, program the thermocycler as follows:
Cycle Denature Anneal Extend
1 55 OC, 4 min 72 OC, 3 min
2 95 OC, 2 min
3-27 95 OC, 30 s 60 OC, 30 s 72 oC, 1 min
28 72 0C, 5 min
The sample can be kept at 4 oC by adding a HOLD step at the end of the program.
(ii) Start program. Midway through the 55 °C step of cycle 1, add 10 pt of Mix B to each tube to hot-start reactions.
If necessary, pause the program so the tubes remain at 55 °C while adding Mix B.
£0
o 611 After PCR is completed, transfer reactions to individual 1.5 mt Eppendorf tubes. Pool samples if appropriate. For each
2 50 itl of PCR reaction, add 25 pit of 7.5 M ammonium acetate and 225 pl of cold EtOH. Incubate for 30 min at -20 °C.Q.
"• 621 Spin at 20,000g for 10 min at 4 oC to pellet DNA. Wash pellets with 500 pl of 80% EtOH. Wash pellets by adding
500 plt of 80% EtOH, vortexing to resuspend pellet and spinning again at 20,000g for 5 min at 4 oC.
0o
631 Dry pellets as described above (Step 56) and resuspend each pellet in 50 pt H20.
i ? TROUBLESHOOTING
i 641 Measure DNA concentration with NanoDrop (use 10-fold dilutions, if necessary) and normalize all samples to
500 ng pt1-'. Run a 2% agarose get to check size of LMPCR products.
N U PAUSE POINT Material can be frozen at -80 °C and stored indefinitely.
8 Cy3/Cy5 Labeling of IP/WCE material @ TIMING Day 6, 6 h
C0 651 Preheat thermal cycler to 95 oC.
.LO 661 For each Labeling reaction, aliquot 2 ptl (1 Rg) of LMPCR-amplified immunoprecipitated or input DNA into a PCR tube.
0.
ý. 671 Add 35 pt of 2.5x random primer solution and 38 pl of double-distilled water. This is a random-primed, Klenow-based
31 extension protocol derived from Invitrogen's CGH kit. Our protocol varies from the instructions provided by Invitrogen
z in both reaction volume and reagent concentrations. We perform 20 reactions per '30 reaction' Invitrogen kit. A pair of
o reactions (one for immunoprecipitation and one for its reference input DNA) yields enough material for 1-2 hybridizations.
N To scale-up for more arrays, we increase number - not volume - of individual reactions.
681 Vortex samples for 30 s.
691 Place tubes in pre-heated thermal cycler. After 5 min at 95 oC, immediately transfer samples to an ice-water slurry
bath for 10 min to flash-cool reagents.
701 While reagents are cooling, make up Label Mix. One mix is required for immunoprecipitation samples (usually Cy5).
A second mix is required for input DNA samples (usually Cy3). If reagents permit, a dye swap can provide a useful
comparison (a second set of replicates where the immunoprecipitate is labeled with Cy3 and the input DNA is labeled with
Cy5).
Label Mix:
Component Amount (per reaction) Final amount/concentration
10x dUTP Nucleotide mix 8.2 pl lx
Cy5 (or Cy3) 1.5 pt 17 gM
Klenow (40 U p[-1) 1.5 pl 60 U
ddH20 1.8 gl
TOTAL volume 13.0 pl
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711 Vortex samples for 30 s.
721 Add 13 il of Label Mix to each sample. Pipette up and down multiple times to mix reagents.
731 Incubate samples for 3 h at 37 *C.
A CRITICAL STEP Keep samples in dark as Cy dyes are sensitive to exposure to light. Other incubation times and
conditions have been tried, but we find that these conditions offer the best yield, while Limiting the accumulation of
smaller DNA fragments (<100 bp) that can contribute to noise in the microarray analysis.
741 Add 9 gL stop buffer to each well and mix by pipetting gently.
75l Clean up DNA using the DNA purification columns provided with the CGH kit. Follow manufacturer's instructions.
to ? TROUBLESHOOTING
0
o
2 761 After eluting Labeled DNA from the column into a microfuge tube, spin tubes at 15,000g for 2 min at room
E temperature to pellet any fine particulates. Carefully transfer supernatants to fresh tubes. Repeat if necessary to ensure
S that the solution is clear.
A CRITICAL STEP It is particularly important to thoroughly remove the particulates at this step. Particulates from the
o purification column can bind to some slide surfaces, making it difficult, if not impossible, to successfully scan the slide.
? TROUBLESHOOTING
771 Measure DNA concentration and dye incorporation with NanoDrop. OptionaL: Run a 2% agarose gel to check size of
Labeling products.
0 PAUSE POINT If this DNA is going to be used within the next day, it can be stored at -20 °C. If the DNA will be stored
: for Longer, we recommend storing it as a pellet. Precipitate the DNA by adding 25 pl of ammonium acetate and 300 pL of
. ice-cold EtOH and placing the tubes at -80 oC for 10 min. Spin at 20,000g for 10 min at 4 OC to pellet DNA. Wash pellets
2 with 500 •l of 80% EtOH. Remove excess ethanoL. Allow pellets to air-dry briefly and store tubes at -80 *C in a Light-
O proof box or wrapped in aluminum foil.
o ? TROUBLESHOOTING
Array hybridization 0 TIMING Day 6, 1-2 h, plus 40-h incubation.
781 For each hybridization, combine 5 gg of the CyS-labeled immunoprecipitated DNA and 5 ig of the appropriate
. Cy3-labeled reference DNA. Keep all tubes on ice. The hybridization can be performed with Less DNA (we have used as
z little as 3 pg of each Cy5-labeled and Cy3-labeled), but better signal:noise ratios are seen with larger amounts of DNA.
0 If working with frozen pellets, resuspend each pellet first in 50 pL of double-distilled water and then combine however
S much you need for the hybridization.S791 For each hybridization, bring the combined DNA up to a total volume of 120 p1. Keep all tubes on ice. If the DNA solutions are
diLute, this volume can be extended as high as 170 jl[ and water can be removed from the hybridization buffer mix as necessary.
801 Make Hybridization Control Master Mix.
Hybridization Control Master Mix
Component Amount (per reaction) Final amount/concentration
Sheared herring sperm DNA 4.0 git 1.6 glg ml-1
(200 ng p-1')
Yeast tRNA (8 gg iL-') 5.0 gL. 80 gig ml-1
Cot-1 DNA (1.6 4lg iL-1) 10.0 WL[ 20 jLg ml-1
Control otigonucleotides (lx) 5.0 gpl O.1x
TOTAL volume 24.0 pCl
811 Add 24 jl of Hybridization Control Master Mix to each hybridization. Mix by pipetting gently. Keep all tubes on ice.
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821 Make Hybridization Buffer Master Mix. This solution should be made fresh before use and kept at room temperature.
Hybridization Buffer Master Mix
Component Amount (per reaction) Final amount/concentration
ddH20 50.0 gl
500 mM Na-MES, pH 6.9 50.0 pI 50 mM
5 M NaCL 50.0 gl 500 mM
500 mM EDTA 6.0 pl 6 mM
5 % N-lauroylsarcosine 50.0 p• 0.5%
Formamide 150.0 j[ 30%
TOTAL volume 356.0 pC
! CAUTION See REAGENTS for precautions when working with formamide.0
0
2 831 Add 356 p• of Hybridization Buffer Master Mix to each hybridization. Mix by pipetting gently. After mixing, do not return
0.
E samples to ice. Instead, leave tubes at room temperature until all samples have been processed. Keep all samples protected
from light.
o 841 Heat samples for 3 min in a heat block that has been set to 95 *C. Cover with foil to prevent exposure to light.
-i851 Transfer tubes to a 40 *C heat block for 15 min. Cover with foil to prevent exposure to Light. At this point, start
preparing hybridization chambers for assembly, aiming to handle 4-6 slides at a time. If there are more slides than this,
samples can sit at this 40 *C step for at least 1 h.
861 After 15 min, spin tubes at 14,000g for 45 s to pellet any particulates.
? TROUBLESHOOTING
C3 871 Assemble hybridizations according to manufacturer's instructions. Use 490 jL of hybridization mix per hybridization.
C
881 Incubate at 40 *C in rotating oven for 40 h. Ensure free rotation of liquid throughout the chamber. We find the best
8 results are obtained with an incubation time of 38-42 h.
a.
M Array washing 0 TIMING Day 8, 1-2 h
z 891 Before disassembling hybridization chambers, prepare Wash I (6x SSPE, 0.005% H-lauroylsarcosine) and Wash II
S (6x SSPE). Filter Wash I and Wash II before use. Place Wash III at 37 *C to dissolve solute. Swirling the bottle of Wash III
occasionally will help to dissolve the solute. Allow the solution to cool to room temperature before use.
! CAUTION As Wash III is volatile, avoid temperatures that are higher than 45 *C.S? TROUBLESHOOTING
901 Prepare and wash all glassware and equipment that is required for slide disassembly (follow manufacturer's instructions)
and for washes described in Steps 91-95. We usually use standard glass 10-slide microscope slide racks and dishes.
? TROUBLESHOOTING
911 After hybridization, disassemble hybridization chambers individually following the manufacturer's instructions.
Batches of 4-6 slides are convenient. Slides are placed in slide racks in dishes containing a magnetic stir bar (thin enough
to spin freely when slides and slide rack are added) and sufficient Wash I to cover the slides.
? TROUBLESHOOTING
921 Once all slides for this batch are in the dish, place dish on stir plate and gently stir for 5 min at room temperature. On
a typical stir plate with settings from 1 to 10, use setting 3 or 4. The surface of the Liquid should barely dimple. During this
wash, prepare two dishes with 270 mL of Wash II, one with a stir bar.
? TROUBLESHOOTING
931 After the 5-min wash in Wash I, remove rack from Wash I, quickly dip it into a dish containing Wash II and
immediately transfer to the second dish containing 270 ml of Wash II and stir bar.
? TROUBLESHOOTING
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941 Place this dish on a stir plate and gently stir for 5 min at room temperature. Use stir plate settings as described in Step 92.
During this wash, prepare the washes for the next step in the fume hood. Pour 270 ml of 100% acetonitrile (FPLC grade) into a
small rectangular dish. Pour 250 ml (one half bottle) of room temperature Wash III into a second, small rectangular dish, add a stir
bar and place on a stir plate. Cover both dishes when not in use to prevent evaporation.
! CAUTION See REAGENTS for precautions when using acetonitrite.
? TROUBLESHOOTING
951 Turn off stir plate and carry dish containing the slides to the hood. Turn on stir plate in the hood to begin agitating Wash III.
Remove rack, quickly dip it into dish containing 100% acetonitrile, and immediately transfer to a final dish containing Wash III
and a rotating stir bar.
? TROUBLESHOOTING
75 961 After 15 s, turn off the stir plate. This allows particulates to settle, and helps prevent them from sticking to your slide as you
o pull the slides out. Wait another 15 s.
2 971 Slowly and smoothly remove rack and slides from Wash III - it should take approximately 10 s to lift the rack from the
solution (the slides should be dry at this point). If you move the rack abruptly as you are removing it, you may create visible lines
of Wash III precipitate. If this happens, re-dip the slide momentarily and try to pull it out again.
o ? TROUBLESHOOTING
S 981 Scan immediately. As fluorescent dyes are sensitive to exposure to atmosphere, it is best to scan slides as soon as possible
after washing. Various ozone-scavenging treatments, such as Wash III, extend the Life of hybridized slides, but still eventually fail.
Slides can be stored in vacuum-sealed bags or a high nitrogen environment for short times (2-5 h) until needed.
: ? TROUBLESHOOTING
Array analysis
3 991 As described above, each Lab is likely to have specific preferences for analysis of the array. A very brief, general outline is
O provided here as an example and a more detailed explanation is available in Lee et al.'4. Scan slides (we use an Agilent DNA
.• microarray scanner) at wavelengths of 532 nm for input (Cy3) and 635 nm for enriched (Cy5).
i 1001 Use GenePix feature-identification software to automatically identify features and to extract data for fluorescence at each
a. wavelength by calculating the average intensities for all pixels within the feature boundaries.
z 1011 Subtract Local background signal for each feature. Normalize the signal intensities of the slide across the entire set of
€ slides using signals from a set of common features that are printed on every slide in the set. Then, subtract the signal intensities
C from a set of negative controls for hybridization.
1021 Median normalize the data from the two channels and generate a log ratio of signal intensities for each feature.
1031 Process the log ratios using a whole chip error model52, which incorporates signal intensity and background noise to
calculate a P-value for the statistical significance of the enrichment ratio that is seen at each feature. We also calculate the P-value
for enrichment for sets of three adjacent features and incorporate information about the enrichment at both individual features
and sets of features to identify genomic regions that qualify as being bound by the protein in question.
? TROUBLESHOOTING
1041 Identify distinct binding events by collapsing adjacent bound regions.
* TIMING
Day 1: Steps 1-2 (approximately 1-4 h, depending on numbers of cells or tissues being collected)
Day 2: Steps 3-9 (approximately 8 h, should be started first)
Day 2: Steps 10-21 (approximately 2 h and overnight incubation)
Day 3: Steps 22-32 (approximately 8-9 h, or approximately 2 h and overnight incubation)
Day 4: Steps 33-53 (approximately 9 h and overnight incubation)
Day 5: Steps 54-64 (approximately 6-7 h)
Day 6: Steps 65-88 (approximately 7-8 h and 40-h hybridization)
Day 8: Steps 89-98 (approximately 1-2 h and scanning time)
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TROUBLESHOOTING
Troubleshooting advice can befound in Table 1.
TABLE 1 I Troubleshooting table.
PROBLEM
Insufficiently sheared chromatin
(detected at Step 42)
POSSIBLE REASON
Over-crosslinked material (Step 1)
Solution foamed (Step 17)
Solution foamed (Step 17)
Under-sonicated (Step 17)
Low signal:noise or failure to
immunoprecipitated DNA
(detected at Step 42 or Step 103)
Debris on slides
(detected at Step 98)
Noise in microarray analysis
(abnormally wide distribution of
immunoprecipitated/input DNA signal
ratios) (detected at Step 103)
Over-crosslinked material
(epitope obscured or denatured) (Step 1)
Under-crosslinked (protein insufficiently
crosslinked to DNA) (Step 1)
Ineffective antibody (Step 7)
Poor conditions for immunoprecipitation
(Step 21)
Particulates not removed from Labeled
material (Step 76, Step 86)
Particulates during wash
(Step 91, Step 92, Step 93, Step 94,
Step 95)
Lines/streaks on slides
(Step 98)
Over-sonicated material
(Step 17)
Beads overwashed (Step 25)
Incubation period too long for
crosslink reversal (Step 31, Step 32)
DNA degraded by phenol (Step 36, Step 47)
Poor recovery of DNA (Step 40, Step 50,
Step 56, Step 63)
Poor blunting (Step 45)
Small DNA fragments post-labeling
(Step 77)
ANTICIPATED RESULTS
Step 42 (i)
Measure DNA concentration of input DNA (from Step 20) with NanoDrop. Input DNA samples should be approximately 70 ll
total volume with a DNA concentration of 300-500 ng lt - 1'. Immunoprecipitation samples are usually too dilute to detect
reliably and measurements are sometimes skewed due to the glycogen that is added to the sample, but we have pooled and
precipitated several immunoprecipitates and, after adjusting for changes in volume, expect a DNA concentration of 2-6 ng Lt- 1.
The immunoprecipitated DNA concentration may be higher if the immunoprecipitation is directed against an abundant protein.
Step 42 (ii)
Run a 2% agarose gel of the input DNA that is saved prior to immunoprecipitation (Step 20). This allows you to visually
check the distribution of fragment sizes that result from sonication, and to confirm digestion of RNA. Examples of
different distributions of fragment sizes resulting from different degrees of sonication are shown in Figure 2. We would
first try ChIP with the fragment distribution that is seen with 12 cycles of sonication, as this is the Lowest amount of
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SOLUTION
Reduce crosslinking time (Step 1)
Keep sonication tip centered and within 1 cm of
bottom of tube (Step 15)
If the solution has foamed before, make sure
that all bubbles are removed (Step 17)
Increase sonication (either power settings or
number of rounds of sonication) (Step 17)
Reduce crosslinking time (Step 1)
Increase crosslinking time. We have gone as long
as 16 h at 4 OC (Step 1)
If possible, try a different antibody (Step 7)
Change salt concentrations of
immunoprecipitation and subsequent washes
(Step 21 and Step 25)
Spin Labeled DNA at high speed to remove
particulates (Step 76, Step 86)
Use clean glassware and filter necessary wash
solutions. If using an ozone-scavenger solution,
dissolve solute completely (Step 89, Step 90)
Transfer slides quickly between washes to
minimize drying. When removing slides from
final wash, avoid sudden movements (Step 93,
Step 95, Step 97)
Reduce sonication (either power settings or
number of rounds of sonication) (Step 17)
Minimize wash times; reduce number of washes
(Step 25)
Reduce incubation for crosslink reversal to 6-8 h
(Step 31, Step 32)
Replace P:C:IA solution (Step 36, Step 47)
Take care when resuspending pellets (Step 40,
Step 50, Step 56, Step 63)
Keep reaction temperature low and incubation
time short (Step 45)
Use a clean-up method that Limits purification of
small (60 bp or less) fragments (Step 75)
PROTOCOL
sonication that results in a majority of fragments, ranging
from 200-600 bp. The fragment distribution that is seen
with eight cycles of sonication is also likely to yield
reasonable ChIP results, but this material has generally
larger fragments that could reduce the ability to resolve
binding events. The fragment distribution that is seen with
16 cycles of sonication is similar to the 12-cycle material,
but we would default to the lower amount of sonication.
Note that different cell types, growth conditions and
crosslinking conditions will change the appearance of
similar sonication time courses. However, the basic
principle of finding a setting that minimizes sonication
while maximizing fragments in the range of 200-600 bp
should still be a useful starting point.
It can also be useful to calculate the fragment-size
distribution more precisely with laser densitometry or a
device such as the Agilent 2100 Bioanalyzer. These values are
useful for computational algorithms that combine knowledge
of the size distribution with genomic probe locations, probe
characteristics and enrichment ratios to develop more
sophisticated models of protein-DNA binding.
Step 42 (iii)
Figure 31 2% agarose
gel showing an
example of input
DNA, DNA after
LMPCR amplification
and Labeled DNA. The
Lane with molecular-
mass markers is
Labeled M. Input DNA
is in Lane 1, LMPCR
DNA is in Lane 2,
Labeled DNA is in
Lane 3. Approximately
200-300 ng of DNA
are Loaded. Note
that Labeled DNA
will fluoresce (and
thus appear more
abundant) when
photographed with
UV illumination due
to the presence of
dye.
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bp
1500 -
1000 -
700 -
500 -
400 -
300 -
200 -
100 -
0o
4.
0.
CL
t-i
aE
C-
2
8t-
C%
LFigure 41 Samples of hybridized arrays and a
scatterplots. (a) A portion of a hybridized
and scanned array. The material is enriched
for RNA polymerase II binding. Red features
indicate enrichment. Bright green features are
hybridization controls. Yellow and yellow-green
features indicate no enrichment. (b) A plot
showing processed results of the hybridization
and scan shown in a. Signal intensities (log base
2) for the RNA polymerase II-enriched DNA are
shown on the y-axis. Signal intensities (Log base
2) for the input DNA are shown on the x-axis.
C t. Ai h I 1, A i idi dA b h.
a,
red lines, are significantly enriched at a threshold Siga intensity (input)
of P<0.001. Features that are below the diagonal
and appear significantly enriched are usually
control features or dust particles that have been mistakenly identified as features. Features that are above the diagonal and appear significantly enriched
usually represent immuno-enriched features and indicate protein binding.
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Whenever possible, you should check that the immunoprecipitation was
successful by looking for enrichment of known positive controls in the
immunoprecipitated DNA sample. This is most easily done by performing PCR using primers for known positive control and
negative control regions and running the products on an agarose gel. Compare the ratio of DNA for the positive control
versus the negative control for both the immunoprecipitated DNA (use 2 gI) and the input DNA (use dilution series). The
immunoprecipitation positive:negative ratio should be at Least twice the input DNA positive:negative ratio. It is important
to perform a serial dilution of the input DNA PCR reactions to ensure that all of the reactions are in the linear range of
detection. Ideally, we run the reactions as a multiplex PCR so the expected positive and the negative control are being
tested in the same PCR reaction (adjust primer concentrations so the input DNA positive:negative ratio is close to 1). This
is not always possible with every combination of primers.
Step 64 (i)
Measure DNA concentration with NanoDrop. DNA samples should be approximately 50 pl total volume with a DNA
concentration of 100-350 ng it- '. ALL samples, immunoprecipitated and input DNA should be comparable in DNA amounts.
Step 64 (ii)
Run a 2% agarose gel of the LMPCR DNA. DNA products should be centered around 200-400 bp. ALL samples,
immunoprecipitated and input DNA should be comparable in distribution of fragment sizes and DNA amounts. An example
of LMPCR DNA run on an agarose gel is shown in Figure 3.
ae ures outs e t e oun a e
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Figure 51 Examples of data from an array that a b C
2ra nmrnccai tn idantifu nannmir raninnc th2t
are enriched for binding and verification by
gene-specific PCR. (a) Another portion of the
hybridized and scanned array shown in Figure
4. The material is enriched for RNA polymerase
II binding. The circled feature is red, indicating
enrichment. Yellow and yellow-green features
indicate no enrichment. (b) A plot showing
IL
ratios of the RNA polymerase II enrichment. 5934100 5935350
Enrichment is plotted on the y-axis. Genomic Chromosomal position (Chr. 20)
Location is plotted on the x-axis. Probe location
is shown by the blue circles. The circled
probe represents the ratio seen for the circled d f
. .. . . . . r
a feature shown in a. The re 
1
o region checked using gene-specific PCR to
0 confirm enrichment in c. (c) Gene-specific
PCR, confirming enrichment. Primers were
used to PCR the genomic region, indicated by
the red box in b for immunoprecipitated DNA
and dilutions of input DNA. Molecular-mass
markers are shown in the left-most lane. which
7
3'
U.
o is labeled M. Three-fold dilutions of input Chromosomal position (Chr. 1) M Ip
( DNA are shown in Lanes 1-3, as indicated. The
immunoprecipitation (IP) is shown in the last
Lane. The amount of immunoprecipitate that is added to the PCR is equivalent to the last dilution of input DNA. (d) A portion of a hybridized and scanned
array. The hybridized material is enriched for RNA polymerase II binding. The circled feature shows no enrichment. Yellow and yettllow-green features
indicate no enrichment. (e) A plot showing ratios of the RNA polymerase II enrichment. Enrichment is plotted on the y-axis. Genomic location is plotted
on the x-axis. Probe location is shown by the blue circles. The circled probe represents the ratio seen for the circled feature shown in d. The red box
indicates the region checked using gene-specific PCR to confirm enrichment in f. (f) Gene-specific PCR confirming Lack of enrichment. Primers were used
to PCR the genomic region, indicated by the red box in d for immunoprecipitated DNA and dilutions of input DNA. Molecular-mass markers are shown in
the left-most lane, which is labeled M. Three-fold dilutions of input DNA are shown in lanes 1-3, as indicated. The immunoprecipitation is shown in the
e last lane. The amount of immunoprecipitate added to the PCR is equivalent to the last dilution of input DNA.
Step 77 (i)
. Measure DNA concentration and dye incorporation with NanoDrop. DNA samples should be approximately 50 plt total volume
with a DNA concentration of 100-150 ng gt- 1 and 4-10 pmot gt- 1 of incorporated dye.
z Step 77 (ii)
$ Run a 2% agarose get of the labeled, purified DNA. DNA products should be centered around 200-300 bp. There should not
0 be significant amounts of DNA fragments that are smaller than 100 bp in the purified sample. An example of Labeled DNA
run on an agarose gel is shown in Figure 3.
Step 98
A sample region of a scanned array is shown in Figure 4. Arrays should have a clean and uniform background, with
Little particulate debris or dust. Features should be evenly arranged and have a uniform shape. Typically, we label
immunoprecipitated material with Cy5 and input DNA material with Cy3, and set array visualization so that Cy5 signals
appear red and Cy3 signals appear green. Thus, for a successful immunoprecipitation, we expect a subpopulation of red
spots, indicating features that have been enriched in the immunoprecipitation channel. We expect few, if any, non-control
features that appear bright green, indicating features enriched in the input DNA channel. We expect the majority of spots
to be yellow or yellowish-green, indicating no enrichment. Note that this assumes there are relatively few binding events
and that the array has been scanned to balance the distributions of signal intensities in the two channels.
Step 104
Figure 5 shows a progression of data from array signal to identification of genomic regions that have been enriched
for binding to verification by gene-specific PCR. The array images (Fig. 5a,d) are from slides that were part of a multi-
slide, whole-genome array that detects binding of the initiating form of RNA polymerase II. The slides were scanned
and processed, as described, to generate ratios of signal intensities. The subsequent ratios were processed to identify
significantly enriched features and binding events.
When we plot enrichment ratios against chromosomal position of array features, we expect binding events to have two
basic characteristics (Fig. 5b). Features identifying a binding event should show significantly higher enrichment ratios than
background. Observed enrichment ratios generally range from 2-fold to 15-fold, although ratios will vary based on antibody
performance and can be as high as 80-fold in some cases. Binding events should be supported by multiple features: two or more
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adjacent features should both indicate enrichment above background. The number of probes that are expected to identify a
binding event will depend on the degree of sonication, which influences the size of DNA fragments in the ChIP and the tiling
density of the array, which affects the average number of probes that could reasonably detect immuno-enriched fragments,
given the distribution of fragment sizes and whether the protein binds over large or smaLL regions.
Legitimate binding events can also be confirmed by PCR (Fig. 5c). PCR should be performed using primers that are designed
to amplify the genomic regions that are bound and run the products should be run on an agarose get. The signals that are
generated using the immunoprecipitated DNA sample should be compared to the signal generated using the input DNA sample.
There should be more signal in the immunoprecipitated DNA sample when equivalent amounts of immunoprecipitated DNA and
input DNA are used in the PCR. A serial dilution of the input DNA PCR reactions should be performed to ensure that all of the
reactions are in the linear range of detection.
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Appendix C
Supplementary Data for Chapter 3
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Supplementary Data and Tables
All supplementary data can be found at the following website:
http://www.cell.com/cgi/content/full/125/2/301/DCl /
All tables can be found on the supporting website; the URLs below can be used to
download the appropriate table.
Table Si. Regions bound by RNA polymerase II and their relationship to known and
predicted genes. http://web.wi.mit.edu/young/hES_PRC/TableS .xls
Table S2. HUGO/EntrezGene identifiers for RNA Pol II bound, annotated genes.
http://web.wi.mit.edu/young/hES_PRC/TableS2.xls
Table S3. RNA polymerase II-bound regions that predict novel gene candidates.
http://web.wi.mit.edu/young/hES_PRC/TableS3.xls
Table S4. Gene models bound by RNA polymerase II.
http://web.wi.mit.edu/young/hES_PRC/TableS4.xls
Table S5. MicroRNA genes bound by RNA polymerase II and Suzl2 in ES cells.
http://web.wi.mit.edu/young/hES_PRC/TableS5.xls
Table S6. Expression of genes bound by RNA polymerase II in ES cells.
http://web.wi.mit.edu/young/hES_PRC/TableS6.xls
Table S7. Regions bound by Suzl2 and their relationship to known and predicted genes.
http://web.wi.mit.edu/young/hES_PRC/TableS7.xls
Table S8. HUGO/EntrezGene identifiers for Suz12-bound, annotated genes.
http://web.wi.mit.edu/young/hES_PRC/TableS8.xls
Table S9. Detection of Suzl2, Eed and H3K27me3 occupancy using promoter arrays.
http://web.wi.mit.edu/young/hES_PRC/TableS9.xls
Table S10. Enriched gene ontologies among RNA Pol II-bound and Suz12-bound genes.
http://web.wi.mit.edu/young/hES_PRC/TableS 10.xls
Table S 11. Developmental transcription factors bound by Suz 12.
http://web.wi.mit.edu/young/hES_PRC/TableS I l.xls
Table S12. Developmental signaling proteins bound by Suz 12.
http://web.wi.mit.edu/young/hES_PRC/TableS 12.xls
Table S13. Expression of Suzl2-bound genes during ES cell differentiation.
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http://web.wi.mit.edu/young/hES_PRC/TableS 13.xls
Table S14. Genes bound by Suzl2 in ES cells and upregulated in Suzl2 -/- mouse cells.
http://web.wi.mit.edu/young/hES_PRC/TableS 14.xls
Table S 15. Developmental regulators associated with PRC2 in ES cells and muscle.
http://web.wi.mit.edu/young/hES_PRC/TableS 15.xls
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Figure S1. Human H9 ES cells cultured on a low density of irradiated murine embryonic
fibroblasts
Bright-field image of H9 cell culture.
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Figure S2. Analysis of human ES cells for markers of pluripotency
(0
0.
Human embryonic stem cells were analyzed by immunohistochemistry for the
characteristic pluripotency markers Oct4 and SSEA-3. For reference, nuclei were stained
with DAPI. Our analysis indicated that >90% of the ES cell colonies were positive for
Oct4 and SSEA-3. Alkaline phosphatase activity was also strongly detected in human ES
cells.
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Figure S3. Analysis of human ES cells for differentiation potential
DAPI Rho-Red MERGE I
Teratomas were analyzed for the presence of markers for ectoderm (Tuj 1), mesoderm
(MF20) and endoderm (AFP). For reference, nuclei are stained with DAPI. Antibody
reactivity was detected for derivatives of all three germ layers confirming that the human
embryonic stem cells used in our analysis have maintained differentiation potential.
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Figure S4. The fraction of annotated promoters bound by RNA polymerase II or
Suzl2
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The fraction of unique gene transcription start sites that lie within 1 kb of a genomic region
bound by RNA polymerase II and Suz12. The total number of start sites in each database is
as follows: MGC n=17,188; RefSeq n=19,349; Ensembl n=30,121; UCSC Known Genes
n=42,160; H-Inv n=42,777.
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Figure S5. Estimating error rates
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Figure S5
A. Example gel images showing PCR products amplified from 16 genomic regions judged
to be bound by RNA polymerase II using the whole-genome arrays. Each primer-pair was
used to amplify unenriched, whole cell extract (WCE) DNA (90, 30 and 10 ng) and
immunoenriched (IP) DNA (10 ng). Enrichment in the IP DNA is indicated by a "+" and a
lack of enrichment by a "-". PCR reactions judged to be inconclusive were labeled with an
"N".
B. Example gel images showing PCR products amplified from 16 genomic regions judged
not to be bound by RNA polymerase II using the whole-genome arrays. Each genomic
region represents an annotated transcription start site.
C. Receiver-operator curve for RNA polymerase II binding in human ES cells. Curve
compares percentage of true positives and false positives in binding events called from
ChIP/chip compared to RT-PCR amplifications of anti-Pol II ChIP DNA. ROC curves
were determined for all regions of the genome (blue) and for the subset of regions located
within I kb of known transcription start sites (red).
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Figure S6. Co-occupation of gene promoters by Suzl2, Eed and H3K37me3
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Figure S6
Suzl2 occupancy (top panel), Eed occupancy (middle panel) and H3K27me3 occupancy
(bottom panel) at transcription start sites. Each row represents a gene considered occupied
by either Suz 12, Eed or H3K27me3 using our high-confidence gene calling algorithm (see
sections on Data Normalization and Analysis and Identification of Bound Regions). The
same genes are illustrated in each of the three panels. Each column represents the data
from an oligonucleotide probe positioned relative to the start site as indicated by the gene
diagram below. The log binding ratios for each oligo are plotted for each protein; blue
indicates enrichment of the immunoprecipitated factor (enrichment ratio >1). A scale for
the binding ratios for each panel is shown. Each factor follows the same binding pattern.
From this we conclude that Suzl2, Eed and H3K27me3 are present at essentially the same
set of genes and that our stringent gene calling algorithm sometimes calls a gene bound by
one factor but not another factor because of the inherent false negative rate of -30% (see
Estimating Error Rates section).
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Figure S7. Protein domain classification of Suzl2- and Pol II-bound transcription
factors
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Fraction of transcription factor categories bound by Suz12 (green) or RNA Pol II (blue).
The percentage is expressed relative to all transcription factor genes assigned to that
category by InterPro domain (PANDORA) annotation at the default resolution.
Abbreviations are b-HLH (basic helix-loop-helix), NHR (nuclear hormone receptor), ETS
(erythroblast transformation specific), b-Zip (basic leucine zipper), PHD finger (plant
homeodomain finger), SMAD (Sma- and Mad-related) and FHA (forkhead-associated). n
indicates the number of transcription factor genes assigned to a given category.
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Figure S8. Suzl2 occupies large regions of DNA
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Number of RNA polymerase II (blue bars, left hand axis) and Suzl2 (green bars, right
hand axis) bound regions of certain sizes (x axis). Unlike RNA polymerase II, Suzl2
occupies over 2 kb of sequence at a significant number of genes.
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Figure S9. H3K27me3 co-occupies large domains with Suzl2
A
t U,
Size d Suz2-bound region
I Il
rii
Chromosman pooition
MWOA Ul I Egxi
Lo
Chromosmal position
c V<cly
14e4ý I
ldiL I
,40 ~s? •
Chrorrmosom pcsion
H..c
Chrom~ooma position
•"m -m
248
;i
1
.;OtOxi.xcI
errJa
AM" go -1 -
Figure S9
A. Correlation between size of domains of Suzl2 binding and H3K27me3 binding. The
trend was calculated by computing the moving average of the size of H3K27me3 regions
using a sliding window of 20 genes across the set of genes bound by Suzl2 and H3K27
and ordered by size of Suz12 bound region. Sizes of bound regions were calculated from
promoter arrays.
B. Binding profile of H3K27me3 (black) across ~500 kb regions encompassing Hox
clusters A-D. Unprocessed enrichment ratios for all probes within a genomic region are
shown (ChIP vs. whole genomic DNA). Approximate Hox cluster region sizes are
indicated within black bars.
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Figure S10. Generation of Suzl2 -/- cells
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Figure S10
A. Targeted deletion of the Suzl2 locus. Homologous recombination was used to replace
the 5' portion of Suz12 with a neo cassette. Location of probe used for southern blot
verification in (b) is shown. Restriction enzymes are denoted B, BamH1; E, EcoRI; X,
Xbal.
B. Southern blot analysis of BamH 1 digested genomic DNA from each genotype.
C. Western blot analysis of whole cell extracts derived from each genotype. Immunoblots
were probed with anti-Suzl2 (top) or anti-Lamin B (bottom).
D. Embryos generated from Suzl2 heterozygous crosses were analyzed at different stages
of development. At 7.75 dpc, normal as well as morphologically smaller embryos were
evident. Genotyping analysis indicated that the abnormal embryos were homozygous for
the Suzl2 null allele confirming that Suzl2 is required for early development.
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Figure S11. Binding of Suzl2 in differentiated muscle
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Figure S 11
A. Suzl2 binding profiles across the muscle regulator MYODI gene in H9 human ES cells
(green) and differentiated myotubes (grey). The plots show unprocessed enrichment ratios
for all probes within a genomic region (ChIP vs. whole genomic DNA). Genes are shown
to scale below plots (exons are represented by vertical bars). The start and direction of
transcription are noted by arrows.
B. H3K27me3 profiles across the muscle regulator MYOD I gene in H9 human ES cells
(black) and differentiated myotubes (blue). The plots show unprocessed enrichment ratios
for all probes within a genomic region (ChIP vs. whole genomic DNA). Genes are shown
to scale below plots (exons are represented by vertical bars). The start and direction of
transcription are noted by arrows.
C. Suzl2 binding profiles across the muscle regulator PAX3 gene, as in a.
D. H3K27me3 profiles across the muscle regulator PAX3 gene, as in b.
E. Suz12 binding profiles across the muscle regulator PAX7 gene, as in a.
F. H3K27me3 profiles across the muscle regulator PAX7 gene, as in b.
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Figure S12. Detection of genes bound by RNA polymerase II and Suzl2 in human ES
cell expression datasets
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Percentages of genes that are bound by RNA polymerase II only, RNA polymerase II and
Suzl2, and Suzl2 only that are detected in 7 ES cell expression datasets and one
differentiated cell expression dataset. The first four ES cell datasets and the differentiated
cell dataset were generated using gene expression arrays HI: U133A arrays; H9, HSFI and
HSF6: U133A+B arrays; differentiated tissues: U133A array. The percentages are relative
to the fraction of bound genes that are represented on the arrays. The last three ES cell
datasets were generated using MPSS.
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Figure S13. Relationship between size of Suzl2 and RNA polymerase II co-occupancy
and gene expression
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The percentage of genes with detectable RNA (grey bars) and associated with RNA
polymerase II (blue bars) as a function of the extent of Suzl2 binding. The frequencies for
genes not bound by Suz12 are indicated on the left as controls.
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Figure S14. Association of Oct4, Sox2 or Nanog with Suzl2-bound regions
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Figure S14
A. The percentage of Oct4-bound regions (purple arrow), Sox2-bound regions (red arrow)
or Nanog-bound regions (green arrow) that overlap with Suzl2-bound regions are shown
along the x-axis. Comparisons were made between promoter array data from Boyer et al.,
2005 and whole genome Suzl2 data presented here. The dashed line indicates the
distribution of the expected overlap based on randomized data. For comparison, we also
show the results for a fourth transcription factor, E2F4 (blue arrow).
B. The percentage of Sox2 and Oct4-cobound regions or Nanog and Oct4-bound regions
(purple arrows) that overlap with Suzl2-bound regions are shown along the x-axis.
Comparisons were made between promoter array data from Boyer et al., 2005 and whole
genome Suzl2 data presented here. The dashed line indicates the distribution of the
expected overlap based on randomized data. For comparison, we also show the results for
Sox2-bound regions that are not bound by Oct4 (red arrow) and Nanog-bound regions that
are not bound by Oct4 (green arrow).
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Figure S15. Motifs associated with DNA regions that are bound by Oct4, Sox2, Nanog
and Suzl2 or bound by Oct4, Sox2 and Nanog
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Figure S15
A. Consensus sequence of a motif associated with DNA regions bound by Oct4, Sox2,
Nanog and Suz12. This motif was found in approximately 50% of the regions bound by
Oct4, Sox2, Nanog and Suzl2 and enriched 4.8-fold compared to regions bound by Oct4,
Sox2 and Nanog but not Suzl2.
B. Consensus sequence of a motif associated with DNA regions bound by Oct4, Sox2 and
Nanog and not bound by Suz 12. This motif was found in approximately 20% of the
regions bound by Oct4, Sox2, Nanog and enriched 3.0-fold compared to regions bound by
Oct4, Sox2, Nanog and Suzl2. Putative transcription factor binding sites are labeled and
indicated by black lines. Binding sites were identified with P-Match (http://www.gene-
regulation.com) using the input sequence CCTGTAATCCCAGC and cut-off selection for
matrix group to minimize the sum of false positives and negatives.
C. Consensus sequence of a motif associated with DNA regions bound by Oct4, Sox2 and
Nanog and not bound by Suz12. This motif was found in approximately 15% of the
regions bound by Oct4, Sox2, Nanog and enriched 2.4-fold compared to regions bound by
Oct4, Sox2, Nanog and Suz 12. No putative transcription factor binding sites were
identified when examined as described in b. using the input sequence
ATCTCGGCTCACTG. More lenient selections for the cut-off selection indicate potential
binding sites for C/EBP, HoxA3, CdxA, Msx-1 and v-Myb.
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Appendix D
Supplementary Data for Chapter 4
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Supplemental Data and Tables
All supplementary data and Tables S 1-S3 can be found at the following website:
http://www.genesdev.org/cgi/content/full/22/6/746/DC 1
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Figure Si. Staining of v6.5 murine embryonic stem cells for pluripotency markers
SSEA-1, Oct4 and Nanog
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Cells were fixed with 4% paraformaldehyde and stained overnight at 40 C with SSEA-1
(DSHB, The University of Iowa, MC-480,1:10), Oct4 (Santa Cruz, SC- 5279, 1:200),
Nanog (Abcam, ab1603, 1:250 dilution) and DAPI Nucleic Acid Stain (Invitrogen
D1306; 1:10000 dilution). After several washes cells were incubated with goat anti-
mouse conjugated Alexa Fluor 488 (Invitrogen 1:200 dilution) or goat anti-rabbit
conjugated Alexa Fluor 568 (Invitrogenl:200 dilution) for 2 hours at room temperature.
Stained cells were visualized at 10x magnification.
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Figure S2. Tcf3 bound regions are in close proximity to Oct4 and Nanog bound
regions.
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Figure S2
A. A histogram of the distance between each Tcf3 bound region to the nearest Oct4 or
Nanog bound region. Distances were calculated as the distance in base pairs between the
midpoints of bound regions.
B. Tcf3, Oct4 and Nanog display nearly identical binding profiles. Binding profiles of
ChIP-chip data are shown for Tcf3 (Santa Cruz sc-8635), Oct4 (Santa Cruz sc-8628),
Nanog (Bethyl Labs A300-398A), Myc (Santa Cruz sc-764) and PollI (Abcam ab817).
Analysis of ChIP-chip data from genes bound by Tcf3, Oct4, Nanog or Myc reveals that
Tcf3, Oct4 and Nanog have a distinct binding profile from Myc. Regions from -4kb to
+4kb around each TSS were divided into bins of 250bp. The raw enrichment ratio for the
probe closest to the center of the bin was used. If there was no probe within 250bp of the
bind center then no value was assigned. For genes with multiple promoters, each
promoter was used for analysis. Promoters are organized according to the distance
between the maximum Tcf3 binding ratio and the maximum PoIllI binding ratio. Array
data used was from Agilent mouse promoter arrays that cover +/- 4kb from the TSS at a
density of approximately I probe every 250bp.
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Figure S3. Tcf3 and Oct4 bind components of the Wnt signaling pathway
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A. Wnt signaling pathway diagram. Genes bound by both Tcf3 and Oct4 are shown in
purple.
B. Genes encoding Wnt pathway components that are bound by both Tcf3 and Oct4.
Proteins are represented by ovals, and genes are represented by rectangles.
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Figure S4. Stimulation of the Wnt pathway
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Figure S4
A. There is active f-catenin in mES cells under standard culture conditions. P-catenin
was detected by western in both the cytoplasm and the nucleus of mES cells. Gapdh was
used as a control to ensure the purity of the nuclear protein prep (P-catenin Cell Signaling
9562 1:1000; Gapdh Santa Cruz 25778 1:1000). Protein was collected using Sigma Cell
Lytic C2978 and Sigma Cell Lytic NuCLEAR Extraction Kit NXTRACT.
B. Wnt3a conditioned media or mock conditioned media were used to stimulate the Wnt
pathway. Pathway activity was measured using a TOPFlash reporter plasmid kit (Upstate
17-285). Murine ES cells were transfected with either TOPFlash or FOPFlash, a negative
control plasmid, along with a Renilla control plasmid using FuGENE HD Transfection
Reagent (Roche 04709691001). Luciferase activity was determined using the Dual-
Luciferase Reporter Assay System (Promega E1910) and measurements were normalized
to the Renilla control and a mock control medium.
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Figure S5. Tcf3 knockdown virus reduces Tcf3 transcript
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mES cells were infected with lentivirus carrying either a hairpin to knockdown Tcf3 or a
control non-silencing hairpin. Infected cells were allowed to grow for 48 hours and cells
were harvested to collect RNA. Real-time PCR demonstrated that cells infected with
Tcf3 KD virus have decreased levels of Tcf3 expression. Values were normalized to
Gapdh transcript levels.
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Figure S6. Genes with significant expression changes upon Tcf3 knockdown are
enriched for Tcf3 binding
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The graph represents the percent of genes with a greater than two-fold increase or
decrease in expression that are bound by Tcf3.
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Figure S7. P-catenin associates with Tcf3 and Oct4 in mES cells
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p-catenin could be detected in crosslinked chromatin extracts immunoprecipitated for 3-
catenin (Santa Cruz sc-1496), Oct4 (Santa Cruz sc-8628) or Tcf3 (Santa Cruz sc8635).
Non-immunoprecipitated extract was used as a positive control and an
immunoprecipitation against IgG (Upstate 12-371) was used as a negative control.
Samples were prepared following the ChIP-chip protocol through reversal of crosslinks
and then loaded onto a 7.5% acrylamide gel. Immunoblot was probed with p-catenin
(Upstate 06-734 1:1000).
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Figure S8. Genes with significant expression changes upon Wnt induction are
enriched for Tcf3 binding
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The graph represents the percent of genes with a greater than two-fold increase or
decrease in expression that are bound by Tcf3.
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Figure S9. Expression datasets from TcJ3 KD cells and cells treated with Wnt CM
significantly correlate
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Expression data was rank ordered according to fold expression change. Various cutoffs
for the percentage of genes to include for analysis were used, and results from each cutoff
are graphed along the x-axis. The top ranking up-regulated genes from each dataset were
compared, and the percent of genes overlapping is graphed on the y-axis. The expected
line represents the expected overlap percentages assuming no correlation between
datasets.
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Figure S10. Tcf3 knockdown cells display stronger staining for Oct4 and Nanog
through several passages
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Cells were passaged off of feeders in the presence or absence of LIF. Cells were fixed
and stained as described in experimental procedures.
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Figure S11. Cells grown 1 passage off of feeders treated with Wnt3a CM display
increased Oct4 staining
Wnt3a CM
Mrock media
1000
- 800
O 600
400
tm 200
Expt 1 Expt 2
Image acquisition and data analysis was performed essentially as described in Moffat et
al. (2006). Cells were grown for 3 days off of feeders in mES cell media supplemented
with either Wnt3a CM or mock media. Cells were fixed and stained with Oct4 and
Hoechst 33342 (1:1000 dilution). Stained cells were imaged on an Arrayscan HCS
Reader (Cellomics) using the standard acquisition camera mode (10x objective, 9 fields).
Hoechst was used as the focus channel and intra-well focusing was done every 3 fields.
Objects selected for analysis were identified based on the Hoechst staining intensity using
the Target Activation Protocol and the Isodata Threshold method. Parameters were
established requiring that individual objects pass an intensity and size threshold. The
Object Segmentation Assay Parameter was adjusted for maximal resolution. Following
object selection the average Oct4 intensity was determined and then a mean value for
each well was calculated. All wells used for subsequent analysis contained at least 5000
selected objects.
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